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Respiratory infections are among the most common infections in humans and are a major health 
issue1,2. Overall, they are the cause of high morbidity and mortality, and as such associated with high 
costs due to absence of work and hospitalization, sometimes even in isolation3-5. 
Respiratory infections can be categorized into upper respiratory tract infections and infections of the 
lower airways. Although upper respiratory tract infections are usually relatively mild, more serious 
infections occur in specific high-risk groups. The most prevalent and well known upper respiratory 
tract infection is the common cold. Infections of the lower airways, mainly bronchiolitis and 
pneumonias, are in general more serious and the leading infectious cause of death world-wide1,6. 
Respiratory infections are caused by a variety of pathogens, but primarily by viruses, with overlapping 
clinical symptoms. The common cold is a syndrome of upper respiratory tract infections caused by 
viral pathogens, with rhinovirus being the most prevalent, detected in 40-50% of the cases of the 
common cold6-8. Other common respiratory viruses are respiratory syncytial virus, adenovirus, para-
influenza viruses, bocavirus and metapneumovirus6. 
Viruses are the most prevalent pathogens detected in hospitalized adults with community acquired 
pneumonia (Figure 1). As with upper respiratory tract infections, rhinovirus is the most frequent 
cause, alone or as co-infection with other viruses or bacteria. Strikingly, in up to 62% of the 
community-acquired pneumonias no causative agent is found with current diagnostic procedures 
(Figure 1)7,8. 
 
Figure 1. Pathogens detected in adults with community acquired pneumonia requiring 







DIAGNOSTICS OF RESPIRATORY INFECTIONS 
Respiratory viral causes of infections are hard to distinguish by their clinical presentation, even so 
from other pathogens such as bacteria. Therefore, a precise diagnosis is important for adequate 
therapy and isolation measures. Over the years the diagnostic possibilities have expanded and the 
conventional routine assays, based on viral culture, antigen detection and serology, have been 
replaced by molecular methods. A routine diagnostic respiratory assay has to be fast, sensitive, 
specific, with limited hands-on time, cost-effective and has to be able to detect a wide variety of 
respiratory pathogens. 
 
History of diagnostics of respiratory viruses 
In the 1950’s, diagnosing viruses was performed by in vitro culture on mono-layer cell lines9. Virus 
culture has been the gold standard for a long time. However, the time to results is considerable and 
generally too slow for clinical actions. Not only different cell lines and skilled staff are required, but 
also special safety requirements regarding viable virus10. Additionally, some viruses as for example 
rhinovirus species C, are hard or even impossible to propagate in cell-culture. 
Later, new diagnostic options were introduced with antigen detection assays and serology. Antigen 
detection assays, such as rapid lateral-flow immunoassays and direct fluorescent antibody assays, 
have been designed for several viruses and are rapid but in general less sensitive and specific10. 
Serology is often limited by the need to detect seroconversion, IgG antibody titer rise or IgM 
detection, which is less sensitive in case of repeated exposure to for example rhinoviruses. As the 
induction of a measurable antibody response may take at least a week, the value of serology in the 
acute phase is limited10. 
In 1985, an in-vitro nucleic acid amplification method was designed. The polymerase chain reaction 
(PCR) relied on exponential amplification and subsequent detection of specific parts of nucleic acid 
sequences, with much improved sensitivity and specificity. Initially, after the amplification protocol 
was completed, the amplified PCR products were visualized by gel electrophoreses, southern-blotting 
or ELISA-like detection systems. In 1992, the real-time PCR concept was launched, which enabled 
detection of PCR products while they were generated using fluorescent probes. This greatly 
enhanced the possibilities as it enabled quantitative detection of targets. Real-time PCR is fast, 
sensitive, specific and has relative low hands-on time. Initially one virus per run was tested, but, using 
multiple fluorophores that could be differentiated, also duplex and multiplex PCR assays could be 
designed. However, the amount of targets that could be detected is limited to a maximum of five (in 
most platforms) by the number of fluorescent probes that could be differentiated and by applying an 





Advances in molecular respiratory viral diagnostics 
Recently introduced molecular platforms offer the possibility of syndromic testing, as extended 
multiplex PCRs detect a wide panel of respiratory pathogens implicated in the clinical syndrome. 
Another benefit is the random and continuous access resulting in very fast and reliable results 
throughout the day. Whether these super-fast time to results diagnostic tests have clinical 
implications needs to be determined in more detail14,15. 
Molecular amplification based methods are still limited by the need to pre-define the targets of 
interest in a diagnostic panel. This is complicated by the high number of possible respiratory 
pathogens, the genetic diversity of the viruses implicated and the occurrence of new respiratory 
pathogens. Rare causes are easily overlooked with sometimes great consequences, as encountered 
for example in the Netherlands during Legionella and Q-fever outbreaks, and MERS-coronavirus in 
South-Korea16-18. The emergence of new clinically relevant respiratory viruses is a real threat, which 
will be clear to anyone after the devastating appearance of SARS-CoV-2 early in 2020 and indeed, 
NGS played a crucial role in its initial diagnosis and phylogenetic analysis19-22. But in addition, such 
new viruses may also be present already, without causing a pandemic, like the pigeon paramyxovirus 
type 1 that was coincidentally found to cause a fatal infection in a stem cell recipient23. We can never 
be informed about the role of such viruses without applying NGS as a broad ‘catch all’ approach. 
While for a large proportion of the pneumonias the causative agent is still unknown, it is suspected 
that the percentage attributed to viral pathogens is higher than currently is assumed. Therefore there 





Figure 2. Cartoon representation of selective conventional testing compared to catch-all 
metagenomic next-generation sequencing. 







The newest diagnostic development, metagenomic next-generation sequencing (mNGS) is such an 
unbiased catch-all method, detecting all the genetic material in a sample. Standardized protocols for 
application of mNGS in the diagnostic field are still lacking and also the time to results and the cost 
of this approach are reason for concern, although the latter is rapidly declining (figure 3). To use 
mNGS as routine diagnostic tool, there is a need for fast, automated, combined DNA and RNA pre-
treatment and analysis protocols with high sensitivity and specificity. 
 
Figure 3. Improvements in costs and speed of genome sequencing.  
(adapted from Otwell25). 
 
Another advantage of this catch-all technique is that additional information is provided on strain 
characteristics, genotyping, susceptibility and virulence markers, pathogen evolution and the virome 






Rhinoviruses are single stranded positive-sense RNA viruses in the family Picornaviridae and the 
genus Enterovirus. Since their discovery in the 1950s over 160 types, subdivided in species A, B and 




Figure 4. Phylogenetic tree of rhinovirus. 
(adapted from Fields et al.28) 
 
The genome of rhinoviruses is approximately 7,200 bp long and consists of a single open reading-
frame that encodes a large polyprotein of nearly 2200 amino acids, which is cleaved to produce 11 
viral proteins (VP). VP1, VP2, VP3 and VP4 compose the viral capsid that embeds the RNA, while the 
non-structural proteins are involved in replication and assembly. At the 5’ end of the genome the 
rhinoviruses have a long untranslated region (UTR), with internal ribosome entry sites (IRES), for 
initiation of translation. The 3’ end untranslated region is much shorter and enables efficient 









Figure 5. The genome structure of rhinoviruses. 
UTR, untranslated region. IRES, internal ribosome entry site (Adapted from Jacobs et al.26) 
 
Epidemiology of rhinoviruses 
Rhinoviruses have a worldwide distribution with a high prevalence, especially in young children. 
Although rhinovirus infections occur all year round, they have a peak incidence in early fall and 
spring30-33. 
Rhinoviruses are transmitted by direct contact, droplets or aerosols, but most important 
experimental evidence supports efficient transmission occurring through (in)direct contact mainly 
through hands, after which the virus attaches and replicates in the nasal mucosa, with an additional 
role for aerosol transmission34-39. 
 
Clinical manifestations of rhinoviruses 
Rhinoviruses can cause a wide variety of respiratory symptoms, but asymptomatic shedding does 
occur as well. Asymptomatic infection tends to be more prevalent in younger patients and was even 
found in 12-32% of children under the age of four40-45. 
The most frequently encountered symptomatic presentation of rhinovirus infection is the, self-
limiting, common cold. This usually starts with a sore throat followed by nasal obstruction and 
rhinorrhea, but a variety of symptoms has been observed. Rhinoviruses can also cause (rhino)sinusitis 
and otitis media, but in those cases co-infection with bacteria is common. Although rhinoviruses have 
long been considered relatively mild viruses, causing benign upper respiratory tract infections, they 
are now implicated in more serious lower respiratory tract infections in high-risk groups. They have 
been associated with the development of asthma, asthma and COPD exacerbations, bronchiolitis and 
life-threatening pneumonia, mainly in children and the elderly7,26,46-48. 
The development of more serious infections by rhinovirus is probably multifactorial and dependent 
on both host and environmental factors (Figure 6). Though several factors associated with more 




Figure 6. Spectrum of human rhinovirus infections and factors involved. 
(adapted from Fields’ Virology 28) 
 
More severe rhinovirus infections have been shown in elderly patients, immunocompromised 
patients and patients with underlying chronic lung disease49-53. In children, risk factors for more 
serious infections are prematurity, congenital heart disease, respiratory syncytial virus co-infections, 
and non-infectious underlying respiratory disease. Finally, rhinoviruses have been associated with a 
complicated post-operative course after cardiac surgery54-56. In children, higher viral loads and 
viremia have been found in association to higher disease severity and more extensive clinical 
symptoms57-65. Whether rhinovirus viremia does occur in adults and is associated with more severe 
disease is still unknown. 
Another gap in knowledge exists on whether rhinovirus infection can lead to serious complications 
in case of extreme stress and special circumstances, for example in children undergoing cardiac 
surgery. 
In addition, the association of specific rhinovirus types to more serious disease is still open for debate. 
Some studies showed rhinovirus type C to cause more severe illness, while others failed to 
demonstrate a difference between the rhinovirus types48,66-70. A longitudinal study with a large 
number of patients with a variety of rhinovirus types is needed to determine the influence of 
rhinovirus species on disease severity. 
Although rhinovirus infections have been associated with mortality, the major disease burden is 
caused by the high frequency of infections, the duration of illness (a median of 7 days) and the 
associated economic burden29,46,71. 
 
Treatment and prevention 
There is currently no licensed treatment available for rhinovirus infections, although several antiviral 
treatments have been described or are under development26,72. Therefore, at the moment, the best 







SCOPE OF THIS THESIS 
The research presented in this thesis aims to determine the implications and performance of new 
viral respiratory diagnostic methods and the aspects of the disease severity of the most common 
respiratory virus, rhinovirus. 
 
Part I: Application and added value of advanced respiratory viral diagnostic methods 
In this part, advanced diagnostic methods for respiratory infections were studied to determine their 
clinical implications and their performance, when applied to routine diagnostics. 
An in-house developed diagnostic mNGS protocol, with simultaneous RNA and DNA detection, was 
developed and compared with real-time PCR (chapter two). This protocol was used to study 
respiratory infections and the respiratory virome in patients with COPD exacerbations and to 
correlate these results with clinical data and real-time PCR (chapter three). 
Rapid molecular syndromic testing by an innovative automated amplification platform was compared 
to lab-developed multiplex real-time PCR assays, focusing on the difference in time to results and its 
implications for clinical decision making, regarding isolation, and antimicrobial therapy (chapter 
four). 
 
Part II: Clinical implications of rhinovirus 
In this part, rhinovirus is studied in different patient populations to determine the clinical impact and 
factors influencing the course of the disease. To determine whether rhinovirus infections, 
symptomatic or asymptomatic, have a negative effect on the post-operative course of children 
undergoing cardiac surgery, a large prospective study screening all children at the time of their 
operation was performed (chapter five). 
A retrospective study to detect rhinovirus viremia and its association with disease severity was 
performed in adult patients with high rhinovirus loads in bronchoalveolar lavage (chapter six). The 
difference in disease severity between different rhinovirus species and types was studied in a 
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Viruses are the main cause of respiratory tract infections. Metagenomic next-generation sequencing 
(mNGS) enables unbiased detection of all potential pathogens. To apply mNGS in viral diagnostics, 
sensitive and simultaneous detection of RNA and DNA viruses is needed. Herein, were studied the 
performance of an in-house mNGS protocol for routine diagnostics of viral respiratory infections with 
potential for automated pan-pathogen detection. The sequencing protocol and bioinformatics 
analysis were designed and optimized, including exogenous internal controls. Subsequently, the 
protocol was retrospectively validated using 25 clinical respiratory samples. The developed protocol 
using Illumina NextSeq 500 sequencing showed high repeatability. Use of the National Center for 
Biotechnology Information’s RefSeq database as opposed to the National Center for Biotechnology 
Information’s nucleotide database led to enhanced specificity of classification of viral pathogens. A 
correlation was established between read counts and PCR cycle threshold value. Sensitivity of mNGS, 
compared with PCR, varied up to 83%, with specificity of 94%, dependent on the cutoff for defining 
positive mNGS results. Viral pathogens only detected by mNGS, not present in the routine diagnostic 
workflow, were influenza C, KI polyomavirus, cytomegalovirus, and enterovirus. Sensitivity and 
analytical specificity of this mNGS protocol were comparable to PCR and higher when considering 
off-PCR target viral pathogens. One single test detected all potential viral pathogens and 
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INTRODUCTION 
Respiratory tract infections pose a great burden on public health, causing extensive morbidity and 
mortality among patients worldwide1-3. The majority of acute respiratory infections is caused by 
viruses, such as rhinovirus (RV), influenza (INF) A and B viruses, metapneumovirus (MPV), and 
respiratory syncytial virus (RSV)4. However, in 20-62% of the patients, no pathogen is detected4-6. 
This might be the result of diagnostic failures or even infection by unknown pathogens, such as the 
Middle East respiratory syndrome coronavirus (MERS-CoV), in 20127. 
Rapid identification of the respiratory pathogen is critical to determine downstream decision-making 
such as isolation measures or treatment, including cessation of antibiotic therapy. Current diagnostic 
amplification methods as real-time polymerase chain reaction (qPCR) are very sensitive and specific, 
but are only targeting predefined virus species or types. Genetic diversity within the virus genome 
and the sheer number of potential pathogens in many clinical conditions pose limitations to 
predefined primer and probe based approaches, leading to false negative results8. These limitations, 
combined with the potential emergence of new or unusual pathogens highlight the need for less 
restricted approaches that could improve the diagnosis and subsequent outbreak management of 
infectious diseases. 
Metagenomics relates to the study of the complete genomic content in a complex mixture of 
(micro)organisms9. Unlike bacteria, viruses do not display a common gene in all virus families, and 
therefore pan-virus detection relies on catch-all analytic methods. Metagenomics or untargeted 
next-generation sequencing (mNGS) offers a culture and nucleotide-sequence-independent method 
that eliminates the need to define the targets for diagnosis beforehand. Besides primary detection, 
mNGS immediately offers additional information, on virulence markers, epidemiology, genotyping, 
and evolution of pathogens7,10-12. Furthermore, quantitative assessment of the presence of virus 
copies in the sample is enabled by the number reads8. 
While original mNGS studies typically aim at analysis of (shifts in) population diversity of abundant 
DNA microbes, detection of viral pathogens in patient samples requires a different technical 
approach because of 1) the usually very low abundance of viral pathogens (<1%) in clinical samples 
and 2) the requisite of detecting both DNA and RNA viruses. Hence, a low limit of detection for RNA 
and DNA in one single assay is essential for implementation of mNGS for routine pathogen detection 
in clinical diagnostic laboratories. Current viral mNGS protocols are optimized for either RNA or DNA 
detection11,13-15. Consequently, detection of both RNA and DNA viruses requires parallel work-up of 
both RNA and DNA pre-treatment methods. Additionally, to increase the relative concentration of 
viral sequences, viral particle enrichment techniques are often applied8,12. These techniques are 
laborious and not easily automated for routine clinical diagnostic use. Moreover, during enrichment 
directed at viral particles, intracellular viral nucleic acids as genomes and mRNAs are being discarded. 
Following sequencing, the bioinformatic classification and interpretation of the results remain a 
major challenge. Bioinformatic classifiers are often developed for usage in either microbiome studies 
or classification of high abundant reads whereas extensive validation for clinical diagnostic usage in 
settings of very low abundance is very limited. After bioinformatics classification, the challenge 
remains to discriminate between viruses that play a role in disease aetiology and non-pathogenic 
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viruses16. Before considering mNGS in routine diagnostics, there is a need for critical evaluation and 
validation of every step in the procedure. 
In this study, we evaluated a metagenomic protocol for NGS-based pathogen detection with sample 
pre-treatment for DNA and RNA in a single tube. The method was validated using a selection of 25 
respiratory paediatric samples with in total 29 positive and 346 negative viral PCR results. The main 
study objective was to define a sensitive and specific method for mNGS to be used as a broad 
diagnostic tool for viral respiratory diseases with the potential for automated pan-pathogen 
detection. 
 
MATERIAL AND METHODS 
Sample selection 
Twenty-five stored clinical respiratory samples (-80 ºC) from paediatric patients, sent to the 
microbiological laboratory for routine viral diagnostics in 2016, were selected from the laboratory 
database (general laboratory information management system, MIPS, Ghent, Belgium) at the Leiden 
University Medical Center (LUMC). Based on previous PCR test results, a variety of 21 positive and 
four negative respiratory virus samples with a wide range of quantification cycle (Cq) values were 
included. The sample types represented routine diagnostic samples from paediatric patients that had 
been sent to our laboratory: 19 nasopharyngeal washings , two sputa, two broncho-alveolar lavages 
(BAL), one bronchial washing and one throat swab (in viral transport medium). The patient selection 
(age range 1.2 months – 15 years) represented the paediatric population with respiratory diagnostics 
in our university hospital in terms of (underlying) illness. 
 
Sample pre-treatment 
Total nucleid acids (NA) were extracted directly from 200 µL of clinical material using the MagNAPure 




Clinical material was spiked with equine arteritis virus (EAV) and phocine herpesvirus 1 (PhHV1, kindly 
provided by prof. dr. H.G.M. Niesters, UMC Groningen, the Netherlands), as internal controls for RNA 
detection17 and DNA detection respectively18. To determine the optimal concentration of the internal 
controls a ten-fold dilution series of PhHV1/EAV was added to a mix of two pooled influenza A 
positive throat swabs (Cq value 25) and read count and Cq values were compared. Concentration was 
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Quality control 
Before sequencing the DNA input concentration was measured with the Qubit (ThermoFisher 
Scientific, Waltham, USA), to determine whether there was sufficient DNA in the sample to obtain 
sequencing results. The range of DNA input for library preparation was 0.5 ng/µl for throat swabs 
(see reproducibility experiment) up to 300 ng/µl for bronchoalveolar lavages and sputa. 
 
Fragmentation 
To compare the effect of different DNA fragmentation techniques, six PCR positive (containing one 
to three viruses) and three PCR negative samples were 1) chemically fragmented using zinc (10 min.) 
as part of the NEB (New England Biolabs) Library Prep Kit protocol as described below (see library 
preparation) and 2) physically fragmented using sonication with the Bioruptor® pico (Diagenode, 
Seraing, Belgium, on/off time: 18/30s, 5 cycli)19. Three samples were also tested with the 3) high 
intensity settings of the Bioruptor® pico (on/off time: 30/40s, 14 cycli). 
 
Library preparation 
Libraries were constructed with 7µL extracted nucleic acids using the NEBNext® Ultra™ 
Directional RNA Library Prep Kit for Illumina® ( New England Biolabs, IpsWich, USA) using single, 
unique adaptors. This kit has been developed for transcriptome analyses. We made several 
adaptations to the manufacturers protocol in order to enable simultaneous detection of both DNA 
and RNA viruses: the following steps were omitted: Poly A mRNA capture isolation (Instruction 
manual NEB #E7420S/L, version 8.0, Chapter 1), rRNA depletion and DNase step (Chapter 2.1-2.4, 
2.5B, 2.11A). 
The size of fragments in the library was 300-700 bp. Adaptors were diluted 30 fold given the low 
RNA/DNA input and 21 PCR cycli were run post-adaptor ligation. 
 
Nucleotide Sequence Analysis 
Sequencing was performed on Illumina HiSeq 4000 and NextSeq 500 sequencing systems (Illumina, 
San Diego, CA, USA), obtaining 10 million 150 bp paired-end reads per sample. 
 
Detection limit 
To determine the detection limit of mNGS, serial dilutions (undiluted, 10-1, 10-2, 10-3, 10-4) of an 
influenza A positive sample was tested with both mNGS and lab developed real-time PCR . Based on 
run-off transcript experiments the typical limit of detection of our real-time RNA PCRs was estimated 




Repeatability (within run precision) 
To estimate the reproducibility of metagenomic sequencing an influenza A positive clinical sample 
(throat swab) was divided into four aliquots, nucleic acids were extracted, library preparation and 
subsequent sequence analysis on the Illumina HiSeq 4000 was performed in one run. 
 
Bioinformatics: taxonomic classification 
All FASTQ files were processed using the BIOPET Gears pipeline version 0.9.0 developed at the 
LUMC (http://biopet-docs.readthedocs.io/en/stable/ accessed 9-12-2018). This pipeline performs 
FASTQ pre-processing (including quality control, quality trimming and adapter clipping) and 
taxonomic classification of sequencing reads. In this project, FastQC version 0.11.2 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ accessed 9-12-2018) was used for 
checking the quality of the raw reads. Low quality read trimming was done using Sickle20 version 
1.33 with default settings. Adapter clipping was performed using Cutadapt21 version 1.10 with 
default settings. Taxonomic classification of reads was performed with Centrifuge22 version 1.0.1-
beta. The pre-built NT index, which contains all sequences from NCBI’s nucleotide database, 
provided by the Centrifuge developers was used 
(ftp://ftp.ccb.jhu.edu/pub/infphilo/centrifuge/data/old-indices accessed 16-11-2017) as the 










































In addition, a customized reference centrifuge index with sequence information obtained from the 
NCBI’s RefSeq23 (accessed February 2019) database was built. RefSeq genomic sequences for the 
domains of bacteria, viruses, archaea, fungi, protozoa, as well as the human reference, along with 
the taxonomy identifiers, were downloaded with the Centrifuge-download utility and were used as 
input for Centrifuge-build. 
Centrifuge settings were evaluated to increase the sensitivity and specificity. The default setting, with 
which a read can be assigned to up to five different taxonomic categories, was compared to one 
unique assignment per read22 where a read is assigned to a single taxonomic category, corresponding 
to the lowest common ancestor of all matching species. 
Kraken-style reports with taxonomical information were produced by the Centrifuge-kreport utility 
for all (default) options. Both unique and non-unique assignments can be reported, and these settings 
were compared. The resulting tree-like structured, Kraken-style reports were visualized with Krona24 
version 2.0. 
Horizontal coverage (%) was determined using GenomeDetective website25 version 1.111 
(https://www.genomedetective.com/, accessed 5-4- 2019). 
In silico simulated EAV reads were analysed in different databases (NCBI’s nucleotide vs RefSeq), 
classification algorithms (max 5 labels per sequence, vs unique, lowest(common ancestor) and 
reporting (non-unique vs unique) to determine the most sensitive an specific bioinformatic analyses 
using Centrifuge. 
To determine the amount of reads needed, results of one and 10 million reads were compared. A 
total of one million reads were randomly selected of the 10 million reads of one FASTQ file and  
analysed. The random selection was performed with the FastqSplitter 
(https://github.com/biopet/biopet/blob/v0.9.0/docs/tools/FastqSplitter.md accessed 9-12-2018), 
which cuts a FASTQ file of 10 million reads is into 10 pieces, of which one was selected. Read counts 
were normalized by the total read count and target virus genome size. 
 
Bioinformatics: assembly of PhHV1 sequences 
Since NCBI’s databases were lacking a complete PhHV1 genome sequence, PhHV1 was sequenced 
and based on the gained sequence reads the genome was build using SPAdes26. Assembly of PhHV1 
was done using the biowdl virus-assembly pipeline 0.1 (https://github.com/biowdl/virus-assembly 
accessed 9-12-2018). The QC part of the biowdl pipeline determines which adapters need to be 
 clipped by using FastQC version 0.11.7 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ accessed 9-12-2018) and cutadapt 
version 1.1621, with minimum length setting “1’’. The resulting reads were downsampled within 
bowdl to 250 000 reads using seqtk 1.2 (https://github.com/lh3/seqtk accessed 9-12-2018) after 
which SPADES version 3.11.126 was run to get the first proposed genome contigs. 
To retrieve longer assembly contigs a reiterative assembly approach was used by processing the 
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contigs of a previous assembly, then selects the aligned reads, downsamples them and runs a new 
assembly using SPADES. Subtools used for this consisted of BWA 0.7.1727 for indexing and mapping, 
SAMtools 1.628 for creating bam files, SAMtools view (version 1.7) for filtering out unmapped reads 
using the setting “-G 12”, Picard SamToFastq (version 2.18.4) and seqtk for creating FASTQ files with 
250 000 reads. The contigs from the reAssembly pipeline were then processed for a second using 
SPADES, with setting the ‘cov-cutoff’ to 5. The resulting contigs were then processed with the 
reAssembly pipeline for the third and last time setting the ‘cov-cutoff’ in SPADES to 20. 
The contigs from the last reAssembly step were then run against the blast NT database using blastn 
2.7.129 Out of 23 contigs only 5 contigs, that showed the lowest % in identity matches with any other 
possible non herpes virus species, were selected. The final 5 contigs contained sequence lengths of 
97893, 8170 3710, 3294 and1279 nucleotides, the average coverage was 206, 131, 211, 285 and 154, 
respectively. The proposed almost complete genome of PhHV1 was added to NCBI’s GenBank 
database (https://www.ncbi.nlm.nih.gov/genbank/, accession number GenBank MH509440, release 
date 4 Dec 2018). 
 
Retrospective validation 
Clinical sensitivity was analysed using the optimized procedure, which in short consisted of total NA 
extraction including internal controls (1:100 dilution),the adapted NEB Next library preparation 
protocol including fragmentation with zinc, for combined RNA and DNA detection (see library 
preparation), and sequencing of 10 million reads(Illumina NextSeq 500). Bioinformatic analyses was 
performed using Centrifuge with NCBI’s RefSeq database and unique assignment of the sequence 
reads. 
Sensitivity and specificity of the metagenomic NGS procedure was compared to a published updated 
version of our lab developed multiplex qPCR30. The routine multiplex PCR panel consisted of 15 
respiratory target pathogens: influenza virus A/ B, respiratory syncytial virus (RSV), metapneumovirus 
(MPV), adenovirus (ADV), human bocavirus (HBoV), parainfluenza viruses (PIV) 1/ 2/ 3/ 4, rhinovirus 
(RV), and the coronaviruses HKU1, NL63, 227E and OC43. Thus, in total 375 PCR results were available 
(15 targets x 25 samples) of which 29 PCR positive and 346 PCR negative for comparison with mNGS. 
 
Ethical approval of patient studies 
The study design was approved by the medical ethics review committee of the Leiden University 







Serial dilutions of EAV and PhHV1 were added to an influenza A PCR positive sample. Serial dilution 
1:10,000 detected EAV with a substantial read count in the presence of a viral infection and without 
a significant decline in target virus family reads (Table 1). Based on these results we determined the 
concentration of internal controls for further experiments. 




The comparison of fragmentation methods was done using a selection of samples with relevant 
target reads and performed on the Illumina Nextseq 500 As shown in Figure 2, the total reads were 
comparable among the three protocols. The protocol with Zinc fragmentation had higher yield in 
target virus reads for all RNA viruses tested and adenovirus. 
 
Table 1. Internal controls EAV/PhHV-1: serial dilutions against a clinical sample background and 
















Centrifuge  Centrifuge  Centrifuge 
1:100 24.52 21.59 23.52 4438 (3.6)  12925 (4.1)  347 (2.5) 
1:1,000 24.67 24.91 26.83 3742 (3.6)  1202 (3.1)  49 (1.7) 
1:10,000 24.76 28.45 30.33 4628 (3.7)  95 (2.0)  14 (1.1) 
1:100,000 24.79 30.85 32.55 4093 (3.6)  18 (1.3)  14 (1.1) 
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Figure 2. Comparison of fragmentation methods on target reads (species level, log scale). 
*Not tested with Bioruptor setting high intensity. 
PIV parainfluenza, NL63: coronavirus NL63, ADV: adenovirus, INFC: influenza C , hBoV: human bocavirus, RSV: 
respiratory syncytial virus 
 
Detection limit 
The detection threshold of our NGS limit, deduced from serial dilutions of influenza A (Figure 3) and 






















Figure 3. Serial dilutions of an influenza A positive clinical sample. 
 
Repeatability: within run precision 
The mNGS results of an influenza A positive sample tested in quadruple could be reproduced with 
only minor differences (table 1): coefficient of variation of 1.1%: 0.04 log SD/ 3.6 log average. 
 
Bioinformatics: taxonomic classification 
The Centrifuge default settings, with NCBI’s nucleotide database and assignment of sequence reads 
to a maximum 5 labels per sequence, resulted in various spurious classifications (Figure 4), for 
example Lassa virus (Figure 5), evidently highly unlikely to be present in patient samples from the 
Netherlands with respiratory complaints. The specificity could be increased by using NCBI’s RefSeq 
database instead of NCBI’s nucleotide database. The classification was further improved by changing 
the Centrifuge tool settings to limit the assignment of homologous reads to the lowest common 
ancestor (maximum 1 label per sequence). 
The Centrifuge reporting of shared sequences between different organisms/ subtypes differs 
dependent of the classification and reporting algorithm. The default classification will assign a shared 
read to a maximum of 5 organisms (one read will be assigned 5 times) and with the lowest common 
ancestor classification setting this read will only be assigned once, namely to the lowest ancestor 
these organisms/ subtypes have in common. Classification with maximum 5 labels per read resulted 
in two different outcomes using the report with all mappings and the report with unique mappings, 
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Comparison of classification using these different settings shows the highest sensitivity and specificity 
using NCBI’s RefSeq database with one label (lowest common ancestor) assignment, both with in 
silico prepared datasets containing solely EAV sequence fragments (Figure 4) and with clinical 
datasets (with highly abundant background) (Figure 5). 
To determine the effect of the total number of sequencing reads obtained per sample on sensitivity, 
one million and 10 million total reads were compared by in silico analysis (Table 2). One million total 
reads resulted in an approximate tenfold decrease in target virus read count as compared to 10 







































































































































































































































































































































































































































































































































































































































































































































































Clinical sensitivity based on PCR target pathogens 
Clinical sensitivity was analysed using the optimized mNGS procedure. The sample collection 
consisted of 21 clinical specimens positive for at least one of the following PCR target viruses: 
rhinovirus, influenza A&B, parainfluenza 1 &4 (PIV), metapneumovirus, respiratory syncytial virus, 
coronaviruses NL63 and HKU1 (CoV), human bocavirus (hBoV), and adenovirus (ADV). Fourteen 
samples were positive for one virus, six samples for two and one sample for three viruses with the 
lab-developed respiratory multiplex qPCR. Cq values ranged from Cq 17 to Cq 35, with a median of 
23. 
With mNGS 24 of the 29 viruses demonstrated in routine diagnostics were detected (Table 3), 
resulting in a sensitivity of 83% for PCR targets. If a cut-off of 15 reads was handled, sensitivity 
declined to 66% (19/29) (Table 4). A Receiver-operating Characteristic (ROC) curve for mNGS 
detection of PCR target viruses, depending on the cut-off level of the number of mapped sequence 
reads for defining a positive result, is shown in Figure 6. 
mNGS target read count (log value) showed a correlation (Pearson correlation coefficient -0.582, 
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Table 4. Sensitivity and specificity of the mNGS protocol tested, based on PCR target viruses, with 
different sequence read cut-off levels for defining a positive result. 




Sensitivity 83 (24/29) 66 (19/29) 62 (18/29) 




Figure 6. Receiver-operating characteristic (ROC) curve for mNGS detection of PCR target viruses 




Figure 7. Semi-quantification of the mNGS assay for target virus detection in clinical samples with 
qPCR confirmed human respiratory viruses. 
 
Detection of additional viral pathogens by mNGS: off-PCR target viruses 
Next to the viral pathogens tested by PCR, mNGS also detected other pathogenic viruses, indicating 
additional viral sequences uncovered by mNGS but not included in the routine diagnostics, with 
influenza C virus being the most prominent. A high amount,2221 reads (99% horizontal coverage), of 
influenza virus C reads (58% of all viral reads and 0.02 of the total reads) was found in one sample, 
confirmatory PCR was not routinely available. Other potential respiratory pathogens detected by 
mNGS and not included in PCR analysis were KI polyomavirus (2 samples: 262 and 46 reads 
respectively, retrospective in-house PCR Cq 25 (1:10 dilution) and 26 respectively), cytomegalovirus 
(human betaherpesvirus 5) (55 and 3 reads, retrospective in-house PCR Cq 22 and 27 respectively) 
and enterovirus (10073 reads, retrospective in-house PCR rhinovirus/ enterovirus Cq 18). All of these 
viruses are not included routinely in the diagnostic multiplex qPCRs. 
 
Internal controls 
The spiked-in internal controls were detected by mNGS in all samples. EAV sequence reads ranged 
from 14 - 19894 (median 362) and PhHV1 ranged from 41 - 1206 (median 121). 
 
Analytical specificity based on PCR target viruses 
In total 25 paediatric respiratory samples were available to evaluate the analytical specificity of 
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RSV, HMPV, ADV, HBoV, PIV1/2/3/4, RV, HKU1, NL63, 227E, OC43) and 21 samples were negative for 
12-14 of these PCR target pathogens. 
Out of in total 346 negative target PCR results of these 25 samples, 325 results corresponded with 
the finding of 0 target specific reads by mNGS. If a cut-off of 15 reads was used 345 of the 346 
negative PCR targets were negative with mNGS. The sample positive by mNGS and negative by PCR 
was human parainfluenzavirus 3 (18 reads). Though no conclusive proof for neither true or false 
positive mNGS results could be found, specificity of mNGS was 94% (325/346) when encountering all 
reads and ≥99% (345/346) with a 15 reads cut-off (Table 4, ROC curve in Figure 6). 
 
Antiviral susceptibility 
Additional to subtyping (Table 3), using the metagenomic sequence data we analysed the nucleotide 
positions that conferred resistance to either oseltamivir or zanamivir. Sequence data of amino acids 
I117, E119, D198, I222, H274, R292, N294 and I314 showed susceptibility to oseltamivir and V116, 
R118, E119, Q136, D151, R152, R224, E276, R292 and R371 revealed susceptibility to zanamivir31,32.  
 
Data access 
The raw sequence data of the samples, after removal of human reads have been deposited to 




Metagenomic sequencing has not yet been implemented as routine tool in clinical diagnostics of viral 
infections. Such application would require the careful definition and validation of several parameters 
to enable the accurate assessment of a clinical sample with regard to the presence or absence of a 
pathogen, in order to fulfil current accreditation guidelines. For this purpose, this study has initiated 
the optimization of several steps throughout the pre- and post-sequencing workflow, which are 
considered essential for sensitive and specific mNGS based virus detection. Many virus discovery or 
virus diagnostic protocols have focussed on the enrichment of viral particles33 with the intention to 
increase the relative amount of virus reads. However, these methods are laborious and intrinsically 
exclude viral nucleic acid located in host cells. Here, a sample pre-treatment protocol was designed 
with potential for: 1) automation, 2) pan-pathogen detection and 3) detection of intracellular viral 
nucleic acids. Consequently, any type of viral enrichment was excluded (filtration, centrifugation, 
nucleases, rRNA removal). The current protocol enabled high throughput sample pre-treatment by 
means of automated NA extraction and without depletion of bacterial nor human genome, with 
potential for pan-pathogen detection. Several adaptations in the bioinformatic script resulted in 
more accurate reporting of the classification output. 
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Addition of an internal control to a PCR reaction is commonly used for quality control in qPCR34. While 
the addition of internal controls in mNGS is not yet an accepted standard procedure, we employed 
EAV and PhHV1 as an RNA and DNA control, respectively, to monitor the workflow in this diagnostic 
application. The amount of internal control reads and target virus reads have been reported to be 
dependent of the amount of background reads (negative correlation)35. In our protocol, the internal 
controls were used as qualitative controls but may be used as indicator of the amount of background. 
PhHV1 showed less linearity in the dilution series, as compared to EAV, which may be indicative for 
a potential relative difference in efficiency of amplification of PhHV1 viral sequences. Since NCBI’s 
databases were lacking a complete PhHV1 genome, the Centrifuge index building and classification 
was limited to classification on a higher taxonomic rank. In order to achieve classification of PhHV1 
at species level, the whole genome of PhHV1 was sequenced, and based on the gained sequence 
reads the genome was built26. The proposed nearly complete genome of PhHV1 was submitted to 
NCBI’s GenBank database. 
Sensitivity of the mNGS protocol was maximum 83% based on PCR target viruses and depended on 
the cut-off level of reads for defining a positive result. Five viruses, that were not recovered by mNGS 
had high Cq values, over 30, i.e. a relatively low viral load. This may be a drawback of the retrospective 
nature of this clinical evaluation as RNA viruses may be degraded due to storage and freeze-thaw 
steps, resulting in lower sensitivity of mNGS. A correlation was found between read counts and PCR 
Cq value, demonstrating the quantitative nature of viral detection by mNGS. Discrepancies between 
the Cq values and the number of mNGS reads may be explained by 1) unrepresentative Cq values, 
e.g. by primer mismatch for highly divergent viruses like rhino/enteroviruses and 2) differences in 
sensitivity of mNGS for several groups of viruses, as has been reported by others36. Additionally, viral 
pathogens were detected that were not targeted by the routine PCR assays, including influenza C 
virus, which is typical of the unbiased nature of the method. In addition, though not within the scope 
of this study, bacterial pathogens, including Bordetella pertussis (qPCR confirmed), were also 
detected. In the current study only viruses were targeted since these could be well compared to qPCR 
results, bacterial targets remain to be studied in clinical sample types as sputum or broncheo-alveolar 
lavages that are more suitable for bacterial detection. The analytical specificity of mNGS appeared to 
be high, especially with a cut-off of 15 reads. However, the clinical specificity, the relevance of the 
lower read numbers, still needs further investigation in clinical studies. 
Sequencing using Illumina HiSeq 4000 with single, unique indexes resulted in rhinovirus-C sequences 
(55-909 reads) in all samples run on one lane, which appeared to be identical sequences. Retesting 
of the samples with Illumina Nextseq 500 resulted in disappearance of these reads. This problem 
could be attributed to ‘index hopping’ (index misassignment) as described earlier37. Due to the 
chemistry, essential for the increased speed, the HiSeq 4000 is more prone to index hopping between 
neighbouring samples. Although the percentage of reads which contributed to the index hopping was 
very low, this is critical for clinical viral diagnostics, as this is aimed specifically at low abundance 
targets37,38. 
Bioinformatics classification of metagenomic sequence data with the pipeline Centrifuge required 
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Default settings of this pipeline resulted in higher rates of both false positive and false negative 
results. NCBI’s nucleotide database includes a wide variety of unannotated viral sequences, such as 
partial sequences and (chimeric) constructs, in contrast to the curated and well-annotated sequences 
in NCBI’s Refseq database, which resulted in a higher specificity. In addition to the database, settings 
for the assignment algorithm were adapted as well. The assignment settings were adjusted to unique 
assignment in the case of homology to the lowest common ancestor. This modification resulted in 
higher sensitivity and specificity than the default settings, however the ability to further subtyping 
diminished. This is likely to be attributed to the limited representation/availability of strain types 
within NCBI’s RefSeq database. In consequence, this leads to a more accurate estimation of the 
common ancestor for particular viruses, but limited typing results in case of highly variable ones. To 
obtain optimal typing results, additional annotated sequences may be added or a new database 
should be built, with a high variety of well-defined and frequently updated virus strain types. 
To conclude, this study contributes to the increasing evidence that metagenomic NGS can effectively 
be used for a wide variety of diagnostic assays in virology, such as unbiased virus detection, resistance 
mutations, virulence markers, and epidemiology, as shown by the ability to detect SNPs in influenza 
virus. 
These findings support the feasibility of moving this promising field forward to a role in the routine 
detection of pathogens by the use of mNGS. Further optimization should include the parallel 
evaluation of adult samples, the inclusion of additional annotated strain sequences to the database, 
and further elaboration of the classification algorithm and reporting for clinical diagnostics. The 
importance of both negative non-template control samples39 and healthy control cases may support 
the critical discrimination of contaminants and viral ‘colonization’ from clinically relevant pathogens. 
 
Conclusions 
Optimal sample preparation and bioinformatics analysis are essential for sensitive and specific mNGS 
based virus detection. 
Using a high-throughput genome extraction method without viral enrichment, both RNA and DNA 
viruses could be detected with a sensitivity comparable to PCR. 
Using mNGS, all potential pathogens can be detected in one single test, while simultaneously 
obtaining additional detailed information on detected viruses. Interpretation of clinical relevance is 
an important issue but essentially not different from the use of PCR based assays and supported by 
the available information on typing and relative quantities. These findings support the feasibility of a 
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Introduction: Exacerbations are major contributors to morbidity and mortality in patients with 
chronic obstructive pulmonary disease (COPD), and respiratory bacterial and viral infections are an 
important trigger. However, using conventional diagnostic techniques, a causative agent is not 
always found. Metagenomic next-generation sequencing (mNGS) allows analysis of the complete 
virome, but has not yet been applied in COPD exacerbations. 
Objectives: To study the respiratory virome in nasopharyngeal samples during COPD exacerbations 
using mNGS. 
Study design: 88 nasopharyngeal swabs from 63 patients from the Bergen COPD Exacerbation Study 
(2006-2010) were analysed by mNGS and in-house qPCR for respiratory viruses. Both DNA and RNA 
were sequenced simultaneously using an Illumina library preparation protocol with in-house 
adaptations. 
Results: By mNGS, 24/88 samples tested positive. Sensitivity and specificity, as compared with PCR, 
were 96% and 98% for diagnostic targets (23/24 and 1093/1120, respectively). Additional viral 
pathogens detected by mNGS were herpes simplex virus type 1 and coronavirus OC43. A positive 
correlation was found between Cq value and mNGS viral normalized species reads (log value) 
(p=0.002). Patients with viral pathogens had lower percentages of bacteriophages (p<0.001). No 
correlation was found between viral reads and clinical markers. 
Conclusions: The mNGS protocol used was highly sensitive and specific for semi-quantitative 
detection of respiratory viruses. Excellent negative predictive value implicates the power of mNGS to 
exclude any pathogenic respiratory viral infectious cause in one test, with consequences for clinical 
decision making. Reduced abundance of bacteriophages in COPD patients with viral pathogens 
implicates skewing of the virome during infection, with potential consequences for the bacterial 
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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is characterized by exacerbations with high morbidity 
and mortality, and over 65 million patients suffer from this disease worldwide1. A COPD exacerbation 
is an acute event leading to worsening of the respiratory symptoms and is associated with a 
deterioration of lung function2. Exacerbations are mainly associated with infections, of which a large 
part is caused by viruses (22-64%)3-6. However, in part of the exacerbations an etiologic agent is not 
detected. 
Current routine virus diagnostics is based on polymerase chain reactions (PCR) and inherently the 
number of detectable pathogens is restricted to the ones included in the assay. Rare, mutated and 
pathogens with an uncommon clinical presentation will be missed, along with new and currently 
unknown ones. Over the last decades, several previously unidentified viruses have been discovered 
as respiratory pathogens, including metapneumovirus7, middle-east respiratory syndrome 
coronavirus8 and human bocavirus9. 
Metagenomic next-generation sequencing (mNGS) is an innovative method, which enables the 
detection of all genomes in a given sample. Proof of principle studies have shown that mNGS on 
respiratory samples can confirm and extend PCR results and deliver typing and resistance data at the 
same time10-14. The performance of mNGS in the clinical diagnostic setting, especially the positive 
and negative predictive value, has not yet been elucidated and is likely to differ per clinical syndrome 
and sample. 
Previous data from reports on 16S rRNA analysis from the respiratory tract have led to increased 
insight in the microbiome in patients with COPD15. Changes in bacterial populations have been 
associated with exacerbation events and clinical phenotypes15. However, these studies are 
intrinsically limited to analysis of the bacterial part of the microbiome. 
So far only a few studies using shotgun metagenomics have focussed on the respiratory virome in 
children with acute respiratory infections16,17. In this study, we analyse the composition of the virome 
in adult patients with exacerbations of COPD. 
 
Objectives 
The aim of this study was to correlate the respiratory virome in COPD patients as found by mNGS 
with qPCR and clinical data. 
 
MATERIALS AND METHODS 
Patients 
Patients with COPD were included in the Bergen COPD exacerbation study (BCES) between 2006 and 
2010 in Bergen, Norway18. All patients lived in the Haukeland University Hospital district. Baseline 
data taken during the first visit while in the stable state included amongst others exacerbation 
history, medications, comorbidities, spirometry and Global Initiative for Chronic Obstructive Lung 
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Disease (GOLD 2007) categorisation. Patients were given a telephone number to a study nurse, whom 
they would contact in case of an exacerbation. Patients with an exacerbation according to a 
predefined set of symptoms were scheduled for an appointment with a study physician the next 
working day. During exacerbations, nasopharynx swabs were sampled and two different markers for 
the severity of the exacerbation were scored. After an exacerbation a control visit was scheduled. 
During the study period 154 patients had at least one exacerbation and in total 325 exacerbations 
were included in BCES, of which 88 exacerbation samples were tested in the current study. 
 
Sample selection 
Nasopharyngeal samples were frozen and stored at -80°C. In total 88 nasopharyngeal samples of 
patients at the time of exacerbation were selected based on the availability of other samples (outside 
the current focus) and sent to the Leiden University Medical Center (The Netherlands) for further 
testing. 
 
Lab-developed real-time PCR testing (qPCR) 
The viral respiratory panel covered by the multiplex real-time PCR (qPCR) developed in our laboratory 
consists of coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, influenza A, 
influenza B, human metapneumovirus, parainfluenza 1-4 (differentiation with probes), respiratory 
syncytial virus, and rhinovirus19. 
Total nucleic acids (NA) were extracted directly from 200 µl clinical sample, using the Total Nucleic 
Acid extraction kit on the MagnaPure LC system (Roche Diagnostics, Almere, the Netherlands) with 
100 µL output eluate. Nucleic acid amplification and detection by real-time PCR was performed on a 
BioRad CFX96 thermocycler, using primers, probes and conditions as described previously19. Cq 
values were normalized using a fixed baseline fluorescence threshold. 
 
Metagenomic next-generation sequencing (mNGS) 
The metagenomics protocol used has been described and optimized for simultaneously RNA and DNA 
detection previously14. In short, internal controls, Equine Arteritis virus (EAV) for RNA and Phocid 
Herpesvirus-1 (PhHV) for DNA (kindly provided by prof. dr. H.G.M. Niesters, the Netherlands), were 
spiked in 200 µl of the virus transport medium in which the nasopharyngeal swab was stored. Nucleic 
acids were extracted directly from 200 µl clinical sample using the Magnapure 96 DNA and Viral NA 
Small volume extraction kit on the MagnaPure 96 system (Roche Diagnostics, Almere, The 
Netherlands) with 100 µL output eluate (an updated version of the isolation method used for qPCR, 
tested previously 14). Extraction buffer was used as negative control (for extraction, library 
preparation, and sequencing). For library preparation, 7 µl of nucleic acids were used, using the 
NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina®, with several in-house adaptations to 
the manufacturers protocol in order to enable simultaneous detection of both DNA and RNA. The 
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step. This resulted in a single tube per sample throughout library preparation containing both DNA 
and RNA. Metagenomic sequencing was performed on an Illumina NextSeq 500 sequencing system 
(Illumina, San Diego, CA, USA), and approximately 10 million 150 bp paired-end reads per sample 
were obtained. 
After quality pre-processing, sequencing reads were taxonomically classified with Centrifuge20 using 
an index constructed from NCBI’s RefSeq and taxonomy databases (accessed February 2019) with 
reference nucleotide sequences for the viruses, bacteria, archaea, fungi, parasites, and protozoa. 
Reads with multiple best matches were uniquely assigned to the lowest common ancestor (k=1 
Centrifuge setting; previously validated14). Both negative and positive results were confirmed using 
GenomeDetective website21 version 1.111 (accessed December 2018 - January 2019) and horizontal 
coverage (%) was determined using GenomeDetective. 
Read counts were normalized, dividing the raw read count by the total number of reads in the sample 
and by the (average) genome size, and multiplied by 10^11 (to achieve comprehensible read counts 
in the same order of magnitude as the raw read counts). 
 
Virus assembly 
For samples with dubious or inconclusive classification results a de novo assembly was performed. 
Pre-processed short reads assigned to a higher taxonomic level of a suspected viral target were 
extracted and de novo assembled with SPAdes version 3.11.122 into longer stretches of contiguous 
sequences (contigs). The resulting contigs were then run against the blast NCBI’s nucleotide (nt) 
database (accessed 2017) using blastn 2.7.123. After identification of a putative target sequence, all 
the reads from the original sample were mapped against the identified best BLAST hit for further 
confirmation using BWA 0.7.17 software package24. 
 
Statistical analysis 
Sensitivity, specificity, positive and negative predictive values were calculated based on 24 PCR 
positive and 1120 PCR negative target results of 88 samples. 
Correlation between qPCR Cq value and logarithm of normalized numbers of mNGS viral reads was 
tested with population Pearson correlation coefficient. 
Potential correlations of mNGS data with clinical variables were tested as follows. Cq value/ viral 
reads and clinical parameters (exacerbation severity, duration of exacerbation or decrease/increase 
in Forced Expiratory Volume in 1 second (FEV1, control visit compared to baseline) were tested with 
one-way ANOVA and Kruskal-Wallis test when appropriate (depending on distribution). Comparison 
of the percentage of phages of all viral reads (after subtraction of the internal control EAV and PhHV 
reads) between mNGS virus positive samples and negative samples was tested with Mann-Whitney 
U test, comparison with clinical parameters with Kruskal-Wallis test. Diversity of the virome in 
different patient groups was characterized by Shannon Diversity Index (H) and tested with Welch two 
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sample t-test. Statistical analyses were performed using IBM SPSS Statistics version 25 software for 
Windows <0.05 were considered statistically significant. 
 
Ethical approval 
Prior to inclusion all subjects received written and oral information and signed informed consent. The 
BCES study was approved by the regional ethical committee in Western Norway (REK-Vest, case- 
number 165.08). The performance of this study, including mNGS, was approved by the medical ethics 
review committee of the Leiden University Medical Center (CME number B16.004); no additional 
consent was necessary. 
 
RESULTS 
Patients and samples 
In total 63 patients with 88 exacerbations were included with a median of one exacerbation per 
patient (range 1-5). Baseline patient characteristics and exacerbation characteristics are shown in 
tables 1 and 2 respectively. 
 
Table 1. Baseline patient characteristics 
 Patients (n=63) 
Age median years (range) 63.5 (46.6-74.5) 
Male sex 40 (64%) 
BMI median, kg/m2 (range) 25 (15-39) 
Body composition  
Cachectic 7 (11%) 
Normal 24 (38%) 
Overweight 22 (35%) 
Obese 10 (16%) 
Smoking  
Never 0 (0%) 
Sometimes 37 (59%) 
Daily 26 (41%) 
GOLD stage  
II (FEV1 50-80%) 29 (46%) 
III (FEV1 30-50%) 27 (43%) 
IV (FEV1 <30%) 7 (11%) 
FEV1 in % median (range) 0.49 (0.23-0.74) 
>1 exacerbation past 12 months 16 (25%) 
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Table 2. COPD patient and exacerbation characteristics among patients having a viral or non-viral 
exacerbation. 
 qPCR target virus  
detected not detected 
 
 
n=23 n=65 P* 
Patient characteristics 




Women 34.5 65.5 
 
Men 22.0 78.0 
 
smoking status, % 
  
0.53 
Ex-smoker 23.4 76.6 
 
Current-smoker 29..3 70.7 
 
GOLD stage (2007), % 
  
0.35 
II (FEV1 50-80%) 26.3 73.7 
 
III (FEV1 30-50%) 30.8 69.2 
 
IV (FEV1 < 30%) 9.1 90.9 
 
Frequent exacerbator, % 
  
0.72 
No 25.0 75.0 
 
Yes 28.6 71.4 
 
Using inhalation steroids, % 
  
0.55 
No 20.0 80.0 
 
Yes 27.4 72.6 
 
Age, mean yrs 63.7 64.9 0.10 
BMI, mean kg/m2 27.0 25.9 0.92 
FEV1 in % predicted 49.3 47.5 0.48 
Exacerbation characteristics 
   
Exacerbation severity for entire exacerbation 
  
0.75 
Mild (not requiring AB or oral steroids or hospitalization) 14.3 85.7 
 
Moderate (requiring AB or oral steroids) 26.9 73.1 
 
Severe (Emergency room or hospital admission) 28.6 71.4 
 
Self-reported exacerbation severity at time of study sampling 
  
0.64 
Dyspnea unchanged or increased on errands outside home 36.4 63.6 
 
Increased dyspnea doing housework 26.5 73.5 
 
Increased dyspnea at rest 28.6 71.4 
 
Must sit up at night due to dyspnea 14.3 85.7 
 
CRP (ng/mL) at time of study sampling† 32.5 34.2 0.27 
* Pearson’s chi-square test for categorical variables and t-test for continuous variables 




Lab developed real-time PCR 
Of the 88 samples, 23 (26%) tested positive with in-house PCR: 14 (61%) were rhinovirus positive, 
three influenza A, two coronavirus NL63, one coronavirus OC43, two parainfluenza 3 and one 
parainfluenza 4. Cq values ranged from 19-38 (Table 3). 
 
Table 3. qPCR positive samples with respective mNGS results 










All targets 23/88 (26) 19-38 23/88 (26) 0-1,317,490 3-100 
Influenza A 3/23 (13) 29-36 3/23 (13) 9-559 3-98 
Cov NL63 2/23 (9) 32 2/23 (9) 1,347-127,284 93-100 
Cov OC43 1/23 (4) 27 2*/23 (4) 72,644-1,317,490 99-99 
PIV3 2/23 (9) 26-36 2/23 (9) 59-288,877 14-99 
PIV4 1/23 (4) 24 1/23 (4) 185,235 100-100 
Rhinovirus 14/23 (61) 19-38 13**/23 (57) 
RV-A:     6/13 
RV-B:     2/13 









*Retesting by qPCR confirmed the OC43 finding of mNGS 
** Rhinovirus not detected with mNGS had PCR Cq value 38 
 
Metagenomic next-generation sequencing 
A median of 11 million (7,522,643-20,906,019) sequence reads per sample were obtained. Of the 11 
million reads, approximately 93% were Homo sapiens reads, 3 % were bacterial and 0.1% viral (Table 
4). A median of 3% of the reads could not be assigned to sequences in the Centrifuge index database 
(NCBI RefSeq). 
 
Table 4. mNGS read counts 
 Median Min Max 
Total reads 10,764,981 7,522,643 20,906,019 
% unassigned reads 3 0.7 22 
Homo sapiens reads(% total) 9,470,904 (93) 2,491,763 18,646,521 
Bacterial reads (% total) 285,567 (3) 6,289 10,490,131 
Viral reads (% total) 15,679 (0.1) 803 1,553,567 
PhHV reads (% viral) 3,289 (22) 299 26,623 
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Comparison of mNGS to qPCR 
Of the 23 qPCR positive samples, 22 tested positive with mNGS, resulting in a sensitivity of mNGS of 
96%. Only one sample, that was rhinovirus positive by qPCR (Cq 38), could not be detected by mNGS 
(Table 3). Coverage of reference genomes was high (93-100%) with the exception of three samples: 
30% coverage of rhinovirus C (1,401,120 mapped reads, 88,353-fold depth), 14% coverage of 
parainfluenza 3 (50 mapped reads, 3-fold depth), and 3% coverage of influenza A virus (single genome 
segment, 8 mapped reads). Aligning reads with Bowtie confirmed the rhinovirus C and parainfluenza 
3 mapping, but not the influenza A mapping. Additional viral pathogens detected by mNGS were 
herpes simplex virus type 1 (17,031 reads, 82% coverage, 36-fold depth) which was not in qPCR viral 
respiratory panel (retrospectively confirmed by means of in-house HSV PCR; Cq 24), in the sample 
with the 8 influenza virus reads, and a betacoronavirus. Since coronaviruses tested negative by means 
of qPCR, and the mNGS classification was inconclusive , the reads were de novo assembled. Of these 
83,252 betacoronavirus reads, de novo assembly resulted in 3 contigs (size 30743, 274 and 232 bp 
respectively) with best BLAST hit coronavirus OC43 (reference genome GenBank accession 
AY391777.1). A coverage plot of all reads against this reference strain (Fig 1) showed good horizontal 
and vertical coverage (read coverage depth 428). The original OC43 qPCR amplification appeared to 
have been inhibited, and repeated OC43 qPCR confirmed the positive mNGS result (Cq 25). 
 
Fig 1. Coverage plot of betacoronavirus reads to coronavirus OC43 reference genome AY391777.1. 
(depth of coverage: 428) 
 
Sensitivity, specificity and predictive value 
The sensitivity, specificity and predictive values of mNGS were calculated based on 24 PCR positive 
and 1120 PCR negative target results of 88 samples and the normalized read counts (Table 5). 
Calculations were made using different cut-off values of respectively ≥0, ≥15 and ≥50 normalized 
read counts. With a cut-off of ≥15, the sensitivity was 92% and specificity 100% and the positive 
predictive value (PPV) increased to 92%. The negative predictive value (NPV) was 100% for all cut-off 
levels. A ROC curve (Fig 2), using Youden’s index25 demonstrated that the optimal sensitivity and 





Table 5. Sensitivity and specificity of mNGS normalized reads for PCR target viruses.  
 Cut-off number of reads 
 0 15 50 
Sensitivity 96% (23/24*) 92% (22/24) 83% (20/24) 
Specificity 98% (1093/1120) 100% (1118/1120) 100% (1118/1120) 
PPV 46% (23/50) 92% (22/24) 91% (20/22) 
NPV 100% (1093/1094) 100% (1118/1120) 100% (1118/1122) 
PPV: positive predictive value, NPV, Negative predictive value. 
*The sample with positive confirmatory OC43 PCR included. 
 
 
Fig 2. ROC curve of cut-off levels of mNGS normalized reads. 
 
Typing 
mNGS provides additional typing data, as compared to qPCR. Of the 13 rhinoviruses detected with 
mNGS, 6 (46.2%) were rhinovirus A, 2 (15.4%) rhinovirus B and 5 (38.5%) rhinovirus C. The three 
influenza viruses were assigned to be H3N2 strains by mNGS. 
 
Semi-quantification by means of mNGS read count 
In order to analyse the semi-quantitative quality of the mNGS assay, the number of the normalized 
sequence reads (log) mapping to qPCR target viruses (species level) as obtained with mNGS were 
compared to the Cq values of qPCR. A significant negative correlation was found (Fig 3; Pearson 
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Fig 3. Correlation between mNGS normalized viral species reads (log) and Cq value.  
(ρ=-0.6, p=0.002) 
 
Clinical parameters and mNGS pathogen read count 
The following markers were tested for potential associations with clinical severity of exacerbation 
(exacerbation severity, self-reported exacerbation severity), length of exacerbation and a 
decrease/increase in FEV1 (control visit compared to baseline): mNGS pathogen positive versus 
negative exacerbation (qPCR targets), the number of normalized reads (log, cut-off of ≥5 normalized 
reads) for the different target viruses (species level). No correlation was found between these 
markers and the different disease severity parameters (results not shown). 
 
The respiratory virome 
Overall proportions of normalized read counts of viral families (excluding EAV and PhHV control 
reads, cut-off of ≥5 normalized reads) detected by mNGS per patient are shown in Fig 4. Patients with 
viral pathogens (PCR target viruses) had significantly reduced proportions of bacteriophages when 
compared to patients without viral pathogen: 0% and 79% bacteriophages respectively (p<0.001) 
bacteriophage reads vs. all viral reads, normalized reads excluding EAV and PhHV control reads. The 
Shannon diversity scores for bacteriophages (normalized reads, cut-off of ≥5 normalized reads) were 
comparable for COPD exacerbations of viral aetiology in PCR positive versus negative patients (Fig 5). 





























reads (P<0.001) and eukaryotic viruses (p=0.028) in patients with viral pathogens (PCR target viruses 
positive). 
No significant association was found between the diversity scores, nor the percentage of 
bacteriophages, and the following parameters: disease severity, length of exacerbation, number of 
exacerbations during the study period, difference in FEV1, GOLD stage, smoking, CRP level, and the 












   
   
  
 













   
   
   
   
   
   
   














































































































































































































































Fig 5. Shannon diversity scores for: (a) viruses, (b) eukaryotic viruses, (c) bacteriophages.  
COPD exacerbations of viral etiology had significant lower diversity (b).Boxes span IQR, *** significant (a) all 
viruses (P<0.001) and (b) eukaryotic viruses (p=0.028), ○ outliers. 
 
The respiratory bacteriome 
The most prevalent phyla were Proteobacteria , Firmicutes Actinobacteria and Bacteroidetes, see 
figure 6. 
The normalized bacterial read count of the most prevalent phyla was not significantly different 
between patients with a PCR-target virus positive and PCR-target negative patients. 
Pathogenic bacterial species detected with an abundance of >10% of the bacterial reads were: H. 
influenza (five samples); M. catarrhalis (20 samples); S. pneumoniae (one sample); and S. aureus (one 
sample). No apparent association with bacteriophages was found, or was a high abundance of 
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Fig 6. Proportion of normalized bacterial reads per phylum. 
 
Data access 
The raw sequence data of the samples, after removal of human reads have been deposited to 




In this study, the respiratory virome in patients with COPD exacerbations was analysed with both 
mNGS and qPCR, and combined with clinical data. The incidence of viral pathogens was 26% with 
both mNGS and qPCR. mNGS failed to detect one Rhinovirus with low load (Cq 38) and PCR failed to 
detect one betacoronavirus OC43 (72644 reads), due to one of the limitations of PCR, i.e. inhibition 
of amplification. One additional viral pathogen, not present in the respiratory PCR panel, was 
detected: herpes simplex virus 1, found by others to be associated with COPD26. 
The incidence of viral pathogens was comparable to that in previous publications (22-64%)3,5,6. The 
viral pathogen with the highest incidence was rhinovirus, followed by influenza, coronaviruses and 





















high resolution of mNGS, with rhinovirus (RV) species A and C being most frequent, followed by RV-
B. RV-C was first identified in 2006 and associated with high symptom burdens in children and 
asthmatics27,28. Recently, an asthma-related cadherin-related family member 3 (CDHR3) gene 
variant29 was associated with greater RV-C receptor display on pulmonary cell surfaces of children 
and adults, and associated with higher susceptibility to severe virus-triggered asthma episodes30,31. 
In line, Romero-Espinoza et al detected predominantly RV-C in children with acute asthma 
exacerbations by mNGS32. The significance of RV-C infection in the adult population is less well 
studied. Although RV-C has been previously associated with exacerbations of COPD33,34, to our 
knowledge, to date, CDHR3 polymorphisms have not yet found to be associated with COPD. 
The sensitivity, specificity and positive and negative predictive values of mNGS were high: 96%, 100%, 
82% and 100%, respectively, when encountering a cut-off of ≥5normalized reads, with a detection 
limit of approximately Cq 38. The high negative predictive value implicates the potential of mNGS to 
exclude the most prevalent viral respiratory infections in one test. The potential to exclude any 
infectious cause, both viral and bacterial, would have significant consequences for starting and/or 
continuation of antimicrobial or, at the other end of the spectrum, immune-modulating treatment. 
The normalized viral species sequence read count might give an indication of the viral burden and 
the clinical relevancy of the detected virus. Although in our dataset we could not find any correlation 
with disease severity, several paediatric studies demonstrated a correlation between virus load and 
severity in respiratory infections35-38. Further analysis with a larger number of infected patients 
and/or a different spectrum of exacerbation severity will be needed to demonstrate or exclude such 
an association in COPD patients. 
Furthermore, the complete respiratory virome showed a high bacteriophage abundance that could 
be linked to the absence of viral pathogens. Lower bacteriophage abundance may be the result of 
viral expansion. Hypothetically, a healthy virome size and diversity fits a certain size and diversity of 
bacteriophages, while during viral infection, pathogens predominate the virome. Alternatively, 
others have hypothesized that viral and microbial diversity may play a role in infection susceptibility 
and the development of acute and chronic respiratory diseases32. Our results indicate that virome 
dysbiosis may be accompanied by bacteriome dysbiosis, though no significant differences were 
detected in line with other reports39,40. However, these studies don’t compare between COPD 
exacerbation with and without viral infections. Others have found a higher phage abundance in a 
patient with severe COPD when compared with one patients with moderate COPD and healthy 
controls, DNA sequencing, in line with the hypothesis of a state of dysbiosis that increases with 
disease progression26. In COPD patients, viral infections have been suggested to trigger bacterial 
overgrowth and infections41,42, demonstrating the significance of viral-bacterial interactions. 
Moreover, hypothetically, bacteriophages play a role in the horizontal gene transfer of bacterial 
virulence factors. 
The most abundant bacterial phyla detected in this study were comparable with other reports. 
Although the percentage of proteobacteria was relatively high when compared to other studies of 
the nasopharyngeal microbiome, our swabs are sampled during COPD exacerbations43,44. Study of 





Respiratory virome in COPD patients
69
analysis of bacterial and viral (sub)populations including comparison with PCR and culture results. 
Studies comparing the respiratory virome during stable disease and exacerbations are needed to 
determine a potential correlation between the virome/bacteriome during stable state and disease 
progression or exacerbation frequency. 
In the current study, most respiratory pathogens detected were RNA viruses. This is in line with 
previous literature3,5,6. However, it must be noted that, despite the fact that a wide range of DNA 
viruses have been detected with the current protocol (DNA bacteriophages with high abundance, 
herpes simplex virus, bocavirus, anelloviruses, CMV, KI polyomavirus14), we cannot exclude 
suboptimal detection of some DNA viruses. Furthermore, highly divergent viruses with sequences 
deviating from their representative NCBI RefSeq sequences may have been missed, as has been 
described by others45. However, bioinformatic classification using alternative databases (both 
GenomeDetective and local databases) did not result in additional findings. 
Though mNGS renders the possibility to detect all viruses in direct respiratory material, this 
revolutionary method is not yet used as routine accredited diagnostic procedure for pathogen 
detection. Before mNGS can be implemented as a routine diagnostics, the optimal protocol must be 
defined and analysis and interpretation of the metagenomic data must be standardized, followed by 
external quality assessment. This study demonstrates good performance of our mNGS protocol, in 
line with other studies36,37,46,47 and seems to overcome some of the current thresholds for 
implementation in clinical diagnostics. 
 
Conclusions 
The mNGS protocol used was highly sensitive and specific for semi-quantitative detection of 
respiratory pathogenic viruses. Excellent negative predictive value implicates the potential of mNGS 
to exclude a known viral infectious cause in one test, with consequences for clinical decision making. 
Reduced abundance of bacteriophages in COPD patients with viral pathogens implicates skewing of 
the virome, and speculatively the bacterial population, during infection. 
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Introduction: Rapid diagnosis of respiratory infections is of great importance for adequate isolation 
and treatment. Due to the batch-wise testing, lab developed real-time PCR assays (LDT) often result 
in a time to result of one day. Here, LDT was compared with rapid ePlex® respiratory pathogen (RP) 
panel testing of GenMark Diagnostics (Carlsbad, CA, USA) with regard to time to result, installed 
isolation precautions and antibacterial/antiviral treatment. 
Methods: Between January and March 2017, 68 specimens of 64 patients suspected of an acute 
respiratory infection were tested with LDT and ePlex® RP panel. Time to result was calculated as time 
between sample reception and result reporting. Information regarding isolation and 
antibacterial/antiviral treatment was obtained from the patient records. 
Results: Thirty specimens tested LDT positive (47%) and 29 ePlex® RP panel positive (45%). The 
median time to result was 27.1 hours (range 6.5-96.6) for LDT vs. 3.4 hours (range 1.5-23.6) for RP 
panel, P-value <0,001. In 14 out of 30 patients, isolation was discontinued based on ePlex® RP panel 
results, saving 21 isolation days. ePlex® RP panel test results were available approximately one day 
ahead of LDT results in the 19 patients receiving antiviral/ antibacterial treatment. In addition, two 
bacterial pathogens, not requested by the physician, were detected using RP panel. 
Conclusions: Analysis of respiratory infections with the ePlex® RP panel resulted in a significant 
decrease in time to result, enabling a reduction in isolation days in half of the patients. Furthermore, 
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INTRODUCTION 
Respiratory tract infections are a leading cause of hospital admission, morbidity, and mortality1-4. At 
presentation aetiological agents of the respiratory tract infection cannot be identified solely based 
on clinical signs and symptoms. Therefore, and awaiting microbiological confirmation, empirical 
antibiotic and antiviral treatment is initiated based on severity score and the influenza season5. Since 
only a minority of the infections is being caused by bacteria, this empiric antibiotic treatment 
approach is redundant and can lead to an increase in antibiotic resistance. Moreover, empiric 
isolation precautions are installed to protect other patients and health care workers from a possible 
(viral) infection. Altogether, there is a need for rapid identification or exclusion of a viral respiratory 
tract infection to reduce inappropriate (unnecessary) hospital hygienic interventions and focus 
(shorten) antibacterial/antiviral treatment. 
Currently, the diagnosis of respiratory infections is usually based on (a combination of) molecular 
amplification methods and bacterial culture. In our laboratory, lab developed real-time PCR multiplex 
assays (LDTs) are used that show excellent sensitivity and specificity. However, this approach is 
limited by the number of targets per multiplex reaction and the need for batch-wise testing. The 
assays are performed once daily, with a time to result of approximately 20 hours. 
Recently, the Respiratory Pathogen (RP) Panel of GenMark Diagnostics (Carlsbad, CA, USA) has 
become available for detection of an extensive panel of respiratory pathogens (21 respiratory viruses, 
3 bacterial species, see Methods) using eSensor technology6. This test is a cartridge based molecular 
assay to be used on the ePlex® platform with a time to result of approximately 90 minutes that 
showed an concordance of >97% compared to LDT7. Hypothetically ePlex® RP panel testing 
represents a considerable reduction in time to diagnosis, as compared to LDT, which could have 
significant clinical benefits. In this paper, a pilot study is reported that analysed the implications of 
using the ePlex® RP panel for the detection of respiratory infections compared to LDT regarding time 
to result, isolation precautions, and antibacterial/antiviral therapy. 
 
METHODS 
Inclusion of patients 
This prospective, single centre study in the Leiden University Medical Center (LUMC) included 
patients from January to March 2017. Patients with symptoms of an acute respiratory infection were 
included upon request of the physician of the acute ward, intensive care unit, and paediatric 
department. Specimens included were obtained during weekdays and tested with both the RP panel 
and the LDTs after consulting the microbiologist. Information regarding baseline characteristics, 
infection parameters, admittance, isolation and treatment was obtained from the electronic patient 
records. Additional information about cultures was retrieved from the laboratory information system 




Primary outcome measure 
The primary endpoint of this study was the time to result of the ePlex® RP panel compared to the LDT. 
 
Secondary outcome measures 
The ePlex® RP panel was offered as a pilot to elevate the pressure on droplet isolation rooms, thus 
isolation was discontinued based on the ePlex® RP panel results. Due to the pilot nature of this study 
antibacterial and antiviral treatment were not adjusted based on the ePlex® RP panel results, 
therefore only the theoretical time reduction in treatment was calculated using the time to results 
of the ePlex® RP panel and the LDT. Secondary outcome measures were the reduction of isolation 
days based on ePlex® RP panel ahead of LDT results, the theoretical reduction in hours in oseltamivir 
and atypical pneumonias treatment calculated with the time to results of LDT and ePlex® RP panel, 
and possible additional diagnosis found with the ePlex® RP panel. 
 
Laboratory-developed test (LDT) 
LDT viral testing and testing for Mycoplasma pneumoniae, Chlamydia pneumoniae and Chlamydia 
psittaci was performed the same day on all samples that arrived at the laboratory before 8:15 A.M. 
Samples arriving at the laboratory before 3:30 P.M., were tested for Legionella pneumophila and 
Bordetella parapertussis the following day. These assays were performed daily from Monday till 
Friday and on request on weekend days. The viral respiratory panel of LDT consists of adenovirus, 
bocavirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, influenza A, 
influenza B, human metapneumovirus, parainfluenza 1-4 (differentiation with differently labelled 
probes), respiratory syncytial virus, and rhinovirus. In addition, testing for bacterial pathogens could 
be requested: Legionella species, Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia 
pneumoniae, Chlamydia psittaci, Bordetella pertussis, and Bordetella parapertussis. 
All sputa samples were 1:5 diluted in PBS and homogenized by bead-beating prior to extraction. Then, 
200 µl of each respiratory sample was used to extract 100 µl total nucleic acids using the Total Nucleic 
Acid extraction kit on the MagnaPure LC system (Roche Diagnostics). Nucleic acid amplification and 
detection by real-time PCR was performed on a BioRad CFX96 thermocycler, using primers, probes 
and conditions as described previously8-10. For the detection of Mycoplasma pneumoniae, Chlamydia 
pneumoniae, and Chlamydia psittaci the b-CAP assay (Biolegio, Nijmegen, the Netherlands) 
developed for the BD-max system was used by testing 200 µl of each respiratory sample according 
to the manufacturer’s instructions11. LDT test results were reported in the electronic patient record. 
Time to result for the LDT was calculated as time of receipt of the sample in the laboratory to the 
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ePlex® RP panel 
Specimens for diagnosis using the CE-IVD cleared RP panel were accepted on weekdays between 8:15 
A.M. and 3:00 P.M. and tested during the day, as soon as possible. The ePlex® respiratory panel was 
not offered during the weekend, while treatment was not adjusted based on the results. The RP panel 
as used in the study was able to detect: adenovirus, bocavirus, coronavirus 229E, coronavirus HKU1, 
coronavirus NL63, Coronavirus OC43, influenza A H1, influenza A 2009 H1N1, influenza A H3, 
influenza B, metapneumovirus, Middle East respiratory syndrome coronavirus, parainfluenza 1-4, 
respiratory syncytial virus A and B, rhinovirus/ enterovirus, Bordetella pertussis, Legionella 
pneumophila, and Mycoplasma pneumoniae. As with LDT, sputa samples were diluted in an 1:5 
dilution using PBS. According to the manufacturer’s instructions 200 µl of the respiratory sample was 
pipetted in a buffer tube and after vortexing transferred to the ePlex cartridge and subsequently to 
the ePlex tower. If the test gave an invalid result, the run was repeated. Results were reported by 
telephone to the requesting physician, since the results were not reported in the electronic patient 
record. Time to result was calculated as time of receipt of the sample to the time results were 
reported by telephone. 
 
Statistics used for comparison 
Time to result was compared with Wilcoxon Signed Rank Test, using IBM SPSS Statistics version 23 
software for Windows. A P-value <0.05 was considered statistically significant. 
 
RESULTS 
LDT and ePlex® RP panel results 
Between January and March 2017 64 patients were included with symptoms of acute respiratory 
infection whose characteristics are summarized in Table 1. A total of 68 samples were tested, 
comprising 40 throat swabs, 13 sputum samples, 11 nasal lavages, and four nasopharyngeal swabs. 
Thirty-four tested positive for a respiratory pathogen in one or both assays. Six samples failed in the 
ePlex® RP panel, of which two gave a valid result upon retesting. The other four were not retested, 
two because of insufficient remaining sample volume. The failed samples, if not retested, were 
excluded from further analysis, leaving 64 samples of 61 patients for further analysis. None of the 
samples failed in the LDT. 
Of the 64 samples 31 tested positive for a total of 37 pathogens with LDT or ePlex® RP panel (Table 
2). Using LDT, 30 tested positive and 34 negative, whereas this was 29 and 35 using the ePlex® RP 
panel. As shown in Table 3A, a discordant result was found in five samples. 
In three patients, different sample types were tested (Table 3B). From the first a sputum and a throat 
swab were collected, of which only the first tested LDT positive for influenza A. The second tested 
rhinovirus positive in a nasal lavage, with LDT only, and negative in sputum. Of the third patient a 











Age, median years (range) 60 0-93 





Pneumonia (%) 25 39 
COPD/ asthma exacerbation (%) 7 11 
RTI other than pneumonia (%) 12 19 
Other diagnosis (%) 20 31 
Leukocytes, median x109/L (range) 11.4 0.44-49.16 
C-reactive protein level, median mg/L (range) 62 2-360 
Cough (%) 49 77 
Sputum (%) 26 41 
Previous antibiotic treatment (%) 20 31 
Duration of symptoms, median days (range) 2 1-21 
Comorbidity 
  
COPD/asthma (%) 17 27 
Diabetes (%) 7 11 
Malignancy (%) 6 9 
Transplantation (%) 12 19 
Auto-immune disease (%) 8 13 
Admission ward   
Acute ward 32 50 
Intensive care (including children) 8 13 
Paediatric department 8 13 
Other departments 15 23 
Not admitted 1 1 
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Table 2. Respiratory pathogens found in clinical samples with lab developed real-time PCR assay or 
ePlex® RP panel 
Pathogens LDT ePlex® RP panel 
Coronavirus 229E 2 2 
Coronavirus HKU1 1 1 
Human bocavirus 1 1 
Human metapneumovirus 5 4 
Influenza A 10 9 (all H3) 
Influenza B 1 1 
Parainfluenza virus type 3 1 1 
Respiratory syncytial virus 4 0 
Respiratory syncytial virus type A  2 
Respiratory syncytial virus type B  2 
Rhinovirus/enterovirus 8 9 
Bordetella pertussis 1 1 
Mycoplasma pneumoniae 1 1 
Abbreviation: LDT, Lab developed real-time PCR 
 
Table 3A. Discrepant results of lab developed real-time PCR assay compared to ePlex® RP panel 
 LDT ePlex® RP panel 
Throat swab Negative (retesting negative) RV/EV 
Nasopharyngeal swab InfA (Cq 26) (enterovirus negative) InfA- RV/EV 
Nasal lavage RV (Cq 39.1) Negative 
Sputum MPV (Cq 30.3) Negative (retesting MPV pos) 
Sputum infA (Cq 33.1) Negative (retesting negative) 
Abbreviations: LDT, Lab developed real-time PCR; RV, rhinovirus; EV, enterovirus; InfA, influenza A; MPV, 
metapneumovirus; Cq,quantification cycle 
 
Table 3B. Different sample types tested 
Patient Material LDT ePlex® RP panel 
1 Sputum infA (Cq 33.1) Negative  
Throat swab Negative Negative 
2 Sputum Negative Negative  
nasal lavage RV (Cq 39.1) Negative 
3 Sputum CoV 229E (Cq 33.4) CoV229E  
Throat swab Negative Negative 




Primary outcome measure: 
Difference in time to result 
For 62 of the 64 samples, both the time of acceptance and the time of result was recorded. The 
calculated time to result was significantly shorter, approximately 24 hours, for the ePlex® RP panel 
than for LDT (P<0.001) (Table 4). A time to result of over 35 hours was seen with LDT testing in 15 
samples, of which 13 had arrived on Friday and were tested on Monday. In the two remaining 
samples there was a delay in requesting and authorisation of the test subsequently. In the ePlex® RP 
panel, four samples had a time to result of more than 18 hours. Two of these samples were already 
at the laboratory for several hours before the ePlex® RP panel testing was requested, while the testing 
of two sample was requested after 3:00 P.M. and therefore performed the next day (one due to 
failure of the initial sample). 
 
Table 4. Time to result in hours of lab developed real-time PCR assay compared to ePlex® RP panel 
Time to result LDT ePlex® RP panel P-value* 
Median (hours) 27.11 3.35 <0,001 
Range (hours) 6.52-96.57 1.45-23.56  
Abbreviation: LDT, Lab developed real-time PCR 
* P-value calculated with Wilcoxon signed rank test 
 
Secondary outcome measures 
Consequences for patient isolation 
Of the 61 patients included in the analysis, 60 were admitted to the hospital at the time respiratory 
testing was requested. Fifty-one of these hospitalised patients were isolated while awaiting test 
results, whereas nine patients were not admitted in isolation. In these cases isolation was not 
installed mainly because of low clinical suspicion of a pathogen requiring isolation. One of these nine 
patients needed isolation, since the ePlex® RP panel tested positive for influenza A (three days ahead 
of LDT). 
The tests showed that 19 out of 51 patients admitted in isolation had a respiratory pathogen 
requiring isolation. Of the remaining 32 patients, one died before test results became available and 
for one patient the duration of isolation was unknown, leaving 30 patients for further analysis. In 14 
of these isolation was discontinued based on ePlex® RP panel results ahead of LDT results. This 
resulted in a total reduction of 21 isolation days, with a median reduction of 2 days (range 1-4 days) 
per patient. In eight of the remaining patients, isolation was discontinued when LDT results became 
available. In the other eight patients, of which three children, isolation was not withdrawn at the 
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Theoretical consequences for antiviral and antibacterial treatment 
A total of 50 out of the 61 patients received antiviral or antibacterial treatment during hospitalization. 
Oseltamivir treatment was initiated in 19 patients awaiting test results, of which five tested positive 
for influenza A. In the 14 influenza ePlex® RP panel negative patients, oseltamivir could have been 
stopped approximately one day earlier (median of 22.59 hours, range 5.33-72.03) based on ePlex® RP 
results compared to LDT (Table 5). Of the in total 11 patients who tested influenza positive, the 
remaining six did not receive oseltamivir at the time of diagnosis. In one patient, oseltamivir 
treatment was started as soon as ePlex® RP panel showed influenza A, one day prior to LDT results, 
and one patient started when LDT was positive. Four patients did not receive any antiviral treatment, 
of which two were already dismissed at the time of definite LDT diagnosis. 
Awaiting test results, 19 patients received antibiotic treatment for bacteria causing atypical 
pneumonias. In none of these patients, either the ePlex® RP panel or the LDT (eight were tested) was 
positive for Bordetella pertussis, Legionella pneumophila, and Mycoplasma pneumoniae. In theory, 
in these 19 patients, a median duration of 23.35 hours (range -0.43- 75.28 hours) antibiotic treatment 
for atypical pneumonia could have been saved, if treatment was stopped when ePlex® RP panel tested 
negative. 
 
Table 5. Theoretical median time in hours of isolation and treatment calculated based on time to 
results 
 
No. LDT (range) ePlex® RP panel (range) Difference (range) 
Oseltamivir, h 14 27.08 (10.10-75.15) 3.38 (2.00-23.56) 22.59 (5.33-72.03) 
Antibiotics atypical 
pneumonias, h 
19 27.12 (8.27-81.11) 3.38 (1.52-23.56) 23.35 (-0.43-75.28) 
Abbreviations: No, number of patients; LDT, Lab developed real-time PCR; h, hours 
 
Additional diagnoses 
Of the 61 patients, two tested positive by ePlex® RP panel for a bacterial agent, one Bordetella 
pertussis and one Mycoplasma pneumoniae. In both patients, testing for these pathogens was not 
requested for by the clinician and as a consequence not included in the routine diagnostic LDT 
workflow. The positive ePlex® RP panel results were confirmed by LDT with Cq-values of 25.6 and 
34.6 for B. pertussis and M. pneumoniae, respectively. LDT testing for atypical bacterial pathogens 
(Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia psittaci) was requested in only 16 






As hypothesized, diagnosis with the ePlex® RP assay significantly reduced the time to result (median 
23.34 hours) as compared to batch wise LDT testing. Consequently, a total of 21 isolation days were 
saved and three days of influenza A exposure prevented. Unnecessary oseltamivir treatment could 
have been shortened at least 20 hours in 14 patients and antibiotic treatment for atypical 
pneumonias by a median of 23.35 hours days in 19 patients. Proper therapeutic and isolation 
measurements could be installed in two patients for bacterial pathogens based on ePlex® RP panel 
detection that were not considered by the treating physicians and therefore not analysed by routine 
LDT. 
To our knowledge this study is the first to report the use of the ePlex® respiratory panel in a clinical 
setting. It demonstrated a significant time reduction, reflecting previous clinical studies 
implementing rapid molecular testing12-15, and significantly reduced the number of isolation days. 
Furthermore, confirmation of a single viral cause of infection in a cohort of patients enabled cohort 
nursing, which increased the number of isolation rooms available to patients awaiting identification 
of their respiratory pathogen. Efficient use of isolation rooms is essential during influenza season 
when the demand for these rooms is high. 
The rapid ePlex® RP panel results could have resulted in a reduction of oseltamivir usage, which is in 
line with previous studies14.Results regarding reduction in antibiotic treatment for atypical 
pneumonias should be interpreted with care, while they are, according to the Dutch guidelines, only 
indicated for Legionella pneumophila in high risk populations and can also been stopped based on 
negative urine-antigen testing. The lack of routine testing for atypical respiratory bacterial pathogens 
(mostly Legionella pneumophila) and the finding of additional respiratory pathogens, initially not 
considered by the clinicians, underline the importance of syndromic respiratory testing. 
Our study has a number of limitations. First, the clinical impact of our pilot study was hampered by 
its design. Since the ePlex® RP assay was readily offered to reduce the quest for isolation rooms during 
the coinciding influenza and RSV epidemics early 2017, its test results were not shown yet in the 
hospital information system but reported by phone, creating a bias. Moreover, the ePlex® RP panel 
result was reported as a provisional result awaiting routine LDT confirmation. The delay in showing 
the test results in the electronic patient record, might have withheld clinicians to discontinue 
isolation and therefore created an underestimation of the true clinical potential. Furthermore, the 
findings of this study cannot be extrapolated readily, since this was a single centre study during just 
a part of one winter season. The benefits of rapid diagnostics might be more pronounced when 
assessing complete respiratory seasons. 
So far, the ePlex® RP panel has been CE-IVD cleared for nasopharyngeal swabs only. However, 
especially samples from the lower respiratory tract as sputum and bronchoalveolar lavage can be 
important to include in the CE-IVD clearance, since our study shows that these samples might have a 
higher diagnostic yield. However, both in our previous and current study several different sample 
types were tested with good results7. Nevertheless, the ePlex® RP panel had a failure rate of nearly 
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panel results showed excellent concordance with our LDT, only three LDT positives (all with Cq-values 
>30) could not be detected using the ePlex® RP panel. This is in line with our previous findings 
reported by Nijhuis et al.7. The ePlex® RP panel is based on syndromic testing and has a standard 
panel containing most common respiratory pathogens that are requested by the physician. However, 
the ePlex® RP panel is not complete, especially when caring for in immunocompromised patients. In 
that case additional LDT testing for Legionella species, cytomegalovirus, herpesvirus, toxoplasmosis 
and fungal pathogens would still be necessary. Compared to LDT, ePlex® RP panel testing is more 
expensive regarding reagents and consumables but cheaper with respect to hand-on-time.In 
addition, rapid diagnostics will result in a cost reduction in the clinical departments as demonstrated 
previously16. 
In conclusion, diagnosis of respiratory infections with the ePlex® RP assay resulted in a significant 
reduction in time to result compared to LDT, which causes a reduction in isolation days and 
theoretically improved treatment regimens. Because of these advantages, we assume this rapid 
diagnostic molecular assay will be of added value for ongoing improvement in patient care. 
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Background: Respiratory infections are considered a potential risk of adverse events in children 
undergoing surgery. Rhinovirus is a common cause of respiratory infections and congenital heart 
disease is a risk factor for severe rhinovirus infection. However, we do not know what the impact of, 
clinical or subclinical, rhinovirus infections is on postoperative course following congenital heart 
surgery in children. 
Based on our clinical experience, one case-controlled study, and a case reported in the literature, we 
hypothesize that paediatric patients with per-operative rhinovirus positive Polymerase Chain 
Reaction testing have a longer paediatric intensive care unit admission, compared to children who 
test negative. 
Methods/ Design: This is a prospective single-center observational study in the Leiden University 
Medical Center with approximately 250 children (<12 years) undergoing elective cardiac surgery, for 
congenital heart disease. 
The parents/guardians of the children will be asked to fill out a questionnaire, to asses respiratory 
symptoms in the last weeks, before the operation of their child. In the operating theatre, a 
nasopharyngeal swab will be collected. Clinical data will be collected daily during paediatric intensive 
care admission and paediatric intensive care unit and hospital length of stay will be recorded. If 
children are still intubated at day 4, a second nasopharyngeal swab and residual blood will be 
collected. The samples will be tested for rhinovirus with polymerase chain reaction.  
Primary outcome is the paediatric intensive care unit length of stay in per-operative rhinovirus –
positive compared to rhinovirus-negative patients. 
Discussion: This is the first study to screen children for rhinovirus before undergoing cardiac surgery 
and to study the effects on paediatric intensive care unit length of stay. Furthermore, we aim to 
identify children at risk for prolonged paediatric intensive care admission after cardiac surgery. 
 















Rhinovirus (RV), a Ribonucleic Acid (RNA) virus of the family Picornaviridae and genus Enterovirus is 
a major cause of upper respiratory tract infections. The clinical spectrum ranges from asymptomatic 
to severe, life-threatening-pneumonia1. 
Asymptomatic shedding of RV is very common, especially in children, and tends to be higher in the 
younger age groups. In a study in the Netherlands, the prevalence of rhinovirus amounted to 20% for 
children under 2 years of age without nasal symptoms2. Risk factors for severe rhinovirus infections 
(lower respiratory tract infections, infections needing hospitalisation) in children are prematurity, 
congenital heart disease, respiratory syncytial virus (RSV) co-infections and non-infectious 
respiratory disease3.  
Upper respiratory tract infections are considered to carry a potential risk of adverse events in children 
undergoing surgery. Surgery in children with symptomatic upper respiratory tract infection is 
commonly postponed, because of the increased risk of complications of anaesthesia in these 
patients4. Adverse events (AE) related to respiratory tract infections are: laryngo-bronchospasm, 
breath holding spells, atelectasis, arterial oxygen desaturation, bacterial pneumonia and unplanned 
hospital admission5,6. Age below 6 years and cardiac surgery are additional specific risk factors for 
postoperative complications. The risk of peri-operative adverse events is increased up to 6 weeks 
after upper respiratory tract infections4. Patients undergoing cardiac surgery might have an 
additional risk, because of the immune-modulatory effect of cardiopulmonary bypass7-9. Children 
with a clinically apparent upper respiratory tract infection at the time of cardiac surgery have higher 
incidences of respiratory complications, multiple complications, postoperative infections and 
significantly longer paediatric intensive care unit (PICU) admission10. Paediatric patients with 
postoperative symptomatic rhinovirus infection appear to have a more complicated and prolonged 
post-operative course compared to other patients undergoing cardiac surgery (unpublished Leiden 
University Medical Center (LUMC) data). Especially PICU length of stay and duration of mechanical 
ventilation seem to be longer in patients with a rhinovirus infection. Every year approximately 20 
paediatric patients in the LUMC have a complicated post-operative course in combination with a 
rhinovirus infection (unpublished LUMC data). Little has been published about the impact of 
rhinovirus infections on the post-operative course after cardiac surgery in paediatric patients. Simsic 
et al. described a case of a nine months old boy with rhinovirus infection and a complicated course 
after cardiac surgery. Based on this case the authors screen all their paediatric patients with single-
ventricle congenital heart disease by polymerase chain reaction (PCR) for respiratory viruses. In case 
of a positive PCR result, they postpone the operation for 4-6 weeks11. Delgado-Corcoran et al. 
recently published a case-control study of 19 cases of infants who tested positive for rhinovirus after 
cardiac surgery compared to 56 matched controls, untested symptom free patients. In this study the 
rhinovirus positive patients had a significantly longer intubation time and a three times longer PICU 
length of stay12.  
Ideally, these complications may be prevented by screening patients for the presence of respiratory 




Based on these retrospective data, we designed a single center prospective observational cohort 
study to analyse the impact of per-operative rhinovirus infection on the post-operative course in 
children undergoing elective cardiac surgery, with PICU length of stay as primary outcome. The 
subsequent goal is to develop an algorithm to identify children with increased risk for prolonged 
respiratory support after cardiac surgery. We named it the RISK study: Rhinovirus Infection & cardiac 




This is a prospective, single-center, observational cohort study of the effects of rhinovirus in children 
undergoing cardiac surgery in the LUMC. 
The LUMC is an academic hospital in Leiden, the Netherlands, and a top referral center for congenital 
heart disease and congenital cardiac surgery with approximately 250 operations each year. 
Combined with the two university medical centers of Amsterdam it constitutes the center for 
congenital heart disease Amsterdam - Leiden, in Dutch CAHAL13.  
Current standard procedures regarding elective cardiac surgery include the following: 
The day before the planned operation patients are assessed by the cardiologist, cardiac surgeon and 
anaesthesiologist who decide if the surgery can go ahead or if it will have to be postponed because 
of possible clinically relevant (respiratory tract) infection. 
After surgery, patients are admitted to the PICU, where ventilation and circulatory support are 
weaned depending on the type of operation, bypass times and clinical stability. If symptoms of 
respiratory tract infection become apparent during the postoperative PICU stay, patients are 
routinely tested for either bacterial infections (culture) and/or viral infections by PCR for respiratory 
viruses on nasal lavage at the discretion of the treating intensive care physician. 
In this study we will test all children for rhinovirus who are < 12 years of age with congenital heart 
disease undergoing elective cardiac surgery in the LUMC. The majority of the children will be 0-1 
years old, since cardiac surgery is preferably performed at (very) young age. 
The primary endpoint of this study is post-operative PICU length of stay in rhinovirus positive 














Secondary endpoints are: 
• Duration of ventilatory support 
• mechanical ventilation conditions (mean airway pressure, Fraction of inspired oxygen (FiO2)) 
• Antibiotic free days (alive at PICU discharge) 
• Inotrope requirement 
• Infection parameters 
• Hospital length of stay (LOS) 
• Secondary infections 
Alternative predictors of the endpoints are viral load (strength of PCR value), duration of respiratory 
shedding, genotype of the different rhinoviruses and rhinovirus viremia. 
 
Inclusion criteria 
In order to be eligible to participate in this study, subjects must meet all of the following criteria: 
• Children (<12 year) with a congenital heart disease undergoing elective cardiac surgery who 
were not admitted pre-operatively 
• Written informed consent by parents or guardian 
 
Exclusion criteria 
A potential subject who meets any of the following criteria will be excluded from participation in this 
study: 
• No informed consent from one of the parents (or the legal representative if applicable) 
• Emergency surgery (postponing of surgery not an option) 
• Children not admitted to the intensive care unit after cardiac surgery (negligible amount of 
children) 
• Children who will certainly have a prolonged PICU length of stay regardless of a possible 
rhinovirus infection: 
o Children undergoing a second elective cardiac operation during the same intensive 
care stay 
o Children with duct-dependent physiology who remain prostaglandin-dependent after 
the heart operation. For example: hypoplastic left heart syndrome following 
pulmonary artery banding who will remain on prostaglandins until the next staged 
operation. 
 
Sample size calculation 
This study will include approximately 250 children. The sample size calculation is based on the 
expected percentage of rhinovirus positive children and the expected difference in duration of PICU 
admission, our primary end point. 
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The estimated prevalence of preoperative children with rhinovirus of 20% was based on a prospective 
birth cohort study in the Netherlands among healthy children followed until the age of 2 years. In 
that study, the prevalence of rhinovirus among children without nasal symptoms was 20% (range 14-
28%) (and 40% among children with rhinitis/upper respiratory tract infection)2.  
The mean duration of PICU admission following cardiac surgery in our PICU is 3.6 days. The study of 
Delgado-Corcoran et al., demonstrated almost a tripling of intensive care (IC) length of stay in 
rhinovirus infected children after surgery for congenital heart disease (up to one year of age), 2,14 
(IQR 2.00-3.22) versus 6,03 days (IQR 2.98-14.22, p<0.0001). Since the control patients in this study 
were not tested for rhinovirus and therefore could be (asymptomatic) rhinovirus positive, the 
difference within our study might turn out to be smaller12. Combining these published data with a 
clinically relevant difference of 1 day and more, we aim to distinguish a difference between the two 
groups of 2 days. We base our sample size calculation on the comparison of two independent 
exponential means (PICU LOS in both groups). 
Given these data for a power of 80% ((β = 0.20), tested with a significance level of 5% (α = 0.05), we 
calculated n 49 (sample size rhinovirus positive group and n=196 (sample size rhinovirus negative 




If a patient is eligible for the study, the parents/ guardians will receive the information folder and a 
questionnaire by mail (see additional file 1) (asking for signs and symptoms of current and/or recent 
respiratory infections) approximately one week prior to the date of operation. 
On the day of admission (day 0) all parents of eligible children will be asked to participate in this study 
and fill out a written informed consent form. 
At day 1, the operation day, in the operating theatre, a nasopharyngeal swab will be collected 
following anaesthetic induction and tested for rhinovirus. All clinicians will be blinded for the PCR 
results which will only be accessible for the investigator from the virology department. 
Clinical and laboratory data will be collected from all patients until discharge from the PICU. Of the 
patients still on mechanical ventilation at day 4, an additional rhinovirus PCR will be tested on a 
nasopharyngeal swab and residual blood will be used to determine rhinovirus viremia in the 









Collection of clinical data 
On admission (i.e. day 0) 
Baseline and demographic characteristics will be collected, including: 
• Age, gender, cardiac diagnosis and medical history, including vaccinations, medication, 
respiratory conditions (asthma) and family medical history of atopic diseases. 
• History of respiratory infections: amount, prior viral testing, symptoms, medication use and 
symptoms of family members. 
• Passive smoking 
• Physical examination: temperature – blood pressure- hearts rate- respiratory rate- cardiac 
sounds – breath sounds – rhinorrhoea (all part of routine preoperative medical screening/ 
care) 
• Additional examination: Chest x-ray- Electrocardiogram (ECG)- Blood tests (C-reactive protein 
(CRP), Leukocytes) (all part of routine preoperative medical screening/ care) 
 
On day of operation (i.e. day 1) 
Collection of operating conditions, including: 
• Anaesthesia: dexamethasone given because of bypass yes/no - type of induction - 
endotracheal tube size (ETT) - redness or swelling during laryngoscopy – secretions (pus) seen 
during intubation - high pressures needed during mechanical ventilation in the operation 
room (OR) - duration of anaesthesia-administration of ketamine yes/no-continuous 
administration of ketamine yes/no - amount of red blood cells, fresh frozen plasma and 
platelet concentrate transfused. 
• Operation: Type of operation, risk adjustment congenital heart surgery score (RACHS-II)14- 






Daily until PICU discharge 
Collection of clinical condition, including: 
• Administered steroids. 
• Infection: Infection parameters (routinely performed) - use of medication (antiviral/ 
antibacterial)- recording of any bacterial/ viral testing of respiratory tract- temperature 
(highest recorded per day) 
• Ventilation: settings (mean airway pressure, fraction of inspired oxygen (FiO2), Peak 
inspiratory pressure and positive end expiratory pressure (PEEP) (maximal values))-use of 
non-invasive ventilation (continuous positive airway pressure (CPAP), optiflow, face mask 
ventilation)- use of nitric oxide- failure of extubation (reintubation within 24 hours after 
extubation) 
• Inotropes, vasoactive medication (milrinone, adrenaline, noradrenaline, dobutamine, 
dopamine, levosimendan) 
Date of PICU and hospital discharge. 
 
Collection of samples see figure 1 
On day of operation (i.e. day 1): nasopharyngeal swab 
On day 4, if still intubated: nasopharyngeal swab and blood from the biochemical laboratory (residual 
material) 
 
After collection, respiratory specimens (nasopharyngeal swabs) will be transported to the Clinical 
Microbiology Laboratory for further processing and storage. Respiratory specimens will be processed 
daily (with routine diagnostics) and stored at –80°C. Blood samples will be stored at –80°C until 










Figure 1. Schematic overview of collection of clinical data and samples 
 
Viral testing 
Testing of rhinovirus in specimens (nasopharyngeal swab, blood) will be performed at the Clinical 
Microbiological Laboratory of the LUMC using a validated internally controlled real-time rhinovirus 
PCR, yielding semi–quantitative results based on Cycle threshold (Ct) values15. Rhinovirus genotyping 
will be performed by PCR and/or amplification and sequence-analysis of the capsid proteins VP3/VP1, 
VP4/VP2 or the 5’UTR genome regions previously described by Zlateva et al.16.  
 
Other respiratory viral pathogens 
In case of suspected clinical infectious respiratory problems during PICU admission, clinical routine 
microbiological diagnostics will be performed for respiratory viral pathogens at the discretion of the 
treating physician. The results of these clinical tests will also be evaluated in the final data analysis to 
help establish the role of potential co-infections in rhinovirus positive patients and the role of other 
viral infections in rhinovirus negative patients. 
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In rhinovirus negative patients with a prolonged duration of mechanical ventilation and/or PICU 
length of stay (> 3 days), at final analysis of the study results, the initial per-operative nasopharyngeal 
swabs will be re-tested for other viral pathogens with in-house real-time multiplex PCR (eg RSV, 




Dichotomous variables will be expressed in numbers and percentages. 
Continuous variables will be expressed as (exponential) means with standard deviations (SD) or 
medians with interquartile ranges [IQR], where appropriate. 
Outcome measures, viral load and demographic features will be expressed for the total study 
population. In addition, these data will be shown for the following subgroups: rhinovirus infection 
(overall), symptomatic rhinovirus infection, asymptomatic rhinovirus infection and no rhinovirus 
infection at admission. 
 
Multivariate analysis 
The primary and secondary outcome measures will be compared between the rhinovirus PCR positive 
patients versus the rhinovirus PCR negative groups. 
Because we expect the distribution of our primary outcome (IC length of stay) to be skewed, we will 
use exponential regression for our primary analysis. We will correct for potential confounders: 
gender and perfusion time. Numerical outcomes that do not show strong deviation from normality 
will be analysed with multivariate linear regression. Logistic regression or log-binomial regression 
where appropriate, will be used for all dichotomous or categorical outcome measures, corrected for 
potential confounders. 
In children with rhinovirus infection investigate the association between viral load (strength of PCR), 
duration of shedding, symptomatic or asymptomatic infection, genotype, viremia and the primary 
and secondary outcome measures shall be investigated. 
 
Adjustment and stratification 
Variables that can affect both LOS and peroperative RV PCR positivity (confounders) are adjusted for 










Figure 2. Flow chart of variables affecting LOS after elective cardiac surgery, in relation to RV 
infection. 
 
Variables that can affect LOS without affecting RV PCR positivity are either implemented as 
a) exclusion criteria, when having an absolute effect on LOS, independent of RV PCR positivity, e.g.: 
-planned 2nd operation for single ventricle physiology, 
-planned prolonged intubation because of (MRI) procedure or transport to other hospital 
-unplanned 2nd operation (exclusion retrospectively) 
b) subgroup, when having a less absolute effect on LOS, e.g.: 
-pre-operative cardiac condition 
-pre-operative viral co-infection 
Here, subgroup analysis might indicate patients vulnerable for enhanced LOS when per-operative RV 
positive. 
c) other predictors for LOS that are either theoretically independent of RV or potentially resulting 
from RV positivity: no adjustment: 
-Per-operative perfusion time (cardio-pulmonary-bypass-time) 
-Post-operative cardiac condition e.g. heart failure leading to prolonged inotrope support and/or 
respiratory support 
-Pre /post-operative pulmonary condition (eg tracheabronchomalacia) 
 
Number of patients excluded from the study will be presented in a Consolidated Standards of 





This is, to our knowledge, the first study to screen all children undergoing elective cardiac surgery for 
rhinovirus and to monitor postoperative outcome. It is important to determine whether rhinovirus is 
a risk factor for prolonged LOS in children undergoing heart surgery as it might have important 
implications in timing of the operation. 
We expect that the effect of rhinovirus on the difference in PICU LOS is the largest in children 
undergoing open heart surgery using cardiopulmonary bypass compared to operations without 
cardiopulmonary bypass (eg repair of coarctation of the aorta, placement of a modified Blalock-
Taussig shunt). 
Secondary aim of the study is to develop an algorithm, based on clinical parameters and 
nasopharyngeal swab results, to help identify asymptomatic children with an increased risk of 
prolonged PICU LOS after cardiac surgery, in the pre-operative stage. The ultimate goal is to prevent 
prolonged PICU admission due to respiratory complications.. 
In this study the children will be tested for rhinovirus at the moment of operation. 
Though this moment may not exactly represent the moment of admission (one day earlier), we have 
chosen this moment to minimize the burden for the participating children. 
It must be noted that if rhinovirus positivity is indeed predictive for prolonged PICU LOS, this study is 
not designed to determine whether postponing the operation is effective in preventing prolonged 
PICU LOS, which would require a specific future trial randomizing between different postponement 
times (eg 2, 4 or 6 weeks). We chose not to perform this trial immediately because we think the effect 
of rhinovirus needs to be determined on forehand. Furthermore the organisation and costs, as well 
as the emotional burden for the children and their family of postponing an operation are 
considerable and can only be warranted if rhinovirus actually is a risk factor. 
While duration of mechanical ventilation seems to be more directly related to rhinovirus infection 
than PICU length of stay, we selected PICU length of stay as primary endpoint. Duration of mechanical 
ventilation as an endpoint is more difficult to define, given the several types of respiratory support 
(invasive and non-invasive) and less clear-cut situations like extubation failure and or re-intubation. 
Because PICU length of stay is a more clear endpoint, easier to compare between studies, and of 
clinical and economical relevance, we chose this as primary endpoint. 
Rhinovirus will be the only respiratory pathogen that is routinely tested on the pre-operative 
nasopharyngeal swabs in this study. However, all nasopharyngeal swabs will be stored and can be 
retested for an entire respiratory viral panel in rhinovirus negative patients with prolonged LOS (>4 










We have designed a prospective observational study to determine the effect of rhinovirus on the 
postoperative course in children who are admitted from home to undergo elective congenital heart 





1.   Jacobs SE, Lamson DM, St George K., Walsh TJ: Human rhinoviruses. Clinical microbiology reviews. 2013, 26: 135-
62. 
2.   van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, van Drunen K, Osterhaus A, Neijens 
H, Fokkens W: Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatric 
Allergy and Immunology. 2003, 14: 363-70. 
3.   Costa LF, Queiroz DA, Lopes da Silveira H, Bernardino Neto M, de Paula NT, Oliveira TF, Tolardo AL, Yokosawa J: 
Human rhinovirus and disease severity in children. Pediatrics. 2014, 133: e312-21. 
4.   Becke K: Anesthesia in children with a cold. Current Opinion in Anaesthesiology. 2012, 25: 333-9. 
5.   Tait AR, Malviya S, Voepel-Lewis T, Munro HM, Seiwert M, Pandit UA: Risk factors for perioperative adverse 
respiratory events in children with upper respiratory tract infections. Anesthesiology. 2001, 95: 299-306. 
6.   von Ungern-Sternberg BS, Boda K, Schwab C, Sims C, Johnson C, Habre W: Laryngeal mask airway is associated 
with an increased incidence of adverse respiratory events in children with recent upper respiratory tract 
infections. Anesthesiology. 2007, 107: 714-719. 
7.   Li YP, Huang J, Huang SG, Xu JG, Xu YY, Liao JY, Feng X, Zhang XG, Wang JH, Wang J: The compromised 
inflammatory response to bacterial components after pediatric cardiac surgery is associated with 
cardiopulmonary bypass-suppressed Toll-like receptor signal transduction pathways. J Crit Care 2014, 29: 31. e7-
13. 
8.   Allen ML, Hoschtitzky JA, Peters MJ, Elliott M, Goldman A, James I, Klein NJ: Interleukin-10 and its role in clinical 
immunoparalysis following pediatric cardiac surgery. Crit Care Med. 2006, 34: 2658-65. 
9.   Cornell TT, Sun L, Hall MW, Gurney JG, Ashbrook MJ, Ohye RG, Shanley TP: Clinical implications and molecular 
mechanisms of immunoparalysis after cardiopulmonary bypass. J.Thorac Cardiovasc surg. 2012, 143: 1160-1166. 
10.  Malviya S, Voepel-Lewis T, Siewert M, Pandit UA, Riegger LQ, Tait AR: Risk factors for adverse postoperative 
outcomes in children presenting for cardiac surgery with upper respiratory tract infections. Anesthesiology 2003, 
98: 628-32. 
11.   Simsic J, Phelps C, Yates A, Galantowicz M: Management strategies after cardiac surgery in an infant with human 
rhinovirus. Pediatric Cardiology. 2013, 34: 1922-4. 
12.   Delgado-Corcoran C, Witte MK, Ampofo K, Castillo R, Bratton SL: The Impact of Human Rhinovirus Infection in 
Pediatric Patients Undergoing Heart Surgery. Pediatric Cardiology . 2014, 35: 1387-94. 
13.   Medweb Development lab. http://www.cahal.nl (2015). Accessed 20 May 2015. 
14.   Jacobs JP, Jacobs ML, Lacour-Gayet FG, Jenkins KJ, Gauvreau K, Bacha E, Maruszewski B, Clarke DR, Tchervenkov 
CI,Gaynor JW, Spray TL, Stellin G, O'Bien SM, Elliott MJ, Mavroudis C: Stratification of complexity improves the 
utility and accuracy of outcomes analysis in a Multi-Institutional Congenital Heart Surgery Database: Application 
of the Risk Adjustment in Congenital Heart Surgery (RACHS-1) and Aristotle Systems in the Society of Thoracic 
Surgeons (STS) Congenital Heart Surgery Database. Pediatric Cardiology. 2009, 30: 1117-30. 
15.   Loens K, van Loon AM, Coenjaerts F, van Aarle Y, Goossens H, Wallace P, Claas EJC, Ieven M, GRACE Study Group: 
Performance of Different Mono- and Multiplex Nucleic AcidAmplification Tests on a Multipathogen External 
Quality AssessmentPanel. Journal of Clinical Microbiology. 2011, 50: 977-87. 
16.   Zlateva KT, de Vries JJ, Coenjaerts FE, van Loon AM, Verheij T, Little P, Butler CC, Goossens H, Ieven M, Claas ECJ, 
GRACE Study Group: Prolonged shedding of rhinovirus and re-infection in adults with respiratory tract illness. 










File 1: Questionnaire, questionnaire, which will be sent to all patients, asking for signs and symptoms 




The impact of rhinovirus in children undergoing cardiac surgery 




2. Does your child have any problems concerning his/ her airways? If yes please specify (for example 








4. Does your child often suffer from respiratory infections? How many episodes a year? 
□ 1 
□ 2 to 4 
□ 5 to 8 
□ More than 8 















































Runny nose □ □ □ □ □ □ 
Nasal congestion □ □ □ □ □ □ 
Sneezing □ □ □ □ □ □ 
Wheezing □ □ □ □ □ □ 
Cough □ □ □ □ □ □ 
Mucous expectorate □ □ □ □ □ □ 
Hoarseness □ □ □ □ □ □ 
Sore throat □ □ □ □ □ □ 
Earache □ □ □ □ □ □ 
Otorrhoea □ □ □ □ □ □ 
Fever □ □ □ □ □ □ 
Being unwell □ □ □ □ □ □ 
 
If your child did not suffer from any of the above symptoms, you can continue to question 12. 
 
 
6. If your child had a fever in the past 6 weeks, what was the maximum temperature? 
□ 37 – 37.5 
□ 37.5 – 38.0 
□ 38.0 – 38.5 
□ 38.5 – 39.0 
□ 39.0 – 39.5 
□ 40 degrees or more 
 





8. Did your child use any medication (for example nose drops/ antibiotic/ analgesics) for the symptoms 
mentioned above, if so which? 
 
 
9. Did you visit a doctor concerning these symptoms? 
□ Yes 
□ No (go to question 11) 
10. Did your doctor order any laboratory tests to determine the cause of the symptoms. If so, do you 
know the results? 
 
 
11. Does your child have any symptoms at this moment, if so which? If not, what was the last time your 
child did have symptoms? 
 
 
12. Are there family members who have had a respiratory infection in the past 6 weeks, if so what is their 
family relation with your child? 
 
 
13. Are there lung diseases in the family, for example asthma or cystic fibrosis? If so, which disease and 
what is the family relation with your child? 
 
 
14. Are there other diseases/ disorders in the family? 
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Objectives: To determine whether children with asymptomatic carriage of rhinovirus in the 
nasopharynx before elective cardiac surgery have an increased risk of prolonged pediatric intensive 
care (PICU) length of stay. 
Study Design: Prospective, single-center, blinded observational cohort study. 
Setting: PICU in a tertiary hospital in the Netherlands. 
Patients: Children under 12 years of age undergoing elective cardiac surgery were enrolled in the 
study after informed consent of the parents/guardians. 
Interventions: The parents/guardians filled out a questionnaire regarding respiratory symptoms. On 
the day of the operation a nasopharyngeal swab was obtained. Clinical data was collected during 
PICU admission, and PICU/hospital length of stay were reported. If a patient was still intubated 3 days 
after operation an additional nasopharyngeal swab was collected. Nasopharyngeal swabs were 
tested for rhinovirus and other respiratory viruses with PCR. 
Measurements and Main Outcomes: Of the 163 included children, 74 (45%) tested rhinovirus 
positive. Rhinovirus positive patients did not have a prolonged PICU LOS (median 2 days each, 
p=0.104). Rhinovirus positive patients had a significantly shorter median hospital length of stay 
compared to rhinovirus negative patients (8 versus 9 days, respectively, p=0.002). 
Overall, 97 (60%) of the patients tested positive for one or more respiratory virus. Virus positive 
patients had significantly shorter PICU and hospital length of stay, ventilatory support, and non-
mechanical ventilation. Virus negative patients had respiratory symptoms suspected for a respiratory 
infection more often. 
In 31% of the children the parents reported mild upper respiratory complaints a day prior the cardiac 
surgery, this was associated with post extubation stridor, but no other clinical outcome measures. 
Conclusions: Preoperative rhinovirus PCR positivity is not associated with prolonged PICU LOS. Our 
findings do not support the use of routine PCR testing for respiratory viruses in asymptomatic 
children admitted for elective cardiac surgery. 
 











Symptomatic respiratory infections have been shown to increase the duration of mechanical 
ventilation, intensive care and hospital length of stay (LOS), and increase the risk of postoperative 
complications in children following cardiac surgery1-5. Previous reports have mainly focused on 
respiratory syncytial virus (RSV)1,5-11, but rhinoviruses (RV) may also impact postoperative outcomes2-
4,12-14. Rhinoviruses in humans worldwide cause more than 50% of upper respiratory tract infections 
(URTI), such as common cold12,13,15,16. They are the leading cause of viral bronchiolitis in infants, the 
most common virus associated with wheezing in infants17, prolonged shedding in specific patient 
groups, and can cause major morbidity and mortality15,18,19. 
Current anesthetic recommendations suggest that children with mild viral respiratory tract infections 
can safely be operated, but in children with wheezing, purulent secretions, fever, and altered general 
condition, surgery is recommend to be postponed20. Although RV infections, both symptomatic and 
asymptomatic, are very prevalent, there are no clear markers to help decide to postpone surgery as 
the evidence is scarce and based on small retrospective perioperative studies with variable 
symptomatology or outdated diagnostic tests1,3,20,21. Children with congenital heart diseases often 
have chronic and mild upper respiratory tract symptoms that may disappear after surgery. 
Postponing the operation is not in the best interest of these patients and might also result in empty 
operating rooms, leading to increased medical costs and waiting lists. Therefore, more evidence is 
needed to better ascertain which patients are at risk of perioperative complications and a protracted 
postoperative course. 
We designed a single center prospective cohort study to determine whether asymptomatic children, 
clinically cleared for elective cardiac surgery, who test PCR positive for RV preoperatively, have an 
increased risk of a prolonged postoperative pediatric intensive care (PICU) LOS compared to those 
who test negative22. We hypothesized that RV positive children would have a prolonged 
postoperative PICU LOS. 
 
MATERIALS AND METHODS 
Design 
A detailed RISK study protocol is previously published22. This prospective, single-center, blinded 
observational cohort study was designed to determine the association of RV with PICU LOS in children 
<12 years undergoing elective cardiac surgery in the Netherlands. Secondary endpoints were hospital 
LOS, duration of mechanical ventilation (MV), oxygenation index on admission, clinical suspicion of 
infection post-surgery, and development of adverse events. We also analyzed RV PCR quantification 
cycle (Cq)-values, RV genotypes, a parental questionnaire, and the occurrence of abnormal findings 
during intubation with the primary and secondary outcome measures. 
Excluded were children admitted to hospital prior to surgery, who required emergency surgery, were 
not admitted to the PICU after operation (negligible amount), would have a planned prolonged PICU 






The parents/guardians of the eligible children received the information folder and a questionnaire 
(see supplement 1). The questionnaire consisted of questions regarding respiratory symptoms during 
the six weeks prior to surgery (e.g. fever, runny nose, coughing, wheezing, etc.), underlying 
pulmonary disease (of the children and their family), medication use, prematurity, and passive 
smoking. 
As per local protocol, children were admitted one day before the operation (day 0), and clinically 
assessed and cleared for the operation by the anesthesiologist, cardiologist and cardiac surgeon 
when no signs of active infection other than rhinorrhea or nasal congestion were present. Written 
informed consent was then asked by the independent researchers. On the day of surgery (day 1) a 
nasopharyngeal swab for viral testing was obtained at the induction of anesthesia. Anesthesia was 
induced with propofol or sevoflurane and maintained with propofol and either sufentanil or 
remifentanil at the discretion of the anesthesiologist. The anesthesiologist filled out a study form (see 
supplement 2) detailing findings at direct laryngoscopy (secretions, redness, pus) and other details 
regarding the induction, the use of steroids, type of anesthesia, and operation conditions. Also, 
cardiopulmonary bypass times, type of operation, and the Risk Adjustment for Congenital Heart 
Surgery Score (RACHS) score were collected 23. After the operation, children were admitted to the 
PICU, and clinical and laboratory data (blood gas analysis, inflammatory markers, inotrope dose, 
respiratory conditions, medication and infection) were prospectively collected until PICU discharge, 
and date of hospital discharge. In case of prolonged PICU admission, a follow-up swab was taken at 
day 4 of the patients with respiratory support. 
All children received 24 hours of peri-operative cefazolin prophylaxis. In the case of postoperative 
open chest management, cefazolin was switched to flucloxacillin after 24 hours and continued until 




A ‘positive’ questionnaire was defined as any respiratory symptoms in the six weeks prior to surgery, 
as reported by the parents. Respiratory ‘complaints on admission’ were defined as rhinorrhea and/or 
nasal congestion present as reported by parents. Hospital LOS was the LOS in the hospital from the 
day of admission prior to operation until discharge. An ‘adverse event’ included reintubation, 
readmission, post-extubation stridor, suspected clinical infection, cardiac arrest requiring 
resuscitation, or arrhythmia requiring treatment. Reintubation was defined as intubation within 48 
hours of extubation and ‘readmission’ as readmission within 48 hours of PICU discharge. Post-
extubation stridor was defined as stridor within 48 hours of extubation requiring treatment with 
inhaled steroids, inhaled adrenaline, or systemic steroids. Clinical suspicion of infection was defined 
as clinical symptoms leading to microbiologic testing and/or antibiotic treatment at the discretion of 
the treating intensivist. We defined ‘abnormal laryngoscopy’ as redness and/or (purulent) secretions 
of the larynx, identified by direct laryngoscopy at the time of intubation. No indirect (fiberoptic) 









atelectasis and/or a consolidation was present. Non-invasive respiratory support was defined as 
nasal or mask with continuous positive airway pressure, mask ventilation, or high-flow nasal cannula. 
 
Respiratory virus testing 
After publication, our protocol was amended, and all viral respiratory pathogens in our assay were 
tested22. The nasopharyngeal swabs (day 1) were tested for respiratory viruses by means of in-house 
PCR 24 targeting adenovirus, bocavirus, RV, influenza A/B, RSV, metapneumovirus, para-influenza 1-
4, human coronaviruses OC43, HKU1, NL63, and 229E. The day four samples were stored at -80°C, 
and tested retrospectively. PCR results were blinded for the clinicians and (research) nurses. 
Genotyping of RV was initially performed by PCR amplification and Sanger sequencing of the VP4/2 
region as previously described by Zlateva et al.25. Later, bulk sequencing of the same amplicons was 
performed by next-generation sequencing (NovaSeq6000, Illumina, San Diego, CA, USA). Sequence 
reads were assembled using SPAdes, version 3.11.126. The reconstructed genome fragments were 
blasted (BLAST version 2.2.31), against a database of complete genomes of Picornaviridae (database 
version as of 25 October 2019, prepared with HAYGENS tool, https:// veb.lumc.nl/HAYGENS). For 
blasting, contigs with a length ranged from 600 to 700 nt concordant to the genome region of 
rhinoviruses consisting of VP4/2 genes only were used. Both nucleotide and amino acid searches for 
these regions and scaffolds were performed. 
 
Statistical Analysis 
Sample size was initially calculated based on the estimated percentage of RV positive children (20%) 
and a difference in PICU LOS of 2 days, to be approximately 250 children (ratio 1:4) 22. However, 11 
months after initiation, the percentage of RV positive children turned out to be nearly 50%, therefore 
the sample size was adjusted to 162 (ratio 1:1) and the protocol was amended accordingly. All 
continuous data were tested for distribution using the Kolmogorov-Smirnov test. Normally 
distributed data were presented as means with standard deviations and not-normally distributed 
data as medians with interquartile range (IQR). 
Significant differences between the different groups for the study endpoints were tested with Mann-
Whitney U test, t-test, Chi-square or Fisher’s exact test where appropriate. Multivariate linear 
regression analysis was used to adjust for potential confounders, and to identify risk factors. To 
compare the Cq values at the day of operation with Cq values during the PICU stay, a paired t-test 
was used. Statistical analyses were performed using IBM SPSS Statistics version 25 software. A p-
value of <0.05 was considered statistically significant. 
 
Ethical approval 
This study was approved by the medical ethics review committee of the Leiden University Medical 





During the study period, June 2015 – June 2018, 814 children (< 18 years) underwent elective cardiac 
surgery of which 359 children were eligible for inclusion. One hundred and eighty one 
parents/guardians were asked for informed consent of which 15 refused (8%), leaving 166/356 (46%) 
to be included in the study (figure 1). The main reason for exclusion was due to inability to ask 
informed consent (language barrier, admission during weekend, and staffing constraints). An 
additional two patients were excluded because of expected prolonged PICU stay (one for mechanical 
ventilation dependency due to hypotonia and one because of planned reoperation). In 164/166 (99%) 
patients a nasopharyngeal swab was obtained. For one sample the PCR failed, this patient was 
















The median age was 15 months and half of the children were male. Of the 163 children included, 74 
(45%) tested RV positive and 89 (55%) RV negative. There were no statistically significant differences 
in baseline demographics between RV positive and RV negative patients (table 1) with the exception 
that RV positive patients had more often received steroids during the operation (p=0.026), and a 
tendency towards current respiratory complaints in the RV positive patients (p=0.070). The most 
frequent operation indication was biventricular repair (91%). There was no difference in complexity 
of surgery (RACHS, CPB duration, cross clamp time, delayed sternal closure), anesthetic management 
(blood products, cumulative fluid) between the groups, or expected mortality (PRISM/PIM) 27,28. 
Out of the 74 RV positive patients, 25 (34%) had a coinfection with another virus, of which five 
patients tested positive for more than two viruses. Of the 89 RV negative patients, 23 tested positive 
for another virus, of which five patients tested positive for two viruses. After RV, adenovirus was the 
most prevalent virus (12%), followed by bocavirus (5%). Two patients (1%) were influenza A positive, 
one influenza B (0.4%) and three patients (2%) tested positive for both rhinovirus and RSV. 
Respiratory viruses were found throughout the year, with the highest percentage of virus positive 
patients in June (93%; figure 2). 
The outcome variables of RV positive and RV negative patients are listed in table 2. Before and after 
correction for age (per-protocol) and steroid use during operation, RV positive patients had similar 
PICU-LOS compared to RV negative patients (median, 2 days each, p=0.104). RV positive patients had 
a significantly shorter hospital length of stay compared to the RV negative patients (median, 8 versus 
9 days, respectively; p=0.002) and were suspected of clinical infection after surgery twice less often 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
  2
3 
   
   
  2
0 
   
   
   
12
   
   
   
  2
4 
   
   
  1
4 
   
   
   
13
   
   
   
  8
   
   
   
   
 6
   
   
   
  7
   
   













































































































































































































































































































































































































































































































































































































































































































































































































































































































PICU: pediatric intensive care unit, LOS: length of stay, IQR: interquartile range, JET: junctional ectopic 
tachycardia, AV: atrioventricular, RV: rhinovirus, Cq: quantification cycle. * corrected for age and steroid use 
during operation.  
 
The outcome variables of ‘any virus positive’ (including RV positive patients, 60%) and ‘virus negative’ 
(40%) patients are listed in table 3. The virus negative patients were smaller, younger, had more 
complicated surgery reflected by their RACHS scores, had more frequent current respiratory 
complaints, and tended to have more steroids during operation (see supplement 3). After correction 
for weight, age (per-protocol), and RACHS score, the virus positive patients compared to virus 
negative patients had significantly shorter PICU LOS (median, 2 versus 3 days, respectively, p=0.048) 
and hospital LOS (8 versus 9.5 days, respectively, p<0.001). Virus positive patients received shorter 
ventilatory support (0.41 versus 0.51 days, p=0.042), shorter non-invasive ventilatory support (18 
versus 45 hours, p=0.009), and were significantly less often suspected of having a clinical infection 
postoperatively (10 versus 24%, p=0.017). In virus positive patients, parents reported respiratory 
complaints on admission significantly more often than in virus negative patients (36 versus 21%, 
respectively, p=0.03). Similar results, regarding PICU/hospital LOS and duration of mechanical 
ventilation, were found between virus positive and virus negative patients when we excluded the RV 
positive patients (data not shown). 
Overall, in 50 patients (31%) there was redness or pus during intubation and were suspected of a 
postoperative clinical infection twice more often than patients without redness or pus (26% versus 
































































































































































































































































































































































































































































































































































































































































































































PICU: pediatric intensive care unit, LOS: Length of Stay, IQR: interquartile range, JET: junctional ectopic 
tachycardia. AV, atrioventricular, RV: rhinovirus, Cq-value: quantification cycle, *corrected for age, weight and 
RACHS score 
 
A ‘positive’ questionnaire, any respiratory symptom in the past six weeks, was found in 96% (153) of 
the 160 patients (data from 3 children could not be collected). Respiratory symptoms in the past six 
weeks were not associated with prolonged PICU LOS or any of the secondary outcome measures. Of 
the 49 (31%) patients whose parents reported mild respiratory complaints on admission, 35 (71%) 
tested positive for respiratory viruses and 27 (55%) tested RV positive. These 49 patients had similar 
PICU LOS and hospital LOS compared to patients without respiratory complaints on admission but 
had significantly longer non-invasive ventilatory support median 17.5 (4.5-38.5) versus 42 (18-73) 
hours, respectively, p=0.028) and post-extubation stridor significantly more often than patients who 
did not have respiratory complaints on admission (18 versus 5%, respectively, p=0.012). 
As mild respiratory complaints on admission alone were not associated with worse clinical outcome 
(defined by duration of MV > 2 days or PICU LOS > 4 days), we performed multivariate linear 
regression analysis to determine if a combination of a positive questionnaire, current complaints, 
abnormal laryngoscopy and RV positive would be predictive of prolonged PICU LOS. However, it was 
not possible to identify/develop a prediction model based on our results. 
Twenty-six patients (15%) developed symptoms suspected for a postoperative respiratory infection. 
They had significantly longer cardiopulmonary bypass (CPB) times, cross-clamp times, higher PRISM 
and RACHS scores, more frequent steroid use during operation, and delayed sternal closure more 
often, indicating more complicated surgeries, as compared to patients without a postoperative 
infection (data not shown). After correction for all these factors and age, this group still had 
significantly increased PICU LOS (7 versus 2 days, p =<0.001), and hospital LOS (8 versus 16 days, 
p=0.002), and prolonged duration of mechanical ventilation (2.8 versus 0.4 days, p =0.003) and 
compared to patients without clinical infection. 
Of all 163 patients, 45 (28%) were still admitted at the PICU at day four, which was similar in RV 
positive and RV negative patients (16 versus 29, respectively, p=0.119, figure 1). Twenty-two (49%) 
of these 45 patients were still intubated, and in 17 (77%) patients an follow-up nasopharyngeal swab 
was obtained for the detection of respiratory viruses. Seven of these 17 patients were RV positive 
prior to surgery, of which 5/7 (71%) were again RV positive in the follow-up sample, no significant 
difference in Cq value was found, of which two patients had an infection with another RV type 
compared to pre-operative (RV-B52 prior to surgery and RV-A41 on day 4, and RV-A71 and RV-A1 
respectively). Ten of these 17 patients were RV negative prior to surgery, of which 1/10 (10%) became 
RV positive in the follow-up sample (RVA9). 
 
The mean Cq value on the day of operation of the 74 rhinovirus positive patients was 27 (range 16.2 
to 34.8). Rhinovirus positive patients with a high viral load (Cq<25) and rhinovirus negative patients 




and steroid use). No significant differences were found between rhinovirus Cq<25 and> 25 in hospital 
length of stay (p=0.812, corrected for age and steroid use). Mixed infections or RV species were not 
associated with a difference in PICU or hospital LOS. 
In 67 (84%) out of 80 RV positive samples RV could be typed, 61 day 1 samples and 6 day 4 samples. 
Of the 64 unique samples, the majority of the patients had RV species A (56%, 36/64), followed by 
species C (27%,17/64) and species B (17%,11/64). An overview of the RV genotypes within each 
































































































































This prospective study, screening 163 children on the day of elective cardiac surgery during all 
seasons over several years, showed that RV was detected in 45% of the children and any respiratory 
virus even in 60%. Contrary to our hypothesis, RV positive patients had a similar duration of PICU LOS 
but a shorter hospital LOS compared to RV negative patients. 
The very high proportion of 45% RV positive patients was unexpected. We predicted to find RV in 
approximately 20% of children, based on earlier reports of asymptomatic children in the Netherlands 
(range 14-28%) and infants undergoing cardiac surgery in Utah, USA14,15. We hypothesize that this 
high prevalence might be explained by our geographical location, inclusion throughout the year, 
young age (15 months), and underlying cardiac disease. 
The earliest studies that demonstrated a negative effect of respiratory viruses on postoperative 
outcomes used ELISA’s, in which positivity might have represented a more serious infection5 
compared to the modern highly sensitive PCR assays, which could represent prolonged shedding and 
asymptomatic carrier status29-31. However, we expected a certain number of asymptomatic carriers 
of RV to develop a symptomatic infection after surgery due to exposure to CPB and subsequent 
immunoparalysis32-34. Our results confirm a very recent and similar, but smaller, study by Delgado et 
al., who also observed no difference in postoperative outcomes in preoperatively tested (all 
respiratory viruses) asymptomatic infants14. 
We found a significantly shorter hospital length of stay in the RV positive patients compared to the 
RV negative patients and they were less often suspected of a postoperative clinical infection. This 
effect was also present in the ‘any virus positive’ patients. This might be the effect of an unknown 
confounder. However, recent studies investigating the relationship between respiratory microbiota 
and disease suggest that the microbiota acquired during childhood may affect immunological 
responses and may be related with health35. Rhinovirus can also very often be found in healthy 
children. In a study by Man et al. for instance, RV was significantly less common in children admitted 
with a lower respiratory infection than in healthy children36.The precise mechanism as to how the 
respiratory viral and bacterial microbiota might be associated with health remains to be elucidated. 
Almost all patients (96%) in our study had a positive questionnaire indicating respiratory symptoms 
in the 6 weeks prior to the operation. We deliberately asked parents about this 6-week period as the 
risk of peri-operative adverse events is increased up to 6 weeks after upper respiratory tract 
infections (URTI)20. Delgado-Corcoran et al. conducted a very similar questionnaire but only focused 
on two weeks pre-operatively and found a positive questionnaire in 66% of their patients, not related 
to clinical outcomes14. 
Thirty-one percent of the parents of patients in our study reported rhinorrhea and/or nasal 
congestion on admission. Parental confirmation of an URTI has been shown to be a better predictor 
of airway complications than the use of symptom criteria alone37. None had signs of active infection 
(fever, malaise, cough, etc.) and all were medically cleared for surgery. They did have significantly 
more post-extubation stridor requiring intervention (18 versus 5%; p=0.012). In a study by Malviya 









complications38. Our results suggest that it is safe to operate children with rhinorrhea and/or nasal 
congestion, but the intensive care team should be aware of the higher chance of post-extubation 
stridor. 
In our study, anesthesiologists reported redness and/or secretions on direct laryngoscopy in 31% of 
all patients, which was significantly associated with the development of a respiratory infection 
postoperatively but did not influence LOS. As far as we are aware, there is no literature about the 
relevance of laryngeal redness and/or secretions during elective intubation, although it might be 
possible that these could represent current mild URTI and might also lead to lower respiratory tract 
infections. 
Patients who developed postoperative clinical signs of infection (16%) had significantly prolonged 
duration of mechanical ventilation, PICU LOS, and hospital LOS which is consistent with previous 
studies of children with symptomatic postoperative RV infections2,4. We could not identify pre-
operative predictors of postoperative clinical infection. We seem to have a similar incidence of 
postoperative suspected infections compared to the study by Moynihan et al., who performed a PCR 
based on clinical suspicion of an infection in 18% (318/1737) of their patients following cardiac 
surgery in Queensland, Australia4. Twenty-three percent of their PCR’s were virus positive compared 
to 45% in our cohort. Four percent of their entire cohort had a confirmed post-operative viral 
infection which is comparable to the 6% in our cohort. 
Clinical RV infections tend to be more severe in patients with a higher viral load39, however we did 
not find an association between viral load and our primary outcome measures though our study was 
not powered on comparison of subcategories. 
The majority of the patients had a RV type A infections, which is the most prevalent species40,41. In 
this paper, although not powered to detect a difference, the different species were not associated 
with prolonged PICU LOS. Although previously RV-C was often linked to more serious disease in 
children, more recent publications do not confirm these findings42-46. Future work is needed to 
determine the optimal rhinovirus genotyping sequencing strategy in the light of recent studies using 
whole genome sequencing for viral typing47. 
Our study has limitations. First, we had a large number of exclusions, which might have introduced a 
selection bias. However, the intended sample size was reached and we included children during all 
months over several years minimizing potential bias. The limited number of patients operated in 
August and December might be explained by the holidays, in which elective operations are 
performed less. The second limitation is the lack of standardized pre-operative assessment. To reflect 
current standard of care we left the decision to clear patients for surgery at the discretion of the 
medical team. Unfortunately, we do not have data on the number of postponed surgeries. Third, 
defining an infection in children remains contentious and therefore we based our incidence of 
postoperative infection on the clinical judgment of the treating intensive care team rather than on 
set criteria, which does reflect the reality of PICU care. Fourth, we only collected PICU details of the 




and secondary endpoints were available. Finally, being a single-center study, results might not be 
applicable to other centers. 
We performed the largest, statistically powered, prospective observational study of pre-operative 
respiratory PCR testing in children undergoing cardiac surgery to date, with as main finding that RV 
positivity did not negatively impact PICU LOS. 
 
Conclusions 
Rhinovirus PCR positivity is highly common in asymptomatic children undergoing cardiac surgery in 
the Netherlands and is not associated with prolonged PICU LOS, but possibly even with shorter 
hospital LOS. Our findings do not support the use of routine testing for respiratory viruses in 
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File 1: Questionnaire, which was sent to all patients, asking for signs and symptoms of current and/or 
recent respiratory infections, see supplementary file study protocol 
File 2: Case report form (CRF) for the anesthesiologist during the operation 










ANESTHESIOLOGY STUDY FORM 
Operation date: …………………………… 
Weight: ……….. (kg) 












o other: …………………………………………………………………………………… 
 
Intubation: 
o secretions? □ yes □ no 
o redness / swelling? □ yes □ no 
o pus? □ yes □ no 
o endotracheal tube size: ………… mm; cuff inflated: □ yes □ no 
o details:…………………………………………………………………………. 
o ventilation difficulties? □ no □ yes: …………………………………………………. 
 
nasopharyngeal swab obtained: □ yes □ no 






- Dexamethasone? □ no □ yes, dose: …………………………………………………... 
- X-Clamping duration: ………..……………………………………………………………………………..(min) 
- CP-Bypass duration: ……………………………………………………………………………………….…(min) 









S3 Table Baseline characteristics of any virus positive/negative patients 
 
Any virus positive n=97 Virus negative n=66 p-value 
Demographics 
   
Age at surgery (months) (median, IQR) 19 (6-47) 10 (3-32) 0.510 
Male (%) 45 (46) 36 (55) 0.307 
Weight at surgery (kg) (median, IQR) 10.7 (7.1-16.1) 7.8 (5.5-12.1) 0.016 
Underlying respiratory conditions (%) 14/94 (15) 8/66 (12) 0.598 
Asthma 3 (21) 1 (13) 
 
Bronchitis 2 (14)) 0 
 
Tracheomalacia 2 (14) 0 
 
Pleural fluid 0 1 (13) 
 
Multiple airway infections 3 (21) 0 
 
Other 4 (29) 6 (75) 
 
Infectious respiratory complaints 
   
Respiratory complaints past 6 weeks (%) 90/94 (96) 63 (95) 1.000 
Current respiratory complaints (%) 35/94 (37) 14 (21) 0.030 
Risk assessment 
   
PRISM score at admission (median, IQR) (II) 5 (3-9) 6 (3-10) 0.492 
PRISM III (median, IQR) 3 (1-3) 3 (3-4) 0.107 
PIM (mean, SD) -3.77(0.60) -3.56 (0.64) 0.073 
Prematurity 11/94 (12) 8 (12) 0.936 




- Univentricular 10(10) 4(6) 
 
- Biventricular 87 (90) 62 (94) 
 
- CPB duration (minutes) (median, IQR) 87 (58-124.2) 97 (59-126.8) 0.722 
- Cross clamp time (minutes) (median, IQR) 49 (25-91) 64.5 (36.2-94.8) 0.191 
RACHS score (%) 
  
0.037 
1 24 (25) 6 (9) 
 
2 53 (55) 48 (73) 
 
3 14 (14) 10 (15) 
 
4 1 (1) 1 (2) 
 
Total blood products (median, IQR) 292 (200-375) 257 (195-330) 0.275 
Cumulative Fluid (median, IQR) 957 (552.8-1290) 973 (604.5-1365) 0.531 
Steroids during operation (%) 31 (32) 14 (21) 0.136 
Number of inotropes (%) 
  
0.756 
0 3 2 
 
1 34 19 
 
2 28 24 
 
3 3 1 
 
4 1 0 
 
Delayed sternal closure (%) 7 (7) 4 (6) 1.000 
IQR: interquartile range, PRISM: pediatric risk of mortality score, PIM: pediatric index of mortality, CPB: 
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Background: In children, rhinovirus viremia has been associated with higher nasopharyngeal loads 
and increase in severity of clinical signs and symptoms. 
Objectives: This study aims to detect rhinovirus viremia in adult patients and to establish potential 
correlations with the clinical course. 
Study design: Adult patients with rhinovirus strongly positive bronchoalveolar lavages (BAL, 
quantitation cycle, Cq values <25) detected between 2008-2014 were studied retrospectively. Blood 
sampled between two weeks before and two weeks after BAL sampling was tested for rhinovirus 
RNA. Underlying conditions, symptoms, radiography, microbiological data, and disease outcome 
were analysed. 
Results: Twenty-seven of 43 patients with rhinovirus positive BAL at Cq values <25 had blood samples 
available within the prespecified time-frame (mean blood 3-4 samples per patient). Four of these 27 
patients (15%) tested rhinovirus RNA positive in their blood (of whom one patient twice). Genotyping 
demonstrated rhinovirus A01, A24, B52 and B92 in these four immunocompromised patients. 
Viremic patients were not significantly different with regard to underlying conditions, respiratory 
symptoms, radiological findings, co-pathogens nor the number of blood samples tested for RV. 
However, patients with rhinovirus viremia had significant higher mortality rates compared to patients 
without viremia, as all four died as a consequence of respiratory problems (100%) versus 22% (5/23), 
p=0.007 (Fisher’s exact). 
Conclusions: Rhinovirus viremia can occur in adult patients with a high viral load in BAL fluid. 
Rhinovirus viremia may be considered a negative prognostic factor, although a causative role with 











Rhinovirus (RV) is the most common virus found in respiratory tract infections in children and adults1-
3. Rhinovirus primarily results in mild upper respiratory tract infections, known as the “common cold”. 
However, a role for rhinovirus in lower respiratory tract infections has also been described. 
Rhinovirus was detected in 2-17% of the community acquired pneumonias4-8, in children even up to 
26%9. Severe rhinovirus-associated pneumonias may give similar symptoms and rates of mortality as 
severe influenza-associated pneumonia, but are more likely to occur in immunocompromised10. 
Generally, the clinical picture of rhinovirus infections appears to be more severe in patients with a 
higher viral load and in elderly patients, immunocompromised hosts and patients with underlying 
chronic lung diseases11-15. Although rhinovirus C has been implicated in more severe disease16, other 
studies failed to show differences in clinical picture between different rhinovirus species17-19. 
In several case reports and prospective case series, rhinovirus RNA has been demonstrated in blood 
of paediatric patients20-27. Approximately 12% of the children with rhinovirus respiratory infections 
were found to be viremic on admission. This percentage dropped to 7 % on day three after 
admission23,25. Of the viremic paediatric patients, the majority were infected with rhinovirus C, 
varying from 67-87%20,23. Viremia was associated with a history of asthma, higher nasopharyngeal 
viral loads and more severe clinical signs and symptoms20,25. In addition, case reports on rhinovirus 
viremia have been published in patients with fatal outcome, suggesting a correlation with more 
severe disease21,26,27. Rhinovirus viremia in adult patients has not yet been demonstrated. Rhinovirus 
RNA was analysed in adult patients, inoculated with rhinovirus-16, by deMore et al.28 This group 
found no evidence of viremia. However this were healthy subjects, or with mild asthma, with upper 
respiratory tract symptoms not requiring hospitalisation. 
 
Objectives 
The aim of this study was to determine whether rhinovirus viremia occurs in adults and whether 
there is a relationship with the clinical course of the infection. 
 
STUDY DESIGN 
Patients and samples 
A laboratory database (GLIMS, MIPS, Belgium) search was performed for bronchoalveolar lavages 
(BAL) in adults between January 2008 and June of 2014 in the tertiary care hospital Leiden University 
Medical Center (LUMC, Leiden, the Netherlands). All BAL samples were included in the initial 
selection, however this invasive diagnostic procedure is performed primarily in respiratory 
insufficient and immunocompromised patients. Adult patients with a rhinovirus PCR positive BAL and 
a quantitation cycle (Cq) value of 25 and below were considered strongly positive, described as risk 
factor for RV viremia in children20, and included in the study. Of these patients, stored plasma (-80⁰C) 
or serum (-20⁰C) samples (previously sent to the microbiological lab for routine diagnostics) were 




weeks before to two weeks after BAL sampling, with a maximum of one per day, were tested for the 
presence of rhinovirus RNA. 
Patient characteristics, underlying diseases, symptoms, laboratory values, chest radiography, and 
disease outcome were retrospectively obtained from the patient records and laboratory databases. 
Stem cell transplantation patients were routinely screened for reactivation of cytomegalovirus 
(CMV), Epstein Barr virus and adenovirus by viral load testing. 
 
Rhinovirus RNA detection 
Nucleic acids were extracted from thawed serum or plasma samples with the MagNA Pure LC, using 
the Total Nucleic Acid Isolation Kit - Large Volume (Roche Diagnostics). The input was 1000 µl serum 
or plasma with elution of 50 µl extracted nucleic acid. If insufficient clinical sample was available, 
negative plasma was added up to 1000 µl. 
Rhinovirus RNA amplification was performed in duplicate with an in-house real-time polymerase 
chain reaction (amplifying a 142-bp fragment of the 5’-UTR region), all samples in one run 
simultaneously, using primers, probes and conditions previously described by Loens et al.29.Cq 
values, normalized using a fixed fluorescence threshold, were used as an indicative measure of viral 
load. Rhinovirus typing of respiratory samples from viremic patients was performed by amplification 
and sequencing of the VP4/VP2 genome region as previously described by Zlateva et al.30. 
 
Statistical analysis 
Underlying respiratory illnesses, transplantation status, symptoms, radiographic changes, 
microbiologic findings, and outcome of rhinovirus viremia positive patients were compared to 
rhinovirus viremia negative patients. Categorical data were compared using 2x 2 tables with Fisher’s 
exact test and Odds ratios. Numeric variables were compared using the independent t-test for 
equality of means. All statistical analysis was performed using IBM SPSS Statistics version 20.00 
software for Windows. 
 
Ethical approval 




Between January 2008 and June of 2014, 791 bronchoalveolar lavages from 638 adult patients were 
tested for rhinovirus RNA. A total of 114 BAL samples from 84 (13%) patients tested positive for 
rhinovirus (range Cq values 15-45, randomly distributed, data not shown). Of 43 patients (51%, 48 
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these 43 patients (63%), on average three- four blood samples per BAL sample (31 BAL samples). In 
14 samples from nine patients, the available plasma volume varied from 200 to 950 µl. 
 
Rhinovirus viremia positive patients 
Four out of the 27 patients (15%) with BAL RV Cq<25 tested rhinovirus RNA positive in their blood 
samples (range Cq values 34 – 42) divided over the years 2010, 2011 and 2012. From these viremic 
patients a total of 22 blood samples were tested of which five tested positive. One patient was found 
viremic twice, on day -six and day +three relative to BAL sampling. For an overview of tested blood 
samples relative to the day of the BAL see Figure 1. 
 
 
Figure 1. Detection of rhinovirus in blood relative to the bronchoalveolar lavage (day 0). 
This figure shows the distribution of the different samples compared to the sample date of the 
bronchoalveolar lavage, the onset of symptoms, and the day of discharge/ death of the patients. Of patients 
3, 4 and 7 multiple BAL samples were included. In this figure the first BAL was shown as day 0 if two BALs were 
available (patients 3 and 7), or the second BAL of three in total (patient 4). 
Horizontal lines represent individual patients; the squares represent individual blood samples, onset of 
respiratory symptoms, discharge, and death. Cq values are shown for the positive samples. 





Genotyping of RV viremic patients 
The rhinovirus load in the blood samples of the viremic patients was considered too low to enable 
successful genotyping. Therefore, the associated BAL samples were used, which resulted in two 
patients with RV-A: A24 and A01, and two patients with RV- B: B52 and B92. 
 
Characteristics of rhinovirus viremic patients 
Patient 1 (Figure 1), was a 60-year-old female who received allogeneic stem cell transplantation for 
multiple myeloma. One month after transplantation she was admitted at the haematology 
department with neutropenic fever with a leukocyte count of 0.1 x109 g/L. During her stay in the 
hospital she developed cough and dyspnoea. One day after symptom onset a BAL was performed, 
which was positive for rhinovirus A01 (Cq 24), parainfluenza 2 (Cq 15), adenovirus (Cq 35) and tested 
galactomannan positive. Bacterial culture showed Stenotrophomonas maltophilia. One of six blood 
samples tested RV positive, Cq 42. Fourteen days after the BAL was performed the patient died with 
multiple, respiratory and systemic infections (CMV reactivation- Aspergillus pneumonia- 
Stenotrophomonas bacteraemia) and unexplained on-going neutropenia. No autopsy was 
performed. The last two blood samples before her death were RV negative. 
Patient 2, was a 68-year-old male with myelodysplastic syndrome for which he received non-
myeloablative allogeneic stem cell transplantation four months prior to admittance to the intensive 
care unit (ICU) due to respiratory failure. At that time leukocyte count was 3.6 x109 /L and lymphocyte 
count 0.6 x109 /L. Four days after symptom onset a BAL was performed, in which a rhinovirus RV-B52 
(Cq 23), was detected. No other pathogen (viral, bacterial, parasitic or fungal) could be found in the 
BAL sample. In total three blood samples were tested. The blood samples drawn six days before and 
three days after the BAL tested rhinovirus positive, Cq 34 to 36. The blood sample drawn three days 
before the BAL was rhinovirus negative. The patient died 11 days after the BAL was performed. 
Autopsy showed extensive pulmonary fibrosis, the lung architecture was completely destroyed 
without specific characteristics. Reported cause of death was respiratory failure of unknown cause. 
Patient 3 was a 65-year-old female with a double cord blood stem cell transplantation for a diffuse 
large B cell lymphoma. She was admitted to the ICU for neurological deterioration three months after 
transplantation, leukocyte count was 2.2 x109 /L and lymphocyte count 0.8 x109 /L. Two 
bronchoalveolar lavages were performed, seven days apart, which both contained RV-A24 with Cq 
values of 19and 18 respectively. Pulmonary symptoms started 15 days prior to the initial BAL. 
Galactomannan was positive in both BALs, no other viral or bacterial pathogens could be found. In 
total seven blood samples were tested, one tested positive, Cq 37, taken 13 days after the initial BAL. 
The patient died 16 days after the first BAL was performed. The last available blood sample before 
the patient died was rhinovirus negative. Shortly before death, progressive neurological 
deterioration, kidney insufficiency and Aspergillus pneumonia were observed. Autopsy was not 
performed. 
Patient 4, a 48-year-old male with a kidney transplant was admitted at the ICU with respiratory 
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at the time of the second BAL. Three BALs were performed, with RV Cq values of 24, 22 and 17 
respectively. The second BAL, containing RV-B92, is used as index BAL in figure 1. The only pathogen 
consistently detected in all three BALs was rhinovirus. In total six blood samples were tested for 
rhinovirus, one tested positive Cq 36, taken 52 days after the first day of illness, being 16 days before 
the patients died of respiratory failure. Autopsy was not performed, but a lung biopsy, taken before 
the patient deceased, showed strongly disturbed lung architecture with few inflammatory infiltrate 
(no PCR performed). This was suggestive for a cryptogenic organizing pneumonia, possibly due to 
recurrent infections. 
 
Rhinovirus viremia risk factors 
In both the viremic and non-viremic groups the majority of patients had received allogeneic stem cell 
transplantation (Table 1). Almost all patients had clinically and radiologically signs of severe lower 
respiratory tract disease (cough, dyspnoea, radiological abnormalities). 
No significant difference could be found between viremic and non-viremic patients with regard to 
underlying condition, symptoms, radiological findings or co-pathogens. 
All patients with rhinovirus viremia died (4/4, 100%) as a consequence of respiratory problems during 
their hospital admission. Only five out of 23 (22%) rhinovirus viremia negative patients died during 
hospital admission, of which three died because of respiratory failure (all three had a co-infection 




















    lower upper  
General       
Age, years, median (range) 60 (48-68) 56 (21-78)  -10.6 18.9 0.57 
Male, no. (%) 2 (50) 15 (65) 0.53 0.06 4.5 0.62 
Admission to hospital (%) 4 (100) 22 (96)    0.67 
Conditions underlying       
Smoking 2 (2/3) 8 (8/17) 2.25 0.2 29.8 1 
Pulmonary condition underlying 1 (1/4) 5 (5/22) 1.13 0.1 13.4 1 
STx (%) 3 (75) 12 (52) 2.75 0.2 30.5 0.61 
Allogeneic 3 (3/3) 11 (11/12)    1 
NMA 2 (2/3) 7 (7/11)    1 
Related 0 (0/3) 4 (4/11) 
   
0.51 
GVHD 0 (0/3) 6 (6/12)    0.23 
Solid organ Tx (%) 1 (25) 5 (22) 1.2 0.1 14.2 1 
Prednisone use (%) 1 (25) 12 (52) 0.31 0.03 3.4 0.60 
Symptoms       
Fever 2 (2/3) 18 (18/23) 0.56 0.04 7.5 1 
Coughing 3 (3/3) 14 (14/15) 
   
1 
Dyspnoea 3 (3/3) 21 (21/21)     
Laboratory findings 
      
CRP mg/L, mean (range) 115 (22-162) 131 (3-417)  -162.4 131.3 0.83 
Leukocytes x109 /L, mean (range) 7.3 (0.1-23.3) 7.7 (0.1-22.9)  -7.8 6.9 0.91 
Lymphocytes x109 /L, mean 
(range) 
0.53 (0-0.83) 1.09 (0.01-
6.16) 
 -2.2 1.0 0.47 
Saturation %, without oxygen , 
mean(range) 
96 (90-100) 94 (88-100)  -3.4 6.6 0.51 
pH, mean (range) 7.45 (7.38-7.54) 7.42 (7.24-
7.52) 
 -0.06 0.1 0.56 
Radiography       
Abnormalities (%) 4 (100) 22 (96)    1 
Ground glass 2 (2/3) 8 (8/16) 2 0.2 26.7 1 
Consolidations (%) 4 (100) 18 (78)  
  
0.56 




   
Duration of respiratory disease 
to BAL, mean (range) 
7 (1-15) 12 (2-36)  -14.8 5.5 0.36 
Days post-Tx and BAL sampling 
date, mean (range) 
343 (60-1034) 517 (17-
4455) 
 -1300.6 951.8 0.75 
Rhinovirus BAL Cq value, mean 
(range) 
22.9 (19.4-24.5) 20.6 (15.5-
24.9) 





Rhinovirus viremia in adult patients
145
 
Abbreviations: RV: rhinovirus, STx: stem cell transplantation, BAL: bronchoalveolar lavage, Tx: transplantation, 
GVHD: Graft-versus-host-disease:* Fisher’s exact or independent T-test 
 
DISCUSSION 
This study demonstrated the presence of rhinovirus viremia in four out of 27 adult patients with high 
loads in the respiratory tract. In addition, an association with higher mortality in the rhinovirus 
viremic patients was found. No other correlations could be found. 
These results indicate that rhinovirus viremia may be a relevant negative prognostic factor given the 
significant association with fatal outcome. No other risk factors for viremia could be identified. In 
previous studies in children, rhinovirus viremia was associated with worse clinical signs and 
symptoms and was found in several fatal cases, also suggesting that viremia may be a predictor of 
poor prognosis20-22,25-27. Whether rhinovirus viremia would play a causative role in this poor 
prognosis, in the presence or absence of co-pathogens, or whether it indicates end stage disease 
needs to be determined. Similarly, while we did not culture our blood samples we cannot deduce 
whether rhinovirus viremia is the result of leakage of viral RNA from the lungs, as may be suggested 
by the severity of illness and the high Cq values, or whether active replication takes place outside the 
respiratory tract. However, others have shown previously that rhinovirus could be cultured from the 
blood of children with severe rhinovirus infections21,26. Furthermore, in vitro, rhinovirus has been 
cultured on Hela cell suspension31 suggestive of a broader cell tropism resembling enterovirus. 
We were able to test an average of three-four blood samples per BAL sample. However, sufficient 
volumes of blood were not always available to enable testing with optimal sensitivity. In addition, a 
potential classification bias may have been introduced if more blood samples were drawn, stored 
and tested from more severely ill patients with high mortality risk compared to less severely ill 
patients. However, our comparison of the mean number of blood samples tested for RV per patient 
shows that this was comparable for the RV viremic patients and controls. 
Patients with high viral loads in the BAL were selected for rhinovirus viremia testing. High viral loads 
in BAL fluid, with an arbitrary threshold of Cq <25, were selected as it was expected these would 
show stronger correlations with viremia. Despite this potentially high-risk population only a minority 
of patients were viremic, with low viral loads. This percentage in the selected group of highly 
immunocompromised adults is comparable to the percentage of viremia described in 
immunocompetent children, while in immunocompromised children the rate of viremia may be 
considerably higher. Viremia in immunocompetent adults may occur even less frequently, although 
Respiratory co-pathogens, viral, 
bacterial or fungal (%) 
3 (75) 17 (74) 1.06 0.09 12.2 1 
No. of blood samples available 
for RV testing per BAL, mean 
(range) 
3.6 (2-6) 2.6 (1-6)  -0.8 2.9 0.26 
Outcome 
      
Days admitted, mean (range) 35 (12-53) 24 (2-106)  -16.4 37.26 0.43 






this could not be studied in our population. It must be noted that the low number of viremic patients 
reduces the power of the risk factor analysis. In children RV viremia has been shown to be associated 
with asthma20,25, therefore adults with asthma or COPD may also have a higher risk of RV viremia. 
The effects of asthma or COPD could not be determined, given the low number of patients with 
underlying pulmonary conditions. 
In children, the percentage of rhinovirus viremia positive cases has been reported to be higher on 
the day of admission compared to three days later23,25. In our adult patients this pattern could not 
be detected, potentially because blood samples were not drawn on a regular basis and the number 
of positive blood samples was low. 
Genotyping of the rhinovirus viremia positive samples revealed two RV-A, two RV-B and no RV-C 
genotypes, though RV-C appeared to be the predominant species in viremic children. The percentage 
RV-C in children with viremia varies from 67% to 87% in studies with six and 30 viremic patients 
respectively20,23. Because the number of viremic patients is low and the local prevalence of the 
different rhinovirus species over the years is unknown, it cannot yet be concluded whether the 
outcome of RV-C viremia is different between children and adults. 
In conclusion, rhinovirus viremia may occur in adult patients, possibly less frequent compared to 
children, and appears to be associated with a higher mortality. The role of such viral markers may 
also be relevant if broader genotypic approaches (sequencing) will increasingly be used in the near 
future. The pathogenesis and risk factors of rhinovirus viremia need further investigation. 
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Background: Differences in clinical impact between rhinovirus (RV) species and types in adults are 
not well established. 
The objective of this study was to determine the epidemiology and clinical impact of the different 
rhinovirus species. 
Methods: We conducted a prospective study of RV infections in adults with acute cough/lower 
respiratory tract infection (LRTI) and asymptomatic controls. Subjects were recruited from 16 primary 
care networks located in 11 European countries between 2007-2010. RV detection and genotyping 
was performed by means of real-time and conventional reverse-transcriptase polymerase-chain-
reaction assays, followed by sequence analysis. Clinical data were obtained from medical records and 
patient symptom diaries. 
Results: RV were detected in 566 (19%) of 3016 symptomatic adults, 102 (4%) of their 2539 follow-
up samples and 67 (4%) of 1677 asymptomatic controls. Genotyping was successful for 538 (95%) 
symptomatic subjects, 86 (84%) follow-up infections, and 62 (93%) controls. RV-A was the prevailing 
species, associated with an increased risk of LRTI as compared to RV-B (relative risk [RR], 4.5; IC 2.5-
7.9; P<0.001) and RV-C (RR, 2.2; IC 1.2-3.9; P=0.010). In symptomatic subjects RV-A loads were higher 
than those of RV-B (P= 0.015). Symptom scores and duration were similar across species. More RV-A 
infected patients felt generally unwell in comparison to RV-C (P=0.023). Of the 140 RV types 
identified, 5 were new types; asymptomatic infections were associated with multiple types. 
Interpretation: In adults RV-A is significantly more often detected in cases with acute cough/ LRTI 











Rhinoviruses (RV) are the most prevalent respiratory pathogens in humans, accounting for 
approximately 20-50% of respiratory tract infections annually1-4. Infection with RV can lead to a wide 
spectrum of clinical manifestations ranging from asymptomatic to severe lower respiratory illness2,5,6. 
RV is also recognized as a major cause of exacerbations of chronic obstructive pulmonary disease 
(COPD), asthma and cystic fibrosis7,8. Co-infections with other viral or bacterial pathogens have been 
frequently reported, potentially increasing clinical severity5,9,10. Over 160 RV types have been 
identified and classified into three genetically distinct species (RV-A, RV-B and RV–C) within the genus 
Enterovirus of the family Picornaviridae11. RV-A has been the most frequently detected RV species, 
followed by RV-C and RV-B respectively3,4. Although the clinical significance of RV species and types 
remains poorly defined, RV-C has been predominantly linked to asthma exacerbations and more 
serious respiratory illness in young children12-14. More recently similar clinical presentations across 
species have been reported15-18. 
Despite the high morbidity and disease burden of RV infections, there are currently no effective and 
safe antiviral treatments, and efforts to develop an effective vaccine have been hampered by the 
substantial antigenic diversity between RV types and species. A more practical approach could be the 
development of vaccines targeting more prevalent or pathogenic rhinovirus types although the 
feasibility of this depends on whether particular RV species or types are associated with more 
frequent or severe respiratory illness. Previous studies have been limited by the absence of 
asymptomatic controls and incomplete microbiological investigation, and were focused mainly on 
hospitalized young children. 
The aim of this study was to determine the epidemiology and clinical impact of the different 
rhinovirus species through a community-based comparative evaluation of disease severity among 
adult subjects infected with different RV species and types. Additionally, the multicentre approach 
provides insight in geographical differences in RV epidemiology. 
 
METHODS 
Study design and subjects 
Respiratory samples were obtained from subjects aged 18 years and older enrolled as part of the 
GRACE European Network of Excellence (www.grace-lrti.org) focusing on improving the management 
of community-acquired LRTIs. Sixteen primary care networks from 11 European countries including: 
Belgium (Antwerp and Ghent); France (Nice), Germany (Rotenberg), Italy (Milan), the Netherlands 
(Utrecht), Poland (Bialystok, Lodz and Szczecin), Slovakia (Bratislava), Slovenia (Jesenice), Spain 
(Barcelona and Mataró), Sweden (Jönköping), and United Kingdom (Cardiff and Southampton) 
participated in prospective recruitment of patients presenting with acute cough and signs of an acute 
LRTI over the period October 2007 - June 2010. Cases were patients presenting at the general 
practitioner (GP) with an acute or worsened cough (≤28 days duration) as the main symptom, or any 
clinical presentation considered by the GP to be caused by lower respiratory tract infection and 




and any condition associated with severe impaired immune status. Asymptomatic controls were 
subjects who consulted their GP for complaints other than respiratory, who had no symptoms and 
signs of a respiratory tract infection (RTI) and had not used antibiotics or antivirals in the previous 2 
weeks. Case and controls were recruited from the same GP center, within 14 days of each other and 
with a maximum 5-year age difference. 
Nasopharyngeal swab (NPS) and sputum (if available) samples were collected from case (V1) and 
control (V0) patients during their first visit to the GP, for which standardization was obtained by 
training of staff. Follow-up NPS samples were obtained from case patients at the second visit (V2) to 
the GP after approximately 28-days. Medical ethics committees in participating countries approved 
the study and all participants provided written informed consent. 
The original study was designed to evaluate the aetiology of lower respiratory tract infections in GP 
settings, as described by Ieven et. al., this study is a post-hoc analysis19.  
 
Data collection 
Clinical data, including medical history, co-morbidities and their management/treatment, and days 
the patient felt unwell were recorded by the GP on a case report form (CRF) at the first consultation. 
The presence or absence of cough, sputum production, shortness of breath, wheeze, coryza, fever, 
chest pain, muscle aching, headache, disturbed sleep, feeling generally unwell, interference with 
normal activities, confusion/disorientation and diarrhoea, were documented. If present, the severity 
of each symptom was rated on a 4-point scale ranging from ‘no problem=1’ to ‘severe problem=4’. 
Following the first GP consultation, patients were requested to complete a daily symptom diary for 
the duration of illness (to a maximum of 28 days). The presence and severity of the above symptoms 
(except diarrhoea), were rated on a 7-point scale ranging from ‘normal/not affected =0’ to ‘as bad as 
it could be=6’. 
 
Clinical assessment 
The disease severity of rhinovirus infections was evaluated by comparing the following clinical 
characteristics: 1) initial symptom score, 2) duration of illness, 3) maximal symptom score, and 4) 
duration of higher symptom score. The ‘initial symptom score’ was estimated as the mean severity 
score of at least 12 of the 14 symptoms evaluated by the GP during the first visit of the patient. The 
‘duration of illness’, ‘maximal symptom score’ and ‘duration of higher symptom score’ were 
estimated based on the presence and severity of 13 symptoms excluding diarrhoea, recorded in the 
patient’s daily symptom diary as described previously. The duration of illness was defined as the total 
sum of days a patient felt unwell before the first GP visit and the number of days the patient 
experienced any of the 13 symptoms over the 28-day follow-up period. The duration of higher 
symptom score was the number of days a patient had a mean daily symptom score of two or more 
based on the 7-point scale19. The occurrence and severity of each symptom recorded during the first 









The overall results of the laboratory diagnostics were previously described by Ieven et al20. In short, 
total nucleic acids were extracted at the University Hospital Antwerp, and examined for RV by real-
time PCR at the Leiden University Medical Center. Cycle quantification (Cq) values, which had been 
normalized using a fixed baseline fluorescence threshold, were used as an indicative measure of viral 
load. Bacterial and fungal infections were detected in NPS or/and sputum samples by conventional 
culture and/or molecular methods21. 
 
RV typing 
RV genotyping was conducted by amplification and sequencing of partial VP3/VP1, VP4/VP2 or/and 
5’-UTR viral genome fragments as described previously19. BLASTn analyses were conducted for initial 
species identification and then confirmed by phylogenetic analysis. RV sequences were compared to 
prototype strains and assigned to types based on phylogenetic analysis and pairwise p-distances (see 
Supplementary Appendix). RV sequences from this study have been deposited in GenBank under the 
accession numbers KP736530-KP737279 and KR045604. 
 
Statistical analysis 
Continuous variables were summarized as medians with interquartile (IQR) ranges or means with 
95% confidence interval and for categorical variables, the frequencies in each category were 
calculated. Demographic and clinical characteristics were compared across RV species within RV-
positive symptomatic and asymptomatic adults by using risk-ratio and/or chi-square tests for 
categorical variables and the non-parametric Kruskal-Wallis test, Mann-Whitney U test or 
independent t-test or one way ANOVA when appropriate for continuous variables. Correction for 
possible confounders (age, sex, geographical location, sample season and sample year) was 
performed using multivariable linear or logistic regression for continuous or binary outcome 
measures, respectively. The statistical analyses were conducted in the IBM SPSS Statistics software 
version 25 for Windows (IBM Corp. Released 2011, Armonk, NY: IBM Corp.). A two-sided P-value 
<0.05 was considered statistically significant. 
 
RESULTS 
RV detection and species distribution 
In this study 3070 (99%) (median age 50, [IQR, 36-63 years]; male/female ratio 1:1.5) of 3104 
recruited adults with acute cough/LRTI and 1677 asymptomatic controls (median age 50, [IQR, 35-62 
years]; male/female ratio 1:1.5) were included. Thirty-four patients with no available NPS material 
or CRF were excluded (Figure 1). NPS samples were obtained from 3016 symptomatic patients during 
the first visit (V1) to the GP and a follow-up (V2) sample was collected from 2485 (82%) of these 
patients19. For 54 symptomatic patients, only a follow-up NPS was available for testing, resulting in a 




3104 symptomatic patients 1844 (60%) tested positive for a respiratory pathogen, of which 350 (11%) 
a bacterial pathogen only, 1190 (39%) a respiratory virus and 304 (10%) a double infection. Of the 
1677 asymptomatic controls, 205 (12%) had an respiratory virus as previously reported by Ieven et 
al19. 
RV was detected in 766 out of 7232 samples (11%) and genotyping was successful for 717 (94%) of 
these samples. Enteroviruses including 13 EV-D68, 10 EV-C104, 5 EV-C105, 2 EV-C117 types, and 1 
EV-C (non-typeable), were identified due to cross-reactivity in our diagnostic RV assay. These 31 EV-
positive samples were excluded from further analysis. Forty-nine (6%) RV-positive samples with 
lower viral loads inferred from quantification cycle (Cq) values could not be genotyped due to 
amplification failure in the genotyping PCR (median Cq values of 29 vs. 36 in the diagnostic RT-PCR 
assay for genotyped and not-genotyped samples respectively; P<0.001). 
RV was detected in 566 (19%) V1 and 102 (4%) V2 samples from case patients (of which 21 were 
positive in both the V1 and V2 samples) and in 67 (4%) V0 samples from asymptomatic control 
patients. Of the 735 RV infection episodes, 182 (25%) were co-infections, of which 68 (9%) with 
another virus, 103 (14%) with a bacterial co-infection, and 11 (2%) had a rhinovirus infection with at 
least 2 other pathogens. Commensals and Candida species were not considered causative pathogens 
and were excluded from the analysis. 
Symptomatic (V1 positive) RV-positive patients tended to be older than asymptomatic patients 
(median 47 years, [IQR, 33-60 years] vs. median 38 years [IQR, 27-58 years]; P=0.058, respectively), 
see Table 1. No significant differences were found in sex, location, and sample season and year 
between RV-positive symptomatic and asymptomatic adults. Of 563 of the 566 V1 patients 
underlying conditions were stated: 238 (42%) had an underlying condition, including 122 (51%) with 
respiratory comorbidities or history of hospitalization for respiratory illness. Mixed infections within 
the RV-positive adults (V1), were associated with symptomatic disease more often (29% vs 7% in the 
asymptomatic patients, RR 4.9 (95% CI 2.0-11.8) p<0.001, adjusted for age, sex, geographical 
location, sample season, sample year, and viral load). Mixed infections were not included in further 
analyses. The RV-viral load was lower in the RV-positive asymptomatic controls (mean Cq value 31 vs 
28 in patients, p<0.001, adjusted for age, sex, geographical location, sample season, sample year, and 
mixed infections). 
Virus genotyping to RV species level was successful in 538 (95%) V1, 86 (84%) V2 RV-positive samples 
from symptomatic patients and in 62 (93%) V0 control subjects. The number and proportion of RV 
species among symptomatic, follow-up and asymptomatic infections are shown in Figure 1. 
Prolonged RV shedding in symptomatic patients (V1) was identified in 6 patients as previously 











Figure 1. Rhinovirus prevalence and species distribution among (A) adults enrolled with acute 
cough/LRTI and asymptomatic (B) controls.  
Abbreviations: LRTI, lower respiratory tract infection; CRF, case report form, NPS, nasopharyngeal swab. 



















263 (42) 229 (40) 34 (51) 0.106 
Age (median,  IQR) 
 
47 (32-60) 47 (33-60) 38 (27-58) 0.058 
Ethical background (%) 563 





















Study site (%) 
    
0.281  
Antwerp BE 95 (15) 85 (15) 10 (15) 
 
 
Barcelona SP 66 (10) 64 (11) 2 (3) 
 
 
Bialystok PL 28 (4) 24 (4) 4 (6) 
 
 
Bratislava SL 30 (5) 29 (5) 1 (1) 
 
 
Cardiff GB 64 (10) 57 (10) 7 (10) 
 
 
Ghent BE 25 (4) 20 (4) 5 (7) 
 
 
Jesenice SVN 10 (2) 10 (2) 0 (0) 
 
 
Jonkoping SW 8 (1) 7 (1) 1 (1) 
 
 
Lodz PL 52 (8) 47 (8) 5 (7) 
 
 
Mataró SP 79 (12) 68 (12) 11 (16) 
 
 
Milan IT 7 (3) 17 (3) 0 (0) 
 
 
Nice FR 3 (0.5) 3 (1) 0 (0) 
 
 
Rotenberg DU 27 (4) 25 (4) 2 (3) 
 
 
Southampton GB 43 (7) 39 (7) 4 (6) 
 
 
Szczecin PL 27 (4) 22 (4) 5 (7) 
 
 
Utrecht NL 59 (9) 49 (9) 10 (15) 
 
Sample season &year (%) 632 565 67 0.918*  
autumn 07 37 (6) 34 (6) 3 (4) 
 
 
winter 07/08 49 (8) 43 (8) 6 (9) 
 
 
spring 08 73 (12) 67 (12) 6 (9) 
 
 
summer 08 4 (1) 4 (1) 0 (0) 
 
 
autumn 08 118 (19) 106 (19) 12 (18) 
 
 
winter 08/09 64 (10) 55 (10) 9 (13) 
 
 
spring 09 44 (7) 40 (7) 4 (6) 
 
 
summer 09 4 (1) 4 (1) 0 (0) 
 
 
autumn 09 131 (37) 118 (21) 13 (19) 
 
 
winter 09/10 77 (12) 69 (12) 8 (12) 
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other respiratory comorbidities 7/563 (1) 
  
 





cardiac disease 47/563 (8) 
  
 
diabetes 35/562 (6) 
  
 
allergic diseases 105/563 (23) 
  
*Overall sample season and year, symptomatic (V1) versus asymptomatic (V0) 
 
Clinical manifestations 
Complete clinical record forms and symptom diaries were available for 563 (99.5%) and 383 (67.7%) 
RV-positive symptomatic V1 patients, respectively. Age and sex characteristics of symptomatic and 
asymptomatic subjects, infection outcome, viral loads inferred from Cq values, and duration and 
severity of disease were compared across RV species (Table 2). The age and sex distribution was 
similar across RV-species in the symptomatic and control groups. In 538 RV-infected symptomatic 
patients the proportion of RV-A infections was 68% versus 12% for RV-B and 20% for RV-C infections. 
In contrast, in the 62 asymptomatic infections the proportions were similar: RV-A: 37%, RV-B: 34% 
and RV-C: 29% (Figure 1). For single infections RV-A was 4.5 and 2.2 times more often associated with 
a LRTI outcome than RV-B (P<0.001) and RV-C (P=0.010), respectively, and RV-C more often than RV-
B (RR 2.1, P=0.015). The results were similar for RV co-infected cases. In symptomatic patients with a 
RV mono-infection RV-A viral loads (mean Cq=27) were significantly higher than RV-B viral loads 
(mean Cq=30, P= 0.015). The duration, overall disease severity, and maximum daily symptom score 
were similar between RV species. The severity of the individual symptoms was also compared across 
RV species (Table 3). Significant differences were observed only for “feeling generally unwell”. In 
particular RV-A infected patients generally felt worse than those with RV-C (P=0.023). No other 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3. Frequency and severity of symptoms in adults with rhinovirus associated acute cough/LRTI 










Cough 1 (0.4) /260(99.6) 1 (2)/42 (98) 1 (1)/79 (99) RV-A vs. RV-B (0.053) 
RV-A vs. RV-C (0.400) 
RV-B vs. RV-C (0.180) 
Phlegm 131 (50)/130 (50) 22 (51)/21 (49) 48 (60)/32 (40) RV-A vs. RV-B (0.739) 
RV-A vs. RV-C (0.091) 
RV-B vs. RV-C (0.397) 
Shortness of 
breath 
171 (66)/90 (34) 27 (63)/16 (37) 55 (69)/25 (31) RV-A vs. RV-B (0.549) 
RV-A vs. RV-C (0.578) 
RV-B vs. RV-C (0.371) 
Wheeze 199 (76)/62 (24) 32 (74)/11 (26) 64 (80)/16 (20) RV-A vs. RV-B (0.798) 
RV-A vs. RV-C (0.606) 
RV-B vs. RV-C (0.566) 
Running nose 109 (42)/152 (58) 21 (49)/22 (51) 37 (46)/43 (54) RV-A vs. RV-B (0.306) 
RV-A vs. RV-C (0.667) 
RV-B vs. RV-C (0.545) 
Fever 226 (87)/35 (13) 38 (88)/5 (12) 69 (86)/11 (14) RV-A vs. RV-B (0.958) 
RV-A vs. RV-C (0.883) 
RV-B vs. RV-C (0.962) 
Chest pain 205 (79)/56 (21) 32 (74)/11 (26) 60 (75)/20 (25) RV-A vs. RV-B (0.352) 
RV-A vs. RV-C (0.534) 
RV-B vs. RV-C (0.690) 
Muscle aching 189 (72)/72 (28) 32 (74)/11 (26) 58 (73)/22 (27) RV-A vs. RV-B (0.662) 
RV-A vs. RV-C (0.990) 
RV-B vs. RV-C (0.708) 
Headache 181 (69)/80 (31) 25 (58)/18 (42) 55 (69)/25 (31) RV-A vs. RV-B (0.287) 
RV-A vs. RV-C (0.996) 
RV-B vs. RV-C (0.361) 
Disturbed sleep 141 (54)/120 (46) 25 (58)/18 (42) 38 (48)/42 (52) RV-A vs. RV-B (0.428) 
RV-A vs. RV-C (0.259) 
RV-B vs. RV-C (0.150) 
Diarrhea 256 (98)/5 (2) 41 (95)/2 (5) 78 (98)/2 (2) RV-A vs. RV-B (0.087) 
RV-A vs. RV-C (0.744) 
RV-B vs. RV-C (0.225) 










257 (98)/4 (2) 43 (100)/0 79 (99)/1 (1) RV-A vs. RV-B (0.999) 
RV-A vs. RV-C (0.999) 




156 (60)/105 (40) 23(53)/20 (47) 54 (68)/26 (33) RV-A vs. RV-B (0.364) 
RV-A vs. RV-C (0.281) 




118 (45)/143 (55) 22 (51)/21(49) 49 (61)/31 (39) RV-A vs. RV-B (0.442) 
RV-A vs. RV-C (0.023) 
RV-B vs. RV-C (0.392) 
† The presence and severity of symptoms were evaluated only for patients with rhinovirus single infections. 
Abbreviations: RV, rhinovirus; CI, confidence interval. *Corrected for age, sex, sample season, and sample year 
 
RV prevalence and species distribution according to site and year of detection 
The number of tested NPS samples, RV detection rate and species distribution among the 16 sites in 
Europe over the 3-year study period are presented in Figure 2. The majority of subjects were 
recruited in the months October to April and years were defined from July until June of the following 
year. No patients were recruited from Nice, Bialystock, Szczecin, Bratislava and Jesenice during 
2007/2008 and only 9 samples from 6 patients were available from Milan for 2009/2010. RV 
accounted for 1% up to 21% of respiratory infections per site during a particular year, when excluding 





Figure 2. Rhinovirus (RV) detection rate and species distribution according to site and year of 
detection.  
Total numbers of tested samples per location and year of isolation are presented under the corresponding 
country panel; ‘NS’ designates that no samples were available. Plot lines represent the proportion (%) of RV 
infections (right side y-axis) and bar graphs represent the number of RV-A (red), RV-B (blue) and RV-C (green) 
infections (left side y-axis). Country abbreviations: BEL (Belgium), FRA (France), DEU (Germany), ITA (Italy), 
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RV type identification 
Of the 686 sequenced rhinoviruses 654 (95%) were characterized by partial VP3/VP1 or/and VP4/VP2 
sequencing and 32 (5%) based only on the 5’-UTR (see Supplementary Appendix). The latter were 
assigned only to species taxa level, because of limited phylogenetic discrimination in the 5’-UTR 
region. Four VP4/VP2 sequences were classified only to species level based on BLASTn results due to 
poor sequence quality. A total of 650 RV sequences were assigned to 73 RV-A, 25 RV-B and 42 RV-C 
types representing 91%, 78% and 76% 11, respectively, of the currently established types within each 
species (Figure 3). Five new RV types were identified and assigned by the Picornaviridae Study Group 


















In our study RV was detected in 19% of adults with acute cough/LRTI and in 4% of follow-up samples 
as well as samples from asymptomatic controls. The overall annual prevalence ranged from 1 to 21% 
between and within communities. These data indicate that the burden of RV associated illness varies 
substantially within and between communities in different years. Several other studies have reported 
rates of RV infection from 7% to 33% in inpatient and outpatient adults with acute LRTI or influenza-
like illness15,22-25, and in 8% or less of asymptomatic adults3,4,15,26. 
RV species were identified with a different frequency among symptomatic and control subjects. With 
68% prevalence RV-A strains were significantly more common in RV infected symptomatic patients 
than RV-B (12%) or RV-C (20%) strains. In contrast, the prevalence of RV-A (37%), RV-B (34%) and RV-
C (29%) was more or less similar in asymptomatic infections, suggesting a more pathogenic role of 
RV-A infections. Also, RV-A was 4.5 and 2.2 times more often associated with LRTI than RV-B and RV-
C (P ≤ 0.010), and RV-C 2.1 times more often than RV-B (P= 0.015). 
Our findings indicate that in adults, the prevalence of RV-A associated LRTI is considerably higher 
than that of RV-B and RV-C, while RV-B infections are more often asymptomatic. The latter 
observation is further supported by the fact that RV-B has been detected infrequently in children and 
adults hospitalized for severe respiratory illness15,17,27-31. Furthermore RV-B symptomatic infections 
had significantly lower viral loads than RV-A symptomatic infections, suggesting lower pathogenicity 
of RV-B viruses. Lower viral loads of RV-B relative to RV-A and RV-C in respiratory specimens have 
previously been reported for adults with pneumonia32 and viral load has been reported as indicator 
for severity of RV infections3. These findings are in agreement with the in vitro study that 
demonstrated that RV-B types replicate less efficiently and induce lower cytokines and/or chemokine 
levels than RV-A or RV-C infections33. 
Our results on RV species distribution (RV-A>RV-C>RV-B) among adults with LRTI are consistent with 
those from a study conducted in Seoul among adults  with pneumonia32. Other studies in 
symptomatic patients found a lower prevalence of RV-C than RV-B infections34,35. These differences 
in the relative proportions of RV species in comparison to our findings could be due to differences in 
the study populations (e.g. URTI instead of LRTI) and annual variations in species distribution. We 
observed no significant differences between RV species in the duration of illness, maximum symptom 
scores, overall disease severity and severity of individual common cold symptoms. However, RV-A 
infected patients subjectively felt in general worse than those infected with RV-C. Our results suggest 
that RV-A infections have a more debilitating impact on the general health as compared to RV-B and 
RV-C infections. In children several studies demonstrated an association between RV-C and more 
serious respiratory illness13,22,28. In adult patients RV-C infection has been reported to cause more 
frequent acute respiratory tract infection and appeared more severe as compared to children22,36. 
Other studies in adults observed no differences in disease severity between rhinovirus 
species15,16,26,32,37, though one study found a higher disease severity associated with RV-A in upper 
respiratory symptoms35. However, these studies are limited due to the short surveillance periods, 




this study had per definition acute cough/LRTI, thus differences in disease severity between RV 
species in patients with milder symptoms cannot be excluded. 
RV-A was the most prevalent species in the majority of study locations, followed by RV-C, while RV-
B occurrence varied considerably between and within certain communities. Substantial antigenic 
variation within RV-A could lead to more frequent re-infections in the community and to a higher 
overall prevalence. Interestingly, not all RV species were identified in the separate locations during 
the study period. Genotyping of the RV samples lead to the discovery of 5 novel RV types and 
revealed a remarkably high diversity of RVs represented by 73 RV-A, 25 RV-B and 42 RV-C types. 
Asymptomatic infections were associated with a variety of RV types, the majority of which were also 
identified in symptomatic cases. 
Although comprehensive, this study has some limitations. Due to the heterogeneity of the RV 
genomes our RV diagnostic and genotyping assays might have varied in efficacy of amplification and 
therefore be suboptimal for some genotypes. In particular RV-C infections might be somewhat 
underrepresented, since a limited number of RV-C complete genome sequences were available at 
the time our diagnostic assay was developed. 
In addition, due to the nature of this study, only associations can be found, and no causality can be 
proven. With the current study design, an association can be made between RV type and disease 
severity. However the population studied, is patients visiting their GP that in general will be older 
and have more co-morbidities as compared to the general population. Nevertheless, these are the 
patients consulting their GP, and therefore this study is very representative for clinical practice. 
Although limited, some CRF’s were missing and not all RV positive samples could be typed. Because 
these numbers are limited a link between the missing data and disease severity is not expected and 
this probably will not result in a bias.   
Finally, the clinical status of cases with RV-positive follow-up samples could not be clearly defined, 
since symptom manifestations were not recorded by the GP at the time of the second visit. 
This is a very comprehensive study, in which RV typing has been performed in symptomatic (LRTI) 
and asymptomatic adult GP patients in 11 countries. RV typing is not part of standard diagnostic care 
and our results do not provide an indication for an added value in relation to disease severity. This 
may change in the future if subtype differences in efficacy are observed following antiviral treatment 
or vaccination. 
In conclusion, LRTI in adults were mainly associated with RV-A, identified in a significantly higher 
proportion of symptomatic than asymptomatic subjects as compared to RV-B and RV-C. Furthermore 
RV-A symptomatic infections were associated with significantly higher viral loads than RV-B 
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Sequence and phylogenetic analyses 
RV-positive samples were initially analysed with the VP3/VP1 genotyping assay and samples with 
negative results were further tested using RT-PCR assays amplifying partial VP4/VP2 or 5’UTR 
genome fragments1. PCR products were purified using the ExoSAP-IT® kit (Isogen, Life Science) and 
Sanger sequencing was performed at the Leiden Genome Technology Center (LGTC, Leiden, The 
Netherlands). Sequences were assembled and edited using Geneious version 7.1.5 software package 
(Biomatters, New Zealand) and BLASTn searches (http://www.ncbi.nlm.gov/BLAST) were conducted 
to establish virus species. RV data sets included, 212 RV-A (Table S1), 77 RV-B (Table S2), and 185 RV-
C (Table S3) reference sequences obtained from the website of the Picornaviridae Study Group 
(http://www.picornastudygroup.com) or through literature search and downloaded from Genbank2-
5. Multiple sequence alignments were generated with the MUSCLE alignment tool6. Neighbor-joining 
phylogenetic trees were constructed in the MEGA 7.0.26 software package7 from 1000 bootstrap 
resampled sequence alignments using the maximum composite likelihood8 model with pairwise 
deletions of missing data. RV sequences from this study were assigned to types based on 
phylogenetic clustering to reference sequences and intra- and inter-clade pairwise nucleotide 
distances p-distances estimated in MEGA 7.0.26 software package (Figure S1, S2, S3 and Tables S1, 
S2 and S3). Additional sequence analysis of VP1, VP4/VP2 or 5’UTR genome regions were performed 
for novel RV types or RV strains with incomplete coverage of the VP3/VP1 analysed fragment, due to 
poor sequence quality. A primer walking approach with universal primers selected from known or 
closely related sequences were used to obtain VP1 sequences from novel RV types. 
 
RESULTS 
A total of 686 rhinovirus positive samples were successfully amplified and sequenced in the VP3/VP1, 
VP4/VP2 or/and 5’UTR genome regions. 
Rhinovirus typing based on partial VP3/VP1 sequence analysis (Figure S1) 
Successful amplification and sequencing of the VP3/VP1 genome region was achieved for 292 RV-
positive samples, including 196 RV-A, 49 RV-B and 49 RV-C sequences. Phylogenetic analyses were 
based on approximately 850 nt and 880 nt VP3-VP1 fragments of respectively RV-A and RV-B 
sequences (nucleotide positions 2144-2978 according to RV-A2 strain, GenBank accession no. 
X02316) and 628 nt fragments of the RV-C VP1 gene (nucleotide positions 2174-2801 according to 
RV-C10 strain, GenBank accession no. EF077278). Twenty-four RV-A, 9 RV-B and 10 RV-C sequences 
were <90% complete across the analyzed region (sequence lengths ≥354 nt). The majority of VP3/VP1 
or VP1 sequences obtained from this study clustered closely with sequences of established RV types 
(Figure S1 and Table S1, S2, S3). Seven sequences had ≥15% nucleotide divergence from their nearest 
neighbor type. These sequences were confirmed as new RV types based on complete VP1 sequence 
analysis and assigned by the Picornaviridae Study Group as RV-A109 (F0062-V1), RV-B105 (H4923-V0 





Figure S1. Phylogenetic RV-A, RV-B and RV-C trees of the VP3/VP1 region 
Unrooted neighbor-joining phylogenetic trees of RV-A and RV-B partial VP3/VP1 sequences and RV-C partial 
VP1 sequences were generated using the maximum composite likelihood model. Numerical values (presented 
when >70%) represent the statistical support for the tree topology as determined by 1000 bootstrap 
replicates. Multiple sequences from the same type are shown as triangles with heights proportional to their 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Rhinovirus typing based on partial VP4/VP2 sequence analysis (Figure S2) 
Successful amplification and sequencing of the VP4/VP2 genome region was achieved for 423 RV-
positive samples, including 253 RV-A, 68 RV-B and 102 RV-C viral strains. Phylogenetic analysis were 
based on approximately 437 nt of the VP4/VP2 genome region (nucleotide positions 611-1047 
according to RV-A2 strain, GenBank accession no. X02316). Four sequences were classified to species 
taxa level based on BLASTn analyses but excluded from the phylogenetic analysis due to bad 
sequence quality (untypable RV strains). Two RV-A and 2 RV-C sequences were <90% complete across 
the analyzed VP4/VP2 region (sequence lengths ≥306 nt). The majority of VP4/VP2 sequences 
clustered closely with reference sequences of established types or potentially assigned types (PAT) 









Figure S2. Phylogenetic RV-A, RV-B and RV-C trees of the VP2/VP4 region 
Unrooted neighbor-joining phylogenetic trees of RV-A, RV-B and RV-C partial VP2/VP4 sequences were 
generated with the maximum composite likelihood model. Multiple sequences from the same type are shown 





Rhinovirus typing based on partial 5’UTR sequence analysis (Figure S3) 
Amplification and sequencing of the 5’UTR was achieved for 38 RV-positive samples, including 6 
samples that were typed also in the VP4/VP2 region. Phylogenetic analysis was based on a 326 nt 
fragment of the 5’UTR (nucleotide positions 218-542 according to RV-A2 strain, GenBank accession 
no. X02316) including 180 RV-A, 41 RV-B and 36 RV-C reference sequences and using Enterovirus D 
sequence type 68 (GenBank accession no. AB601882) as an outgroup. The phylogenetic dendogram 
inferred from the 5’UTR revealed that recombination events occur between certain RV-A and RV-C 
types. Although 5’UTR sequences do not reliably segregate RV-A and RV-C types9-11, this region can 
be useful for predicting virus genotype and distinguishing RV from EV types. In our study the 5’ UTR 
genotyping assay was used as a supplemental typing tool. Twenty-four 5’ UTR sequences from this 











Figure S3. Phylogenetic tree of the 5’ UTR region 
Neighbor-joining phylogenetic tree of partial 5’ UTR of 38 RV clinical isolates and 180 RV-A (red), 41 RV-B (blue) 
and 36 RV-C (green) GenBank sequences was generated with the maximum composite likelihood model. The 







1. Zlateva KT, de Vries JJ, Coenjaerts FE, et al. Prolonged shedding of rhinovirus and re-infection in adults with 
respiratory tract illness. The European respiratory journal 2014; 44(1): 169-77. 
2. McIntyre CL, Knowles NJ, Simmonds P. Proposals for the classification of human rhinovirus species A, B and C 
into genotypically assigned types. The Journal of general virology 2013; 94(Pt 8): 1791-806. 
3. Liggett SB, Bochkov YA, Pappas T, et al. Genome sequences of rhinovirus C isolates from wisconsin pediatric 
respiratory studies. Genome announcements 2014; 2(2). 
4. Liggett SB, Bochkov YA, Pappas T, et al. Genome sequences of rhinovirus B isolates from wisconsin pediatric 
respiratory studies. Genome announcements 2014; 2(2). 
5. Liggett SB, Bochkov YA, Pappas T, et al. Genome sequences of rhinovirus a isolates from wisconsin pediatric 
respiratory studies. Genome announcements 2014; 2(2). 
6. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic acids 
research 2004; 32(5): 1792-7. 
7. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics 
analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Molecular 
biology and evolution 2011; 28(10): 2731-9. 
8. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum 
likelihood. Systematic biology 2003; 52(5): 696-704. 
9. Savolainen-Kopra C, Blomqvist S, Smura T, et al. 5' noncoding region alone does not unequivocally determine 
genetic type of human rhinovirus strains. Journal of clinical microbiology 2009; 47(4): 1278-80. 
10. McIntyre CL, Savolainen-Kopra C, Hovi T, Simmonds P. Recombination in the evolution of human rhinovirus 
genomes. Archives of virology 2013; 158(7): 1497-515. 
11. Thoelen I, Moes E, Lemey P, et al. Analysis of the serotype and genotype correlation of VP1 and the 5' 
noncoding region in an epidemiological survey of the human enterovirus B species. Journal of clinical 














The research described in this thesis aimed to evaluate several new diagnostic approaches to viral 
respiratory infections. In addition, relevant patient cohorts were specifically tested for rhinovirus, 
including subtyping, to increase our insight in the clinical implications of rhinovirus infections, the 
most prevalent respiratory pathogens. 
The first chapters of the thesis present findings regarding new diagnostics. mNGS can result in the 
detection of all pathogens in a single test and the current protocol already had very high sensitivity 
and specificity as compared to PCR (chapter 2). Because of the excellent negative predictive value 
observed in COPD patients, mNGS may be used to exclude any viral infection (chapter 3). In addition, 
mNGS enabled obtaining detailed information about the pathogens, antiviral resistance, virulence 
and typing information simultaneously (chapter 2). The advantage of the ePlex® RP assay over in-
house respiratory PCR lies in the syndromic testing panel which resulted in the detection of additional 
pathogens and the reduced time to result, accomplishing a reduction in isolation days and improved 
antimicrobial and antiviral treatment (chapter 4). 
The importance of a short time to result for diagnosing respiratory tract infections is shown in this 
thesis, and moreover during epidemics when shortage of isolation rooms is reason for concern. 
Although the mNGS procedure currently takes much more time than rapid syndromic assays like 
ePlex® RP, it is also capable to detect new pathogens, non-viral pathogens and all relevant properties 
of pathogens. At a certain moment in future, mNGS may even result in cost-reduction, for example 
in clinical scenarios where a high number of diagnostic tests are indicated. The potential to analyse 
expression of immunological human host genes might help to determine severity markers of viral 
infections, for example the upregulation of ICAM-1, the major receptor of rhinovirus, in COPD 
patients1. 
The importance of mNGS is also supported by the devastating 2020 SARS-CoV-2 outbreak. This new 
virus was discovered when a number of patients were admitted with fever and respiratory complaints 
to a hospital in Wuhan, China, all with an epidemiological link to the Wuhan South China Seafood 
City. Routine respiratory pathogens, including SARS-CoV and MERS-CoV, all tested negative. 
Fortunately, by means of mNGS a relevant pathogen could be identified, a novel coronavirus, with 
around 70% homology to SARS, that was later named SARS-CoV-2. Subsequently, PCR primers and 
probes became rapidly available for routine diagnostics2,3. Although the first known patient with 
atypical pneumonia of unexplained cause was reported as early as 20 December 2019, of which a 
bronchoalveolar lavage was collected on December 30, 2019 it was not until 8 January 2020 the first 
sequence results revealed a novel coronavirus4,5. This delay demonstrates that to benefit from the 
advantages of mNGS, it is essential to obtain results as soon as possible. mNGS testing in this case 
was only performed when routine diagnostics tested negative. Besides, it is possible other patients 
with this novel coronavirus, probably solitary cases, before the first recognized patient, were missed 
at all. Such delay in diagnosis might even have resulted in increased initial spread of the virus. The 
subsequent development, with spread of the SARS-CoV-2 virus over all continents and a clinical 
spectrum ranging from asymptomatic to life-threatening pneumonias, still suffered from initial 








adequate diagnostic tool, when applied readily, however when mNGS is used as primary diagnostic 
tool, all cases will be also diagnosed together with any alternative diagnosis, which is helpful to 
differentiate an epidemic pathogen reliably from other causes of respiratory infection. 
While by NGS analysis this new virus appeared to be genetically related to SARS-CoV it is formally 
named called SARS-CoV-23. However, the disease it causes is not SARS (severe acute respiratory 
syndrome) but has been named COVID-19 (corona virus disease). This split in name of the virus and 
its clinical picture appears confusing, as the virus is often indicated by COVID-19 virus now. It would 
be advisable to give a new virus a name independent of its clinical picture. 
Technically, for viral diagnostics by mNGS, with only a very limited number of viral reads, ultra-deep 
sequencing, such as Illumina sequencing is necessary. But to be applicable in routine diagnostics the 
runtime must be as short as possible. In this thesis (chapter 2 and 3) Illumina NextSeq 500 sequencing 
is used, although several sequencing platforms are available and new platforms are being developed. 
The advantage of this system is the high output and deep sequencing, the disadvantage is the long 
runtime, a minimum of 12 hours. Newer machines, like the MiSeq have a minimum runtime of only 
4 hours. Other sequencing by synthesis platforms, for example Ion Torrent sequencing, do also have 
a shorter runtime, however they are not real-time as single molecule sequencing by PacBio or 
nanopore sequencing. These real-time platforms seem promising, although the limited capacity, high 
error rates and higher costs limits is usefulness for viral mNGS in routine diagnostics. But with still 
emerging technologies a combination of deep sequencing, without many errors and with a short 
runtime might be possible in the near future 
Other aspects of the mNGS process have been optimized as well. For example, in this thesis we used 
Centrifuge software for analysing the sequence data, although several pipelines are available. There 
are pipelines specifically for virus analyses, for example VirFind, but also total pathogen pipelines like 
Centrifuge, Surpi, Taxonomer and Kaiju. They can differ in several aspects, such as quality control, 
database used, speed of processing, output format and user-friendliness. To be applicable in clinical 
diagnostics a tool suitable to detect all possible pathogens is necessary, as is a tool that is fast and 
user-friendly. In the context of new viruses, such as SARS-Cov-2, the pipeline must be able to detect 
these new viruses as well, for example by assigning these reads to the family of Coronaviridae. This 
or a large proportion of unassigned reads should make the clinical microbiologist aware of a possible 
new virus variant. A good comparison of several pipelines regarding these aspects would be 
recommendable for implementation in clinical diagnostics. 
Another aspect of mNGS to be considered before it will be used in routine diagnostics is the normal 
background, the virome, and the cut-off number of reads to be considered clinically relevant. In this 
thesis we have calculated sensitivity as well as specificity with several different cut-off number of 
reads, but the optimal number must be determined in larger groups with a variety of patients. This 
might even differ between patient populations, sequencing platforms and bioinformatic pipelines. 
When applying mNGS the microbiome is readily available as well. Although the importance of this 
“bacteriome” is widely demonstrated in many biomedical fields, the virome is studied much less. 




and bacteriome interact closely, and the virome might be of greater importance than suspected 
before. It appears mNGS is the ideal tool to study this interaction. 
Most likely, mNGS will ultimately determine the future for viral respiratory testing. However, at this 
moment mNGS is not ready for primary viral respiratory testing, because the advantage of rapid 
results of current methods still outweighs the additional information gained using mNGS for clinical 
diagnostics. However, when conventional viral diagnostic tests are negative, mNGS can already be of 
added value by detection of potential new or unexpected pathogens. 
As mentioned before, the other aim of the thesis was to determine several aspects of disease severity 
of rhinovirus infections. To summarize the new insights obtained, rhinovirus infections in young 
children cleared for cardiac surgery were not associated with more severe clinical outcome (chapter 
5). On the other hand, rhinovirus viremia was associated with fatal outcome in adult stem cell 
transplant patients (chapter 6). In adult primary care patients, rhinovirus type A was a severity 
marker, as it was associated, more often than type B and C, with lower respiratory tract infections 
(chapter 7). 
Although the causality of rhinovirus infections with regard to clinical manifestations was already 
demonstrated in 1978 by inoculation of RV-16 in healthy volunteers, it is still up for debate7. The 
reason is the high percentage of asymptomatic infections, and the high incidence of co-pathogens in 
symptomatic patients. In this thesis, the high incidence of rhinovirus infections in young children 
without or with only very mild upper respiratory tract complaints was demonstrated as well. 
Although several studies have shown an association between rhinovirus and severe disease, it is often 
still not considered to be a serious pathogen8,9. And when rhinovirus is found in patients with a 
pneumonia admitted to the intensive care unit, it is usually not believed to be the causative agent. 
mNGS might be the tool solve this long-lasting dubiety, studying not only the virus, but also the 
virome and the immune response of the host. These factors and their interaction might be the key in 
understanding the pathophysiology of rhinovirus and the divergence of symptomatology. 
Rhinovirus RNA-emia was found in this thesis in adults with high viral loads in their bronchoalveolar 
lavages. All adults had underlying diseases, and 75% harboured co-pathogens. Another study failed 
to demonstrate rhinovirus in the blood of adults admitted to the hospital with a community acquired 
pneumonia10. Whether this is because of the difference in patient population (immunocompromised 
patients were studied in this thesis) or because of differences in the viral load remains to be 
determined.  
In children rhinovirus-C is associated with rhinovirus viremia more often, as well as with the 
development of asthma and in several studies with more severe disease10-13. In this thesis rhinovirus-
C was not associated with longer hospital admission in children undergoing cardiac surgery as 
compared to the other rhinovirus types. While on the contrary in adults rhinovirus-A (instead of C) 
was associated with respiratory infections more often and only rhinovirus-A and B were found in the 
viremic patients. The observed differences in pathogenicity between the different rhinovirus species 
may contribute to the differences in clinical presentation, although host factors will play an important 








The demonstration of rhinovirus in the lower airways, the blood and even in the stool of patients, 
and the close relatedness with enterovirus, might suggest the virus is able to cause an ever wider 
variety of clinical pictures, in which mNGS might provide more insight10,16. 
The shorter duration of hospital length of stay after cardiac surgery in children with rhinovirus was a 
surprising result. A speculative explanation would be an immunomodulating effect of rhinovirus 
infections in children. Although strengthening of the immune system has been suggested previously, 
it is not supported by experimental evidence17. The exact role of the different rhinovirus species (as 
well as types) and the effects of the immune system need further investigation. 
Future studies should expand on the performance of mNGS for respiratory infections caused by 
bacteria, parasites and fungi as well. Using a pan-pathogen protocol, mNGS performance can be 
compared to standard microbiological testing (PCR and culture) on preferably bronchoalveolar 
lavages. 
To consolidate the findings of this thesis, to investigate the hypothesis of immunomodulation by 
rhinovirus, and to demonstrate a correlation between disease severity and differences in expression 
of receptors or inflammatory markers in the host, further investigations on the detection of 
rhinovirus are required. For such a study, respiratory and plasma samples may be tested with mNGS, 
involving the host genome as well, in order to study the viral as well as the host factors. 
Immunocompetent patients, with varying disease severity (from common cold to pneumonia 
needing hospitalisation), as well as controls without respiratory complaints should be tested. It would 
be interesting to compare the proportion of rhinovirus positive samples, the rhinovirus species and 
types, the relative abundancies in the different compartments as well as the expression of host-
factors/ inflammatory markers, e.g. rhinovirus receptors. 
In conclusion, for the future, when a reduction in time to results is accomplished, mNGS will likely be 
the primary diagnostic tool for respiratory viral infections. This is mainly due to its abilities to detect 
all viruses in a single test, to determine precisely all species and types (in for example rhinovirus 
infections), and to detect resistance and virulence markers, enabling a possible prediction of the 
disease severity and treatment adjustment in case of antiviral resistant strains (for example, with 
oseltamivir resistance in influenza cases). For these reasons, the application of this new approach will 
greatly expand our possibilities to deal effectively with the serious burden respiratory infections 
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Ontwikkelingen in de diagnostiek van virale luchtweginfecties en inzicht in 




Diagnose van virale luchtweginfecties 
Respiratoire virussen, virussen die luchtweginfecties veroorzaken, kunnen op verschillende manieren 
worden gedetecteerd. 
Polymerase chain reaction (PCR) is tegenwoordig de meest gebruikte detectiemethode.  Hierbij 
wordt een stukje van het genetische materiaal van het virus vermenigvuldigd, net zo lang tot de 
hoeveelheid boven de detectielimiet komt. Het nadeel van deze techniek is dat je van te voren moet 
bepalen naar welke virussen je gaat zoeken. Je kijkt namelijk naar specifieke stukken genetisch 
materiaal, en het aantal virussen dat je kan detecteren in één test is beperkt. Daarnaast kan het 
genetisch materiaal binnen een groep virussen variëren of veranderen, waardoor het specifieke stuk 
genetisch materiaal waar je naar zoekt er niet meer in zit. 
Metagenomic next generation sequencing (mNGS) is de nieuwste diagnostische ontwikkeling. 
Hiermee kan al het genetisch materiaal in één sample gedetecteerd worden. Groot voordeel is dat 
hierdoor naast de detectie van alle virussen in het sample (het viroom), ook additionele informatie 
over de virussen, zoals type, virulentie markers en gevoeligheid beschikbaar komt. Helaas zijn de 
kosten van deze detectiemethode hoog en is de doorlooptijd lang, alhoewel beiden snel afnemen. 
Syndromale testen, zoals ePlex® RP panel, zijn andere diagnostische ontwikkelingen, waarbij de 
meest voorkomende verwekkers van een ziektebeeld, syndroom, tegelijk getest worden. Daarnaast 
hebben ze als groot voordeel dat ze een hoge doorloopsnelheid hebben.   
 
Rhinovirussen  
Rhinovirussen zijn de meest voorkomende respiratoire virussen. Er zijn sinds de ontdekking van dit 
virus in de jaren 50 meer dan 160 types ontdekt. Deze 160 types worden onderverdeeld in rhinovirus 
species A, B en C. 
Rhinovirussen staan bekend als verwekker van “verkoudheid”. Het klinische spectrum van rhinovirus 
infecties varieert echter van asymptomatisch tot ernstige onderste luchtweginfecties. Dit verschil in 
klinische presentatie is waarschijnlijk multifactorieel, maar welke factoren allemaal op welke manier 
een rol spelen is nog onduidelijk. 
 
DIT PROEFSCHRIFT 
Het doel van het onderzoek in dit proefschrift is tweeledig, (I) evalueren van nieuwe virale 
diagnostiek en (II) meer inzicht krijgen in de klinische implicaties van rhinovirus infecties. 
 
Deel I: Toepassing en toegevoegde waarde van ontwikkelingen in respiratoire virale diagnostiek 
In hoofdstuk 2 wordt een nieuw ontwikkelt mNGS protocol getest, waarbij met één voorbehandeling 
(in tegenstelling tot wat meestal gedaan wordt; een aparte voorbewerking voor de twee groepen 
virussen, RNA en DNA virussen) alle virussen in één test gedetecteerd worden. Dit protocol wordt 
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geëvalueerd met 24 klinische kindersamples en vergeleken met PCR. Het ontwikkelde mNGS protocol 
had in dit cohort een goede sensitiviteit (bij 83% van de zieke patiënten is de test positief) en 
specificiteit (bij 94% van de niet zieke patiënten is de test negatief).  
In hoofdstuk 3 wordt met dit nieuw ontwikkelde mNGS protocol luchtwegmateriaal van 88 COPD 
patiënten met longaanvallen getest en gekeken naar het viroom en naar een mogelijk verband tussen 
de samenstelling van het viroom en de kliniek. Ook in dit geval wordt een goede sensitiviteit (96%) 
en specificiteit (98%) van mNGS t.o.v. PCR aangetoond. De negatief voorspellende waarde (dat bij 
een negatieve testuitslag de patiënt de ziekte ook echt niet heeft) was zelfs 100%, waardoor deze 
test uitermate geschikt is om in één keer alle respiratoire virussen uit te sluiten. Er kan geen link 
gevonden worden tussen de kliniek en de samenstelling van het viroom. 
In hoofdstuk 4 wordt het belang van snelle diagnostiek onderzocht. Snelle syndromale diagnostiek 
(ePlex® RP panel) wordt vergeleken met PCR. Bij 64 patiënten met symptomen passend bij een 
luchtweginfectie werd tegelijk ePlex® RP panel en PCR diagnostiek aangevraagd. De testen waren qua 
sensitiviteit en specificiteit vergelijkbaar, maar de ePlex® RP panel gaf significant snellere resultaten 
(3,4 uur t.o.v. 27,1 uur voor PCR). Dit resulteerde in een reductie van 21 isolatiedagen en een 
mogelijke reductie van antimicrobiële therapie. Het syndromale testen middels de ePlex® RP panel 
resulteerde in 2 additionele pathogenen. 
 
Deel II: Klinische implicaties van rhinovirus infecties 
In hoofdstuk 5 worden de gevolgen van een rhinovirus infectie bij kinderen die aan hun hart werden 
geopereerd beschreven. Van de 163 kinderen testten 74 kinderen (45%) rhinovirus positief ten tijde 
van hun operatie. In tegenstelling tot onze verwachting hadden de kinderen met een rhinovirus 
infectie geen verlengde opnameduur op de kinder intensive care. Ze hadden zelfs een kortere 
opnameduur in het ziekenhuis en hadden minder vaak een klinische verdenking op een 
postoperatieve luchtweginfectie.  
In hoofdstuk 6 wordt gekeken naar de aanwezigheid van het rhinovirus in het bloed (viremie) van 
volwassenen en wordt gekeken naar een eventuele associatie met de ziekte ernst. Van de 27  
volwassen patiënten met een aangetoonde rhinovirus infectie in de longen, werd bij vier patiënten 
rhinovirus in het bloed gevonden. Deze rhinovirus viremie wordt geassocieerd met een hogere 
mortaliteit (100% versus  22% van de patiënten zonder rhinovirus viremie) 
Tot slot wordt in hoofdstuk 7 de associatie tussen de verschillende rhinovirus species en de ziekte 
ernst beschreven. In 566 (19%) van de 3016 mensen die hun huisarts bezochten vanwege acuut 
hoesten/ klachten van de onderste luchtwegen werd rhinovirus aangetoond t.o.v. 67 (4%) van de 
1677 asymptomatisch controles. Rhinovirus A kwam in verhouding vaker voor bij patiënten met 
klachten. Daarnaast hadden patiënten met een rhinovirus A infectie over het algemeen meer last van 





In de toekomst, wanneer een reductie in doorloopsnelheid van de mNGS detectiemethode is 
behaald, zal mNGS waarschijnlijk het primaire diagnosticum zijn voor virale respiratoire infecties. Dit 
komt voornamelijk doordat mNGS in één test (I) alle virussen kan detecteren, (II) alle species en types 
kan differentiëren (in bv geval van het rhinovirus) en (III) resistentie kan aantonen, waardoor je 
mogelijk de ziekte ernst van de infectie kan voorspellen en de behandeling kan aanpassen in het geval 
van resistentie. Hierdoor zullen we effectiever op kunnen treden tegen de hoge morbiditeit en 
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